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Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease, causing 
progressive muscle wasting and eventual paralysis. A number of the cellular functions 
that are disrupted in ALS are mediated by signalling between the endoplasmic reticulum 
(ER) and mitochondria. This signalling is facilitated by close physical contacts between 
areas of ER and mitochondrial membranes. The ER membrane protein, VAPB, and the 
outer mitochondrial membrane protein, PTPIP51, interact to act as tethers, mediating the 
formation of ER-mitochondria contacts. Transgenic mouse and cellular studies have 
shown that ER-mitochondria contacts are disrupted by ALS insults, some of which 
disrupt the VAPB-PTPIP51 interaction via activation of the kinase GSK-3β. However, 
ER-mitochondria contacts have not been studied in ALS in humans and the mechanism 
by which GSK-3β disrupts the VAPB-PTPIP51 interaction is yet to be elucidated.  
 
The first hypothesis that underlies this thesis is that damage to ER-mitochondria 
signalling, involving disruption of the VAPB-PTPIP51 tethers, is a feature of disease in 
ALS in humans. This was investigated by quantifying the VAPB-PTPIP51 interaction 
using proximity ligation assays in post-mortem spinal cord tissues from ALS and control 
cases, and in iPSC-derived motor neurons from control donors and ALS donors carrying 
familial pathogenic TDP-43 mutations. The VAPB-PTPIP51 interaction was reduced in 
both ALS post-mortem spinal cord and iPSC-derived motor neurons. VAPB protein levels 
were reduced in ALS, but other ER-mitochondria proteins investigated were unchanged. 
 
The second hypothesis of this thesis is that GSK-3β phosphorylates VAPB or PTPIP51, 
reducing their interaction as ER-mitochondria tethers. Recombinant VAPB and PTPIP51 
were phosphorylated in vitro by GSK-3β and then analysed by mass spectrometry. Novel 
potential GSK-3β phosphorylation sites were identified in both proteins. Using phospho-
mimicking mutants in a cellular GAL4 based 2-hybrid binding assay, one phosphorylation 
site in VAPB was shown to alter its binding to PTPIP51. To complement these in vitro 
studies, cellular phosphorylation of VAPB and PTPIP51 was also investigated. This 
involved immunoprecipitation of VAPB and PTPIP51 from cells in which GSK-3β or AMP 
kinase activities were increased, and mass spectrometry. These studies identified novel 
phosphorylation sites in both proteins, which may facilitate future studies on the role of 
the VAPB-PTPIP51 interaction in ER-mitochondria signalling. 
 
In summary, the studies presented in this thesis identify disruption of the VAPB-PTPIP51 
ER-mitochondria tethers as a novel feature of ALS in humans and provide insight into a 
mechanism for this disruption. These studies also provide further support for correcting 
damage to the VAPB-PTPIP51 interaction as a novel therapeutic target for ALS. 
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MND  Motor Neuron Disease 
MOSPD2 Motile Sperm Domain Containing Protein-2 
MS/MS Tandem Mass Spectrometry 
MSP  Motile Sperm Protein 
MW  Molecular Weight 
m/z  Mass to Charge Ratio 
NLR  NOD-like Receptor 
NPC  Nuclear Pore Complex 
NSE  Neuron Specific Enolase 
OD  Optical Density  
OPTN  Optineurin  
ORP  Oxysterol Binding Protein-Related Protein 
PACS-2 Phosphofurin Acid Cluster Sorting Protein 2 
PBS  Phosphate Buffered Saline 
PC  Phosphatidylcholine 
PD  Parkinson’s Disease  
PDI  Protein Disulfide Isomerase 
PDZD8 PDZ Domain-containing Protein 8 
PE  Phosphatidylethanolamine 
PERK  Protein Kinase R-like ER Kinase 
PFA  Paraformaldehyde 
PINK1  PTEN-induced Kinase 1 
PLA  Proximity Ligation Assay 
PMD  Post-mortem Delay 
Presenilin PSN 
PS  Phosphatidylserine 
PTPIP51 Protein Tyrosine Phosphatase Interacting Protein 51 kDa 
RA  Retinoic Acid 
Ri  ROCK inhibitor 
RIPA  Radio-Immunoprecipitation Assay 
RM  Reaction Mix 
RNA  Ribonucleic Acid 
ROCK   Rho-associated Protein Kinase 
ROS  Reactive Oxygen Species  
RRBP1 Ribosome-Binding Protein 1 
SAG  Smoothened Agonist 
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SB  SB431542, Activin Inhibitor 
SDS  Sodium Dodecyl Sulfate  
SDS-PAGE SDS-Polyacrylamide Gel Electrophoresis 
S.e.m.  Standard Error of the Mean 
SOD1  Superoxide Dismutase 
SQSTM1 Sequestosome 1 
SYNJ2BP Synaptojanin 2 Binding Protein 
TA  Trans-Activating 
TAR  Transactivating Response Element 
TBK-1  TANK-Binding Kinase 1 
TBS  Tris-Buffered Saline 
TDP-43 TAR DNA Binding Protein 43 kDa 
TEMED N,N,N`,N`-Tetramethyl Ethylenediamine 
TM  Transmembrane  
TOM20 Translocase of Outer Membrane 20 kDa 
TPR  Tetratricopeptide Repeat 
TRAK  Trafficking Kinesin Protein 
UAS  Upstream Activating Sequence  
UPR  Unfolded Protein Response 
VAPB  Vesicle Associated Membrane Protein Associated Protein B 
VCP  Valosin-Containing Protein  
VDAC  Voltage Dependant Anion Channels 
WT  Wild Type 
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1.1 Amyotrophic Lateral Sclerosis 
1.1.1 Clinical overview 
Amyotrophic Lateral Sclerosis (ALS) is the most common cause of adult-onset motor 
neuron disease (MND), thought to account for 80-90 % of MND cases (Yedavalli et al., 
2018). The disease is characterised by the degeneration of upper and lower motor 
neurons which leads to the atrophy and progressive paralysis of muscles. ALS is a fatal 
neurodegenerative disease and paralysis of respiratory muscles typically causes patient 
fatality within 2 – 5 years of diagnosis (Ringel et al., 1993). Most cases of ALS are thought 
to be sporadic, occurring in patients with no family history of the disease; approximately 
5-10 % are diagnosed as familial cases of ALS (Mathis et al., 2019). 
 
The clinical symptoms of ALS are largely heterogeneous. The majority of ALS cases, 
approximately 80 %, are categorised as limb onset disease in which patients present first 
with weakness in a specific limb which eventually progresses to various other muscles. 
The other 20 % are categorised as bulbar onset in which facial, pharyngeal or respiratory 
muscles are affected first, leading to symptoms such as sialorrhea, facial weakness and 
dysphagia. Bulbar onset cases tend to progress more quickly due to the importance of 
the muscle groups affected early on in the disease. Most patients will develop bulbar 
symptoms at some stage of disease progression (Tiryaki and Horak, 2014). Clinical 
variation also arises from the contribution of upper or lower motor neuron degeneration. 
Upper motor neurons originate in the motor cortex and transmit signals to the lower motor 
neurons in the spinal cord which directly innervate muscle fibres. Degeneration of lower 
motor neurons leads to rapid atrophy of the muscles due to denervation of the fibres. 
This presents clinically as progressive muscle weakness. Degeneration of upper motor 
neurons presents as muscle spasticity caused by a lack of motor signal transmission 
(Tiryaki and Horak, 2014).  
 
There is currently no cure or effective disease modifying treatment for ALS. Treatment 
primarily focuses on alleviating the clinical symptoms such as treating dysphagia or 
respiratory difficulties. There are only two approved drugs for the treatment of ALS, 
Riluzole and Edaravone (Jaiswal, 2019). Riluzole blocks the release of the 
neurotransmitter glutamate, reducing neuronal excitotoxicity which can contribute to cell 
death in damaged cells. Riluzole can only modestly extend life, or the time until a patient 
requires mechanical ventilation (Hinchcliffe and Smith, 2017; Miller et al., 2003). 
Edaravone is a free radical scavenger thought to minimise oxidative stress and also 
offers only modestly improved survival time for ALS patients (Group and Group, 2017; 




Approximately 15 % of patients with ALS also display some of the clinical symptoms of 
frontotemporal dementia (FTD) (Ringholz et al., 2005; Woollacott and Rohrer, 2016). 
FTD is the most prevalent subtype of frontotemporal lobar dementia (FTLD) and is 
characterised by degeneration of neurons in the frontal and temporal cortex (Mann and 
Snowden, 2017). FTD can present clinically with a variety of changes in behaviour 
including social disinhibition, apathy and obsessive behaviours which develop into 
progressive loss of executive function. Reports suggest that up to 40 % of patients with 
FTLD display motor symptoms, with the majority of these being FTD patients displaying 
the clinical symptoms of ALS (Bang et al., 2015). As well as clinical features, ALS and 
FTD share some genetic and pathological features which lead to the reference of a 
spectrum disorder, ALS/FTD. It is worth noting this overlap because it suggests that 
therapeutic targets may also be shared between the two diseases. The work in this thesis 
however focuses on ALS because the donors from which cells and tissues were used 
were clinically diagnosed with ALS rather than FTD. 
 
1.1.2 Genetics of Amyotrophic Lateral Sclerosis 
Mutations in more than 30 genes have been identified as likely to cause ALS and 
mutations in almost another 100 genes are thought to increase the likelihood of 
developing ALS (Wroe et al., 2008). A full list of ALS-associated genes can be found at 
https://alsod.ac.uk. ALS is genetically as well as clinically heterogeneous; various clinical 
symptoms can be caused by the same genetic mutation and likewise different genetic 
backgrounds can give rise to similar clinical symptoms (Tiryaki and Horak, 2014). 
 
The first identified genetic cause of familial ALS was a mutation in SOD1 (Rosen et al., 
1993), encoding the protein Cu/Zn superoxide dismutase (SOD1). SOD1 catalyses the 
conversion of the free radical superoxide (O2-) into either oxygen or hydrogen peroxide, 
thus protecting the cell against oxidative stress (Sangwan and Eisenberg, 2016). Across 
familial and sporadic cases of ALS, more than 180 mutations have been found in the 
gene encoding the protein SOD1. It is not yet known if all of these are causative for the 
disease and many may be risk factors. Some have been shown to cause misfolding and 
aggregation of the protein (Sangwan and Eisenberg, 2016). 
 
Intronic hexanucleotide repeat expansions (GGGGCC) in the C9ORF72 gene cause a 
third of European ALS cases. In the wild-type (WT) gene, up to 30 hexanucleotide 
repeats may be found but expansions of hundreds or more are found in patients, causing 
autosomal dominantly inherited ALS (DeJesus-Hernandez et al., 2011; Renton et al., 
2011). The protein encoded by C9ORF72 is predicted to be a guanine nucleotide 
exchange factor with proposed activity in processes including autophagy and vesicle 
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trafficking (Iyer et al., 2018). However, the extent of its physiological function in ALS is 
not yet fully understood. The C9ORF72 repeat expansion is transcribed into extended 
repeats of RNA that undergo non-ATG mediated translation to form five different 
polypeptides of two repeating amino acids (poly-GR, -PR, -GA, -PA, -GP); these are 
known as dipeptide repeats (DPRs) (Mori et al., 2013a). Loss of function, toxic gain of 
function, the formation of RNA foci and toxicity of some of the DPRs have been 
investigated as mechanisms arising from the C9ORF72 repeat expansion (Iyer et al., 
2018), but the mechanism of disease is still not fully understood.  
 
Several ALS-causing mutations have been identified in the gene encoding Trans-Active 
Response (TAR) DNA-binding protein of 43 kDa (TDP-43), TARDBP. More than 30 point 
mutations, including M337V and G298S, have been identified in ALS patients (Gitcho et 
al., 2008; Kabashi et al., 2008; Rutherford et al., 2008; Sreedharan et al., 2008; Van 
Deerlin et al., 2008). Together these mutations account for approximately 5 % of familial 
ALS cases. TDP-43 is an RNA binding protein with roles in splicing and the regulation of 
translation. Mutations in TARDBP cause autosomal dominantly inherited ALS and a large 
proportion of the mutations are found in the glycine-rich region of the protein which 
mediates the binding of TDP-43 to RNA; these mutations therefore affect TDP-43 
translational and splicing regulation functions (Kabashi et al., 2008; Pesiridis et al., 2009; 
Sreedharan et al., 2008). Point mutations in the gene FUS, which encodes another RNA 
binding protein, Fused in Sarcoma (FUS), also cause ALS (Kwiatkowski et al., 2009; 
Neumann et al., 2019; Vance et al., 2009).  Both autosomal dominant and recessive 
mutations in FUS have been found. Like TDP-43, FUS is an RNA binding protein which 
functions to regulate splicing and translation of a large number of transcripts. Mutations 
in FUS are primarily found in the C-terminal region of the protein, which is responsible 
for the targeting of FUS to the nucleus, these mutations therefore cause mislocalisation 
of the protein (Kwiatkowski et al., 2009; Vance et al., 2009). 
 
Mutations have also been identified in ALS patients in a number of other genes. These 
genes encode proteins which function in autophagy, such as Optineurin (OPTN) (Belzil 
et al., 2011; Del Bo et al., 2011; Maruyama et al., 2010; Naruse et al., 2012; Tumer et 
al., 2012; van Blitterswijk et al., 2012) and TANK-binding kinase 1 (TBK-1) (Cirulli et al., 
2015; Freischmidt et al., 2015), axonal transport, such as Dynactin (DCTN) (Munch et 
al., 2005; Munch et al., 2004) and Kinesin family 5A (KIF5A) (Brenner et al., 2018), and 
signalling between the endoplasmic reticulum (ER) and mitochondria, such as Vesicle 
associated membrane protein associated protein B (VAPB) (Kanekura et al., 2006) and 




DCTN is a component of the molecular motor complex dynein/dynactin, which facilitates 
the movement of cargos along microtubules in the axon. Mutations in the DCTN1 gene 
are thought to affect its interaction with the molecular motor dynein and are autosomal 
dominantly inherited (Munch et al., 2005; Munch et al., 2004). OPTN is an autophagy 
receptor and is phosphorylated by TBK-1 (Morton et al., 2008). OPTN and TBK-1 are 
recruited to damaged mitochondria in order to facilitate mitophagy. ALS-related 
mutations in either OPTN or TBK-1 disrupt this process (Moore and Holzbaur, 2016). 
VAPB is an integral ER membrane protein and plays a role in the ER unfolded protein 
response (UPR) and signalling between the ER and mitochondria. A dominantly inherited 
point mutation in VAPB, P56S, leads to familial ALS (Nishimura et al., 2004). The P56S 
mutation causes mutant VAPB to aggregate and sequester WT VAPB, causing a loss of 
VAPB function (Kanekura et al., 2006). Sigma1R mutations are autosomal recessive and 
produce unstable forms of the protein, altering its function at contact sites between the 
ER and mitochondria (Gregianin et al., 2016). The role of these proteins in ER-
mitochondrial signalling and ALS will be discussed in more detail in section 1.2.  
 
1.1.3 Pathology of Amyotrophic Lateral Sclerosis  
ALS is characterised by cytoplasmic inclusions of ubiquitinated proteins. In 97 % of 
cases, these inclusions are formed of ubiquitinated and phosphorylated TDP-43 (Arai et 
al., 2006; Neumann et al., 2006). As stated above, TDP-43 is an RNA binding protein 
which functions in mRNA splicing and the regulation of mRNA translation (Buratti and 
Baralle, 2001; Neumann et al., 2006). In healthy cells, TDP-43 is primarily localised to 
the nucleus of the cell. However, in ALS TDP-43 is ubiquitinated and 
hyperphosphorylated and is found aggregated in both the nucleus and the cytoplasm 
(Arai et al., 2006; Hasegawa et al., 2008; Neumann et al., 2006).   
 
Approximately 2 % of ALS cases, also including familial and sporadic cases, display 
cytoplasmic inclusions of the protein SOD1. These inclusions are positive for ubiquitin. 
Accumulations of phosphorylated neurofilaments and several chaperones are also seen 
in SOD1 ALS (Ince et al., 1998; Kato et al., 2000; Stewart et al., 2006). Some of the 
remaining cytoplasmic inclusions in ALS cases are formed of the protein FUS (Vance et 
al., 2009). In ALS cases caused by C9ORF72 mutations, inclusions contain DPRs (Ash 
et al., 2013; Mori et al., 2013a; Mori et al., 2013b), and in some cases the hallmark 
ubiquitinated and phosphorylated TDP-43 (Arai et al., 2006; Hasegawa et al., 2008; 
Neumann et al., 2006). Post-mortem studies also identify inflammation as an ALS 
pathology. Glial activation, as measured by staining of markers for activated astrocytes 
(glial fibrillary acidic protein, GFAP) and activated microglia (cluster of differentiation 68, 
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CD68), is found in ALS patient tissue and is a correlate of disease (Brettschneider et al., 
2012).  
 
1.1.4 Pathological mechanisms in Amyotrophic Lateral Sclerosis 
1.1.4.1 Protein misfolding and aggregation and damage to autophagy 
Abnormal accumulations of disease-related proteins are features of numerous 
neurodegenerative diseases. Misfolding and ubiquitination of pathological proteins can 
induce aggregation and lead to the formation of pathological inclusions. Autophagy is 
the process by which misfolded or damaged proteins are degraded and recycled and 
damage to autophagy is another feature of ALS which is believed to contribute to the 
formation of pathological inclusions (Guo et al., 2018).   
 
The major hallmark protein pathologies in ALS patients are cytoplasmic inclusions of 
TDP-43, FUS or SOD1 in motor neurons. Many ALS causing mutations increase the 
propensity of these proteins to misfold whilst other mutations increase the mislocalisation 
of pathological proteins to the cytoplasm. These features suggest a role for misfolding 
and aggregation in the pathogenesis of the disease. ALS causing mutations are also 
found in proteins in the autophagic pathway, such as OPTN, Sequestosome 1 
(SQSTM1), TBK1 and C9ORF72 are reported to disrupt the process of autophagy, 
contributing to the ubiquitination and build-up of pathological proteins (Guo et al., 2018). 
Enhancing autophagic pathways clears inclusions to an extent and is reported to reduce 
pathogenesis (Castillo et al., 2013; Chen et al., 2015; Mandrioli et al., 2018; Zhang et al., 
2014). The activation of heat shock proteins, which act as protein folding chaperones, 
reduces TDP-43 aggregation and these have also been found sequestered in neuronal 
inclusions in ALS (Chang et al., 2013). This finding further implicates protein misfolding 
in the formation of pathological inclusions. Misfolding and subsequent aggregation of 
proteins can be damaging in itself but can also lead to reductions in the normal function 
of the sequestered proteins. 
 
1.1.4.2 Nucleocytoplasmic trafficking damage 
Nucleocytoplasmic trafficking is the process by which proteins are shuttled between the 
cytoplasm and the nucleus across the nuclear membrane. This transport occurs via a 
complex of proteins which form a pore in the nuclear envelope known as the nuclear 
pore complex (NPC). Importins facilitate protein transport across the NPC. The specificity 
of the NPC to allow certain proteins to be transported into the nucleus relies on various 
receptors on the surface of the pore and a hydrogel-like structure within the lumen of the 




Two hallmark ALS proteins, TDP-43 and FUS, are shuttled between the nucleus and the 
cytoplasm via the NPC, and there is evidence that this trafficking is damaged in ALS. 
Mutations in the nuclear localisation sequence of FUS account for approximately half of 
the ALS-related mutations found in the gene (Ling et al., 2013). In ALS pathology, a 
deficit of disease-related proteins such as TDP-43 in the nucleus and a build-up in the 
cytoplasm, suggests that the net movement across the NPC is shifted in the cytoplasmic 
direction (Chou et al., 2018). In studies of ALS patient cells and tissue, components of 
the nuclear pore are mislocalised and the expression of importins is reduced (Neumann 
et al., 2012; Nishimura et al., 2010; Takeuchi et al., 2013; Zhang et al., 2015b). This 
evidence indicates a role for damaged nucleocytoplasmic trafficking of proteins in ALS 
pathogenesis.  
 
1.1.4.3 RNA Toxicity  
RNA toxicity can arise via the sequestration of RNA and RNA binding proteins such as 
splicing and transcription factors. Certain RNA and RNA-binding proteins are 
sequestered in response to stress; these accumulate to form non-membrane bound 
organelles known as stress granules (Vance et al., 2013). The formation of stress 
granules occurs by a dynamic and reversible process known as liquid-liquid phase 
separation. It is thought that the sequestration of RNA and proteins in these granules 
reversibly reduces the activity of cellular process such as translation to preserve energy 
during the stress response. Dissociation of these granules then releases sequestered 
RNA and proteins, allowing these processes to resume (Baradaran-Heravi et al., 2020; 
Mandrioli et al., 2019; Vance et al., 2013). 
 
Many of the genes and proteins related to ALS, including TDP-43 and FUS, are RNA-
binding proteins involved in the processing of RNA and are sequestered into stress 
granules (Baradaran-Heravi et al., 2020; Vance et al., 2013; Zhang et al., 2018). Certain 
ALS-related mutations in proteins including TDP-43, FUS and Ataxin2 reduce the speed 
with which stress granules dissociate and increase their susceptibility to irreversible 
aggregation. This traps crucial RNA and RNA processing components in the stress 
granule, prolonging and enhancing the stress response of the cell (Zhang et al., 2018). 
 
1.1.4.4 Axonal transport dysfunction 
Organelles, proteins and other molecules in the cell require transport to their site of 
function; these sites can often be distant from their site of production. Motor neurons are 
the largest cells in the human body with axons of up to 1 m in length (Shaw, 1999). This 
creates potentially huge distances between soma and synapses and makes these cells 
highly reliant on the transport of cargos through axons. Axonal transport is driven by the 
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molecular motors kinesin and dynein which move along microtubules. Kinesins facilitate 
most anterograde transport; that from the cell body towards the synapse. Dynein 
facilitates most retrograde transport; from synapses to the cell body (Guedes-Dias and 
Holzbaur, 2019; Saxton and Hollenbeck, 2012; Sleigh et al., 2019).  
 
Damage to axonal transport is well reported in several models of ALS. In particular, 
disruption to the transport of mitochondria is commonly seen. The expression of Miro1, 
which mediates the binding of mitochondria to axonal transport motors, is decreased in 
ALS patient spinal cord tissue (Zhang et al., 2015a). Mutations in genes encoding 
components of the molecular motors responsible for axonal transport have been reported 
in ALS patients. These include DCTN, a subunit of the dynein complex and the molecular 
motor subunit KIF5A, (Brenner et al., 2018; Munch et al., 2005; Munch et al., 2004; 
Nicolas et al., 2018). Mitochondrial transport in axons is impaired in cells expressing 
ALS-causing mutants, including in TDP-43, VAPB and SOD1 (Moller et al., 2017; Morotz 
et al., 2012; Wang et al., 2013). Transgenic mouse models of ALS also show reduced 
expression of Miro1 and reduced numbers of mitochondria in axons, indicating transport 
deficits (Vande Velde et al., 2011; Zhang et al., 2015a).  
 
1.1.4.5 Excitotoxicity  
Excitotoxicity refers to damage caused to neurons due to overstimulation by 
neurotransmitters, which eventually leads to neuronal death. In ALS, excitotoxicity 
occurs due to excessive glutamatergic neurotransmission in motor neurons. This leads 
to an influx of ions such as calcium, which if not properly buffered leads to activation of 
calcium-induced apoptotic pathways. There are a number of mechanisms thought to lead 
to increased glutamate excitability of motor neurons in ALS (Blasco et al., 2014). 
 
Glutamate receptors including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptors (AMPARs) on the surface of motor neurons modulate calcium influx into the 
cell. Astroglia protect against excitotoxicity by removing glutamate from the extracellular 
neuronal environment, reducing the concentration of glutamate available to neurons and 
therefore reducing the capacity for stimulation (Starr and Sattler, 2018). Motor neurons 
derived from ALS patient induced pluripotent stem cells (iPSCs) and motor neurons from 
ALS mouse models show increased permeability of AMPARs to calcium. Glutamate 
uptake activity of astroglia is also reduced in ALS models. This combination reduces the 
calcium buffering ability of neurons and increases their susceptibility to calcium-induced 
cell death (Selvaraj et al., 2018; Starr and Sattler, 2018). Further evidence that glutamate 
excitotoxicity is a pathogenic mechanism in ALS is that Riluzole, one of only two 
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approved treatments for ALS, acts by inhibiting glutamatergic neurotransmission 
(Hinchcliffe and Smith, 2017; Miller et al., 2003).  
 
1.1.4.6 Inflammation 
Neuroinflammation is an inflammatory response within the central nervous system which 
stimulates the production of inflammatory molecules such as cytokines and activates 
microglia and astrocytes. Neuroinflammation is a protective response in healthy 
physiology but activation of neuroinflammation has been reported in a number of 
neurodegenerative diseases including ALS. It is now widely hypothesised that 
neuroinflammation begins as a protective response to neurodegenerative disease insults 
but becomes a damaging process during the course of the disease (Geloso et al., 2017; 
Komine and Yamanaka, 2015).   
 
In post-mortem patient tissue, glial activation, as measured by staining of GFAP and 
CD68 to indicate activated astrocytes and microglia respectively is a correlate of disease 
(Brettschneider et al., 2012). Imaging in ALS patients has shown that markers for 
activated glia are present early in disease and correlate with motor symptoms (Cagnin 
et al., 2004; Corcia et al., 2012; Turner et al., 2004). Glial activation is also a feature in 
a number of transgenic models of ALS including mutant SOD1 transgenic mice; in these 
mice microglial activation occurs before the onset of symptoms (Jara et al., 2017; Liao 
et al., 2012; McCauley and Baloh, 2019). In addition, mutant OPTN transgenic mice that 
model aspects of ALS display some necrosis which can be an inflammation-induced form 
of cell death (Ito et al., 2016). Finally, there is evidence of an increased systemic 
inflammatory response in ALS. Some transgenic mouse models of ALS display 
downregulated regulatory T cells and ALS patient blood is found to have increased levels 
of inflammatory markers and dysfunctional regulatory T cells (Beers et al., 2017; Zhao 
et al., 2012). 
 
1.1.4.7 Mitochondrial dysfunction and oxidative stress 
Damage to mitochondria results in bioenergetic deficiency due to impaired mitochondrial 
membrane potential, reduced electron transport chain activity and in turn reduced 
generation of ATP. A large body of work points to damage to mitochondria as a 
pathogenic mechanism in ALS. ALS patient tissue shows reduced oxidative 
phosphorylation indicative of defective ATP production (Jiang et al., 2015). ALS mutant 
proteins including FUS, TDP-43 and Valosin-containing protein (VCP) cause reduced 
ATP production and morphological damage to mitochondria which is seen in animal and 




Oxidative stress refers to the damage caused to cellular processes by free radicals and 
reactive oxygen species (ROS). ROS are produced by mitochondria and in healthy cells 
they can act as signalling molecules that are eventually converted to stable molecules. 
In damaged cells, mitochondrial dysfunction leads to ROS being produced in greater 
quantities and converted to stable molecules less efficiently. SOD1 catalyses the 
dismutation of the free radical species superoxide into hydrogen peroxide. Increased 
ROS are found in ALS mouse models including C9ORF72, TDP-43 and FUS models 
and in turn, oxidative damage has been shown to enhance the aggregation of FUS and 
TDP-43, suggesting a potential feed-forward loop for damage in ALS (Jiang et al., 2015; 
Smith et al., 2017). Finally Edaravone, an approved treatment for ALS, acts as a 
scavenger of free radicals to reduce oxidative stress (Group and Group, 2017; Rothstein, 
2017; Smith et al., 2017; Yoshino, 2019).  
 
1.1.4.8 ER stress and the unfolded protein response 
The ER UPR is a pathway activated in response to ER stress and is caused by the 
accumulation and misfolding of proteins in the ER. There are three pathways of the UPR 
which together aim to alleviate ER stress and to return proteostasis to normal levels. The 
first pathway involves activation of Protein kinase R (PKR)-like ER kinase (PERK) and 
Eukaryotic initiation of translation factor 2α (eIF2α) and leads to decreased global 
translation to reduce ER protein load. This same pathway also activates Activating 
Transcription Factor (ATF) 4, to increase the expression of genes involved in autophagy 
so as to clear misfolded proteins. The second pathway involves dimerization of Inositol-
requiring enzyme-1a (IRE1a) and activates alternative splicing to produce the active form 
of X-Box Binding Protein 1 (XBP1) which in turn increases the expression of protein 
folding chaperone genes and genes involved in ER-associated degradation (ERAD). The 
third pathway involves proteolysis of the transcription factor ATF 6 to enhance the 
expression of ERAD related genes (Bernales et al., 2006; Kanekura et al., 2009).  
 
As in many neurodegenerative diseases, dysfunction of the UPR is implicated in the 
pathogenesis of ALS. Misfolded or aggregated proteins such as TDP-43 and FUS, are 
hallmarks of the disease and indicate UPR dysfunction (Walker and Atkin, 2011). The 
expression of various UPR genes including VAPB are altered in ALS patient tissues and 
inhibiting UPR pathways reduced disease progression in a transgenic mouse model of 
ALS (Anagnostou et al., 2010; Jiang et al., 2014; Scheper and Hoozemans, 2015). 
Perhaps most compelling is the evidence that mutations in VAPB, which functions in the 





1.1.4.9 ER-mitochondrial signalling damage 
The ER serves vital functions in the cell, including folding of proteins, storage of calcium 
and the UPR. The primary function of mitochondria is the generation of energy in the 
form of ATP. Many of the functions of ER and mitochondria require communication 
between these two organelles. There is now evidence that ER-mitochondria signalling 
and communications are disrupted in several neurodegenerative diseases including ALS 
(Csordas et al., 2006; Lau et al., 2018; Paillusson et al., 2016; Rowland and Voeltz, 
2012). Damage to ER-mitochondria signalling is the focus of this work and is therefore 
discussed in detail below.   
 
1.2 ER-mitochondrial signalling  
1.2.1 ER-mitochondrial signalling regulates a number of fundamental cellular 
processes 
As mentioned above, some of the primary roles of the ER include protein and lipid 
synthesis and the storage of calcium. Likewise, mitochondria control important cellular 
functions, especially the generation of energy in the form of ATP via oxidative 
phosphorylation, apoptosis and calcium signalling. Many ER and mitochondrial functions 
require communication between the two organelles. In order to facilitate these 
communications, ER and mitochondria are physically tethered to form close contacts (10 
to 30 nm distances). The regions of ER associated with mitochondria are known as 
mitochondria-associated ER membranes (MAM) (Csordas et al., 2006; Lau et al., 2018; 
Paillusson et al., 2016; Rowland and Voeltz, 2012). Below, the major functions of ER-
mitochondria contacts and signalling are discussed.  
 
1.2.1.1 Calcium signalling and ATP production 
ATP production by the mitochondria is critically dependant on calcium, because this 
stimulates the activity of the calcium dependant dehydrogenase enzymes in the 
tricarboxylic acid cycle (Griffiths and Rutter, 2009). The ER is the primary source of 
intracellular calcium, from where it is released at ER-mitochondria contact sites via 
Inositol trisphosphate receptors (IP3Rs). Calcium uptake into the mitochondria occurs 
via Voltage dependant anion channels (VDACs) in the outer mitochondrial membrane 
and the mitochondrial calcium uniporter (Csordas et al., 2006; Lau et al., 2018; 
Paillusson et al., 2016; Rowland and Voeltz, 2012). 
 
For the efficient transfer of calcium, the concentration of calcium ions at the mitochondrial 
membrane must be sufficiently high. IP3Rs are clustered at ER-mitochondria contact 
sites, aided by the chaperone Sigma1R (Hayashi and Su, 2007; Ryskamp et al., 2019) 
and interact with VDAC, as mediated by the molecular chaperone glucose-regulated 
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protein 75 (grp75) (Szabadkai et al., 2006). Areas of IP3R clustering enable high local 
calcium concentrations when calcium is released from the ER. This enhances the 
efficiency with which the required calcium concentration for uptake is reached and 
increases both the speed and amount of calcium transfer from ER to mitochondria 
(Giacomello et al., 2010; Lau et al., 2018; Paillusson et al., 2016).  
 
Whilst delivery of calcium to mitochondria is beneficial in stimulating ATP production, 
excessive delivery of calcium to mitochondria can be detrimental. This is because 
excessively high levels of mitochondrial calcium stimulate opening of the mitochondrial 
permeability transition pore which stimulates signals for apoptosis (Hurst et al., 2017).  
 
1.2.1.2 Phospholipid biosynthesis 
The ER is the major site of lipid production and this represents another function facilitated 
by close contact between the ER and the mitochondria (Rowland and Voeltz, 2012). 
Several of the most abundant phospholipids including Phosphatidylserine (PS), 
Phosphatidylethanolamine (PE) and Phosphatidylcholine (PC) are synthesised in an as 
yet undefined multistep process involving various enzymes. A number of the synthase 
enzymes involved in these steps reside at MAM or the inner mitochondrial membrane. 
Some lipid synthesis therefore relies on efficient exchange of precursor lipids between 
the ER and mitochondria and close contacts between ER and mitochondria facilitate this 
exchange (Filadi et al., 2017; Rusinol et al., 1994; Stone and Vance, 2000; Vance, 1990). 
As an example, synthesis of PE and PC which are the two most abundant phospholipids 
in mammalian cells commences in MAM via conversion of phosphatidic acid to PS by 
phosphatidylserine synthase. This is then transported to mitochondria and converted to 
PE which is transported to MAM for conversion to PC which is in turn transported back 
to mitochondria (Rowland and Voeltz, 2012).   
 
1.2.1.3. Mitochondrial biogenesis    
ER-mitochondria contact sites also regulate mitochondrial biogenesis and division. 
Mitochondria with damaged DNA fuse with other mitochondria to enable recombining of 
this DNA to generate a complete and correct mitochondrial genome. Mitofusin 1 and 2 
regulate mitochondrial fusion and reside at ER-mitochondria contact sites (Chen et al., 
2003; Cosson et al., 2012; de Brito and Scorrano, 2008; Koshiba et al., 2004; Leal et al., 
2016; Naon et al., 2016). 
 
In addition, FUN14 Domain-Containing Protein 1 (FUNDC1) plays a crucial role in 
mitochondrial turnover by recruiting Dynamin related protein 1 (DRP1) during mitophagy 
to enable mitochondrial fission. FUNDC1 is also enriched at MAM (Wu et al., 2016a; Wu 
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et al., 2016b). Mitochondrial division has been found to occur in close association with 
the ER and it is thought that ER tubules physically aid division by wrapping around and 
constricting mitochondria along with actin filaments (Friedman et al., 2011; Korobova et 
al., 2013). Finally, mitochondrial DNA (mtDNA) synthesis occurs at ER-mitochondria 
contact sites. There is evidence for a role for these contacts in the coupling of mtDNA 
replication with mitochondrial division to ensure the correct distribution of mtDNA (Lewis 
et al., 2016).  
 
1.2.1.4 Mitochondria and ER trafficking and transport 
ER-mitochondria contact is also implicated in the transport of both organelles along 
axons. Mitochondria and ER are transported along microtubules anterogradely by the 
molecular motor kinesin-1. Attachment of mitochondria to the kinesin-1 motor is 
mediated by binding of the outer mitochondrial membrane protein Miro-1 to Trafficking 
Kinesin Proteins (TRAKs)  which interact with kinesin-1 (Macaskill et al., 2009; Saotome 
et al., 2008). Miro-1 is a calcium sensing protein found localised at ER-mitochondria 
contact sites (Kornmann et al., 2011). Calcium causes Miro-1 to detach from KIF5A of 
the kinesin motor, preventing further movement of mitochondria along the microtubules 
(Macaskill et al., 2009). Since Miro-1 is found at ER-mitochondria contact sites and these 
contacts mediate local calcium concentrations, it is likely that ER-mitochondria contacts 
affect the transport of mitochondria via Miro-1. In addition to this, mitochondria and ER 
have been shown to remain in contact during transport along microtubules (Friedman et 
al., 2010). Together this evidence suggests that ER-mitochondria contacts play a role in 
the co-transport of the organelles.  
 
1.2.1.5 Inflammasome formation 
ER-mitochondria contacts sites are also implicated in the formation of inflammasomes. 
The inflammasome is a multiprotein oligomer of the immune system which activates 
inflammatory responses (Gross et al., 2011; Missiroli et al., 2018). Tissue and cell 
damage are sensed by pattern recognition receptors such as the NOD-like receptors 
(NLRs) which are a part of the innate immune system and form an inflammasome. This 
complex of NLRs stimulates the cleavage of interleukin 1β into its active form to induce 
the activation of an inflammatory response (Gross et al., 2011). One of these NLRs, 
known as NLRP3 localises to ER-mitochondria contact sites and recent research has 
found that the cell stressors such as ROS, produced by the mitochondria, stimulate 
relocation of NLRP3 to ER-mitochondria contact sites (Zhou et al., 2011). ER-





1.2.1.6 Proteostasis; the ER unfolded protein response and autophagy 
Proteostasis is the balance of protein synthesis, folding, modification and degradation 
that is required to maintain the correct expression levels of functional proteins within the 
cell. The ER plays an important role in proteostasis, being responsible for the correct 
folding of proteins and responding to abnormal proteostasis through the UPR.  
 
As detailed above the UPR is a cellular response which is induced due to an 
accumulation of unfolded proteins in the ER (Bernales et al., 2006; Kanekura et al., 
2009). A number of ER resident protein folding chaperones including Binding 
immunoglobulin protein (BiP), calnexin, calreticulin and the Sigma1R require calcium for 
their chaperone activity and are found to be localised to ER-mitochondria contact sites 
(Hayashi and Su, 2007; Simmen et al., 2010). Moreover, VAPB which is an ER-
mitochondria tethering protein, has been shown to modulate the UPR (Gkogkas et al., 
2008; Kanekura et al., 2006). There is also evidence that ER-mitochondria contacts and 
related bioenergetics are crucial for regulating whether the UPR acts to restore 
proteostasis or stimulates apoptotic pathways (Bravo et al., 2011; Cardenas et al., 2010). 
 
Autophagy is a degradative process for proteins that is used to recycle obsolete cellular 
constituents and remove damaged organelles and protein aggregates. It involves 
transport of damaged proteins and organelles to an organelle known as the aggresome. 
Elimination of damaged substrates at the aggresome then involves their delivery to lyso-
somes via autophagosomes, where lysosomal enzymes digest the components so that 
their individual components (e.g. amino acids) can be recycled by the cell (Nixon et al., 
2013; Rubinsztein et al., 2012). 
 
A number of lines of evidence support the idea that ER-mitochondria contacts regulate 
autophagy. Firstly, autophagosomes have been shown to form at ER-mitochondria con-
tact sites (Hamasaki et al., 2013). Secondly, inhibition of the delivery of calcium to the 
mitochondria by IP3Rs located at MAM, induces autophagy (Cardenas and Foskett, 
2012; Cardenas et al., 2010; Gomez-Suaga et al., 2017a; Sarkar et al., 2005). Finally, 
experimental manipulation of ER-mitochondria contact sites has been shown to regulate 
autophagy (Gomez-Suaga et al., 2017b; Hamasaki et al., 2013; Mao et al., 2019). How-
ever, not all of these results are consistent, with some studies showing that increasing 
ER-mitochondria contacts and signalling stimulates, whereas others show that it inhibits, 





1.2.2 ER-mitochondrial signalling is mediated by tethering proteins 
Studies investigating the ER and mitochondria by electron microscopy identified ER-
mitochondria contact sites. These studies revealed the presence of structures which 
appear to act as physical tethers between the membranes of the two organelles (Csordas 
et al., 2006; Csordas et al., 2010; Lau et al., 2018; Paillusson et al., 2016). Further 
studies have identified ER and mitochondrial proteins which interact to form these 
structures and some of which specifically function as tethers between ER and 
mitochondria. Proteins found at ER-mitochondria contact sites are shown in Figure 1.1. 
VAPB and PTPIP51 (dark red and dark blue) are the focus of this thesis and the rationale 
for this, including discussion of the current knowledge about each of the ER-mitochondria 
resident proteins, is discussed below.  
 
 
Figure 1.1: Protein interactions found at ER-mitochondria contact sites 
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In yeast, proteins of the ER-mitochondria encounter structure (ERMES) act as tethers 
(Kornmann et al., 2009). The ER protein PDZ domain containing protein 8 (PDZD8) has 
recently been proposed as an ortholog of the ERMES protein Maintenance of mitochon-
drial morphology protein 1 (Mmm1) (Hirabayashi et al., 2017). Knock down of PDZ in 
mammalian cells significantly reduced ER-mitochondria contacts, however rescue of 
broken ER-mitochondria contacts by PDZ8 has not yet been evidenced so it cannot be 
concluded that PDZ8 directly tethers the two organelles. In addition, current studies are 
yet to identify a mitochondrial interacting partner for PDZ8. 
 
Mitofusin-2 has been proposed a number of times as a physical tether of ER-
mitochondrial membranes (de Brito and Scorrano, 2008; Naon et al., 2016). Mitofusin-2 
is found in both ER and mitochondrial membranes and is able to form homodimers 
between the two membranes as well as binding to Mitofusin-1 in the mitochondrial 
membrane. However, more recent studies have shown that knockdown of Mitofusin-2 
does not reduce the contact between ER and mitochondrial membranes and as such 
there is question over the role of Mitofusin proteins in ER-mitochondria contacts (Cosson 
et al., 2012; Filadi et al., 2015; Leal et al., 2016; Wang et al., 2015). 
 
As previously discussed, IP3Rs reside in the ER membrane and VDACs reside in the 
mitochondrial membrane. Both proteins are found to be enriched at sites of ER-
mitochondrial membrane contact and interact via glucose-regulated protein 75 (Grp75) 
(Rapizzi et al., 2002; Szabadkai et al., 2006), making them a likely ER-mitochondria 
tether. However, studies in which IP3R is knocked out showed no effect on the presence 
of ER-mitochondria contacts, as would be expected if IP3R-VDAC binding did indeed 
tether the two membranes (Csordas et al., 2006). A more recent study, in which all three 
isoforms of IP3R are addressed, has revisited the possibility that IP3R-VDAC 
interactions tether ER and mitochondrial membranes (Bartok et al., 2019). There is still 
no consensus as to whether this interacting pair act to provide structure and regulate the 
presence of ER-mitochondria contacts or solely function to exchange calcium at MAM.  
ER protein B-cell receptor-associated protein 31 (Bap31) and mitochondrial membrane 
protein Fission protein 1 (Fis1) form complexes at ER-mitochondrial membranes and 
facilitate signalling to induce apoptosis (Iwasawa et al., 2011). Whether these proteins 
act as tethers or act solely as signalling molecules at contact sites is not yet known. 
 
Likewise, Phosphofurin acid cluster sorting protein 2 (PACS-2) is enriched at ER-
mitochondria contacts and depletion of the protein results in reduced ER-mitochondria 
contacts (Simmen et al., 2005). However, PACS-2 depletion causes fragmentation of 
mitochondria which could be responsible for the reduction in ER-mitochondria contact 
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(Simmen et al., 2005). PACS-2 is also involved in organelle trafficking and signalling to 
the nucleus (Atkins et al., 2014; Youker et al., 2009). It is not yet clear how these 
functions relate to ER-mitochondria signalling and it remains possible that PACS-2 plays 
a functional rather than structural role at ER-mitochondria contact sites.  
 
A further proposed tether involves the outer mitochondrial membrane protein 
Synaptojanin 2 binding protein (SYNJ2BP) which has been shown to interact with 
Ribosome-binding protein 1 (RRBP1). This interaction mediates contact sites between 
mitochondria and rough ER membranes (Hung et al., 2017). The SYNJ2BP-RRBP1 
interaction may be a specific ER-mitochondria tether for rough ER.  
 
1.2.2.1 VAPB and PTPIP51 ER-mitochondria tethers  
Finally, an interaction between the integral ER membrane protein VAPB and the outer 
mitochondrial membrane protein Protein tyrosine phosphatase interacting protein of 51 
kDa (PTPIP51) has been identified as a tether between ER and mitochondria. Tethering 
between VAPB and PTPIP51 is the focus of this thesis.  
 
VAPB is anchored into the ER membrane by a C-terminal ER-targeting sequence and 
its N-terminus projects into the cytosol. VAPB also comprises an alpha helical coiled-coil 
domain and an N-terminal motile sperm protein (MSP) domain which is structurally sim-
ilar to the C. elegans major sperm protein (Figure 1.2) (De Vos et al., 2012). PTPIP51 is 
anchored into the outer mitochondrial membrane by an N-terminal mitochondrial target-
ing sequence and its C-terminus projects into the cytosol. PTPIP51 also comprises an 
alpha-helical coiled-coil domain, four low complexity regions and a C-terminally located 
tetratricopeptide repeat (TPR) domain (Figure 1.3) (De Vos et al., 2012). TPR domains 






Figure 1.2: Domain structure of VAPB. MSP, motile sperm domain. CC, coiled-coil 




Figure 1.3: Domain structure of PTPIP51. TM, transmembrane domain. CC, coiled-
coil domain. TPR, tetratricopeptide repeat domain.  
 
Work from our group identified VAPB and PTPIP51 as direct binding partners using both 
recombinant and in vitro assays including yeast-two hybrid, immunoprecipitation and 
glutathione S transferase (GST)-pull downs (De Vos et al., 2012; Stoica et al., 2014).  
There is much evidence that this interaction forms a physical tether between areas of 
ER and mitochondrial membranes and mediates ER-mitochondrial signalling. In cells, 
VAPB and PTPIP51 co-localise at sites of ER-mitochondria contact (Stoica et al., 2014). 
More importantly, knockdown of either VAPB or PTPIP51 significantly reduces the 
contact between ER and mitochondrial membranes, as measured in electron microscopy 
studies. Knockdown of both proteins together reduces this contact even further and over 
expression of either protein increases the amount of mitochondrial membrane in contact 
with ER  (Morotz et al., 2012; Stoica et al., 2014). 
 
Altering the expression of VAPB or PTPIP51 also affects downstream function of ER-
mitochondria membrane contact. This is evidenced by studies of calcium transfer in 
which reduced expression of either VAPB or PTPIP51 leads to a significant increase in 
the lag time between ER calcium release and mitochondrial calcium uptake. These 
studies also show significantly reduced mitochondrial calcium concentration overall, 
suggesting not only a slower but also a less efficient transfer of calcium from the ER to 
the mitochondria (De Vos et al., 2012; Morotz et al., 2012; Stoica et al., 2014). These 
experiments confirm that binding between VAPB and PTPIP51 is necessary for the 
contact between ER and mitochondrial membranes and identifies them as tethering 
molecules which mediate ER-mitochondrial signalling. Importantly, other studies have 
also identified VAPB and PTPIP51 as ER-mitochondria tethering proteins (Di Mattia et 
al., 2018; Galmes et al., 2016; Huttlin et al., 2015; Puri et al., 2019; Qiao et al., 2017; 




There is also evidence that VAPB and PTPIP51 may interact with other ER and 
mitochondrial proteins to function as tethers. VAPB binds to the outer mitochondrial 
membrane protein Mitoguardin 2 (MIGA2). PTPIP51 has been shown to bind to 
Oxysterol binding protein-related proteins ORP5 and ORP8 which are also found at ER-
mitochondria contact sites, and a VAPB homologue termed Motile sperm domain 
containing protein-2 (MOSPD2) (Di Mattia et al., 2018; Freyre et al., 2019; Galmes et al., 
2016). 
 
In mediating ER-mitochondria contact, VAPB-PTPIP51 binding is also expected to 
regulate some of the functions reliant on ER-mitochondria signalling that are discussed 
in 1.2.1. In addition to the evidence already discussed of the role for VAPB-PTPIP51 in 
calcium exchange, there is emerging evidence that they regulate functions including 
autophagy, energy metabolism, and in particular mitochondrial ATP production (Gomez-
Suaga et al., 2017b; Paillusson et al., 2017). Importantly, VAPB-PTPIP51 interactions 
have been shown to be dynamic which is an important feature when considering whether 
an interaction acts to regulate dynamic cellular processes. In response to stimulating 
synaptic activity, VAPB-PTPIP51 binding increases (Gomez-Suaga et al., 2019) and it 
can be considered that this is to stimulate ATP production for the energy dependant 
activity of synapses.  
 
How the dynamics of VAPB-PTPIP51 binding is mediated has not yet been fully 
elucidated. However, Glycogen synthase kinase 3 beta (GSK-3β) activity has been found 
to affect the VAPB-PTPIP51 interaction. Activation of GSK-3β inhibits VAPB-PTPIP51 
binding and reduces ER-mitochondria contacts, whilst inhibition of GSK-3 stimulates 
VAPB-PTPIP51 binding and ER-mitochondria contacts (Stoica et al., 2014; Stoica et al., 
2016). The mechanism by which GSK-3 affects the interaction is as yet unknown and 
investigating this mechanism forms part of this thesis.  
 
1.2.3 ER-mitochondrial signalling in neurodegenerative disease 
Alzheimer’s disease (AD), Parkinson’s disease (PD) and ALS are major 
neurodegenerative diseases and yet there are currently no effective treatments for them. 
There is therefore a pressing need for novel drug targets for these diseases. Many 
physiological processes within the cell are disrupted in AD, PD and ALS including 
mitochondrial function, the ER UPR, axonal transport, autophagy, calcium homeostasis, 
lipid metabolism and the inflammatory response. Disruption to these cellular functions 





As discussed in 1.2.1 and 1.2.2, signalling between the ER and mitochondria is 
necessary for a number of cellular functions, including some of those processes that are 
disrupted in neurodegenerative diseases. There is emerging evidence that ER-
mitochondria contacts are altered in various neurodegenerative diseases, suggesting 
disruption to these contact sites as a potential common disease mechanism, and a 
potential novel therapeutic target.  
 
Perhaps the two most convincing lines of evidence that ER-mitochondrial signalling plays 
a role in neurodegenerative disease is that genetic mutations in proteins facilitating ER-
mitochondria contacts can cause ALS and that correcting ER-mitochondrial signalling is 
protective in models of disease. Mutations in the ER-mitochondria tether VAPB and the 
IP3R chaperone Sigma1R which is enriched at ER-mitochondria contacts have been 
found to cause ALS (Al-Saif et al., 2011; Bernard-Marissal et al., 2015; De Vos et al., 
2012; Hayashi and Su, 2007; Luty et al., 2010; Nishimura et al., 2004; Watanabe et al., 
2016). Similarly, increasing ER-mitochondria contacts by expression of tethering protein 
VAPB is protective in alpha-synuclein cell models of PD and in a mutant SOD1 model of 
ALS (Kim et al., 2016; Paillusson et al., 2017). 
 
There is much evidence that ER-mitochondria contacts and signalling are disrupted in 
AD, PD and most convincingly in ALS. This evidence suggests the potential for novel 
therapeutic targets and is discussed below.  
 
1.2.3.1 Alzheimer’s Disease 
AD is a late onset neurodegenerative disease. It is characterised by extracellular 
accumulations of the protein amyloid beta (A) and cytoplasmic accumulation of the 
protein tau in the brain (Goedert and Spillantini, 2006). A is formed by cleavage of 
Amyloid precursor protein (APP) by enzymes known as β-secretase and -secretase. 
Presenilin-1 and -2 (PSN1 and2) are the catalytic components of -secretase and some 
familial forms of Alzheimer’s disease are caused by mutations in presenilin proteins or 
APP (Goedert and Spillantini, 2006; Schellenberg and Montine, 2012). 
 
Presenilin proteins are found to be enriched at sites of ER-mitochondria membrane 
contact (Area-Gomez et al., 2009) and A peptides are reported to be produced at ER-
mitochondria contact sites (Schreiner et al., 2015). There is much experimental evidence 
that ER-mitochondria contacts and signalling are altered in AD, but there is not yet a 




Animal and cell studies of AD-mutant PSN2 have shown conflicting effects, with some 
reporting increases in ER-mitochondrial colocalization and others reporting reduced 
mitochondrial calcium uptake as would be expected in response to a decrease in ER-
mitochondria contact (Area-Gomez et al., 2012; Kipanyula et al., 2012). A and APP cell 
and animal models have also reported both increased and disrupted ER-mitochondria 
contacts (Del Prete et al., 2017; Hedskog et al., 2013; Martino Adami et al., 2019). In 
addition, cell models mimicking the biggest genetic risk factor for AD, ApoE4 also appear 
to increase ER-mitochondrial signalling (Tambini et al., 2016). 
 
Differences in the sensitivity with which ER-mitochondria contact or co-localisation may 
account for some of the discrepancies between studies, as may the use of different 
assays and quantification methods (Paillusson et al., 2016). It is however clear that ER-
mitochondria contacts are altered in AD. Finally, work in our lab, alongside that described 
in this thesis, has found that ER-mitochondria contacts as measured by VAPB-PTPIP51 
binding, are reduced in the brains of early AD patients (manuscript in submission).  
 
1.2.3.2 Parkinson’s Disease 
PD is a neurodegenerative disease characterised by intraneuronal inclusions of the 
protein alpha-synuclein and loss of dopaminergic neurons. A number of genetic causes 
of PD have been identified. These include mutations in alpha-synuclein, Leucine rich 
repeat kinase 2 (LRRK2) and mitochondrial proteins PTEN-induced kinase 1 (PINK1), 
Parkin and Deglycase (DJ-1) (Balestrino and Schapira, 2020; Simon et al., 2020).   
 
There are a number of studies pointing to the disruption of ER-mitochondrial signalling 
in PD. For example, the major protein contributing to PD pathology, alpha-synuclein, is 
found to be enriched at ER-mitochondria contact sites (Guardia-Laguarta et al., 2014; 
Paillusson et al., 2017). It has also been shown that alpha-synuclein disrupts contacts at 
these sites by binding to the ER-mitochondrial tether VAPB and thereby reducing its 
interaction with the tethering protein PTPIP51 (Paillusson et al., 2017). PD-related 
mutations in alpha-synuclein also lead to disruption of ER-mitochondria contacts 
(Guardia-Laguarta et al., 2014). Indeed, neurons generated from iPSCs derived from PD 
patients harbouring alpha-synuclein triplication displayed reduced ER-mitochondrial 
membrane tethering when compared to iPSC-neurons derived from control donors 
(Paillusson et al., 2017). 
 
LRRK2 mutations, which cause most familial PD, have been shown to modulate ER-
mitochondria signalling (Toyofuku et al., 2019). Notably, LRRK2 mutant G2019S, which 
is one of the most common mutations, causing 2 % of PD, stimulates degradation of 
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some ER-mitochondrial tethering proteins by E3 ubiquitin ligase activity. G2019S mutant 
LRRK2 therefore reduces ER-mitochondria contacts (Toyofuku et al., 2019). PD-related 
mutations are also found in the protein DJ-1 which itself is found at ER-mitochondria 
contacts. PD-related mutation in DJ-1 alters its interaction with IP3R3-Gpr75-VDAC and 
in turn disrupts ER-mitochondria contacts (Liu et al., 2019).  
 
There is currently contrasting evidence on the role of Parkin in ER-mitochondria contacts 
in PD. Fibroblasts from humans with mutations in the gene encoding Parkin have been 
reported to display increased ER-mitochondria contacts in one study (Gautier et al., 
2016) and reduced ER-mitochondria contacts in another (Basso et al., 2018). In vitro, 
Parkin knock down experiments have shown reductions in ER-mitochondria contacts 
and damage to mitochondria (Cali et al., 2013b). Changes in ER-mitochondria contacts 
have also been found to affect the regulation of mitophagy in PD (Gelmetti et al., 2017; 
Puri et al., 2019). Whilst there is not yet a consensus on the precise effect, there is much 
evidence that ER-mitochondrial signalling is altered in PD.  
 
1.2.3.3 Amyotrophic Lateral Sclerosis 
Evidence that ER-mitochondria contacts are affected in neurodegenerative disease is 
perhaps strongest in the case of ALS. There is a detailed body of evidence showing that 
VAPB-PTPIP51 interactions and consequently ER-mitochondrial signalling are disrupted 
in both in vitro and in vivo models of ALS.  
 
Overexpression of either WT or familial disease causing mutant TDP-43 reduces the 
extent of ER-mitochondria contacts, as measured in electron microscopy studies. Upon 
stimulation of neurons over-expressing WT or ALS-mutant TDP-43, ER-mitochondria 
calcium transfer is reduced, indicating disruption to a major function of ER-mitochondria 
contacts. Co-immunoprecipitation studies show that this effect is due to reduced binding 
between VAPB and PTPIP51 (Stoica et al., 2014).  
 
Similarly, overexpression of both WT and ALS-mutant FUS disrupts ER-mitochondria 
contacts as measured by electron microscopy and calcium transfer in cell and transgenic 
animal models. This effect is caused by reduced VAPB-PTPIP51 binding, as shown 
directly by immunoprecipitation and by proximity ligation assays (PLAs), which stain for 
proteins in close proximity (Stoica et al., 2016). Evidence that both WT and mutants of 
TDP-43 or FUS disrupt ER-mitochondria contacts aligns with evidence that over-
expression of WT or mutant TDP-43 or FUS cause disease in transgenic mice (Mitchell 




The mechanism by which TDP-43 and FUS alter ER-mitochondria contacts in ALS is yet 
to be fully identified, but initial studies have indicated a role for kinases in regulating the 
binding of ER-mitochondria tethering proteins. The ubiquitously expressed serine 
threonine kinase GSK-3β is activated by TDP-43 and FUS and in turn disrupts ER-
mitochondrial signalling by reducing the binding between VAPB and PTPIP51 (Stoica et 
al., 2014; Stoica et al., 2016). 
 
In humans, the most direct indication for a role of ER-mitochondrial signalling in disease 
is the identification of point mutations in the ER-mitochondrial tether VAPB, which cause 
ALS (Nishimura et al., 2004). ALS-causing mutant VAPB P56S has increased affinity for 
PTPIP51 in vitro, however evidence suggests that mutant VAPB sequesters WT VAPB, 
reducing the overall amount of functional VAPB in patients (Teuling et al., 2007). 
Furthermore, it has been shown in vivo that overexpression of VAPB slows impairment 
of motor neurons (Kim et al., 2016), though the mechanism by which VAPB is protective 
is not yet fully understood. VAPB expression is reduced in iPSC-derived neurons from 
ALS patients harbouring the VAPB P56S mutation (Mitne-Neto et al., 2011) and 
importantly, VAPB expression is reduced in the spinal cord of sporadic ALS patients 
(Anagnostou et al., 2010).  
 
As previously discussed, Sigma1R acts as a chaperone to induce IP3R clustering at ER-
mitochondria contact sites and therefore enhances the efficiency of calcium transfer 
(Bernard-Marissal et al., 2015; Hayashi and Su, 2007). Loss of function mutations in 
Sigma1R have been reported to cause cases of familial ALS (Al-Saif et al., 2011; 
Bernard-Marissal et al., 2015; Dreser et al., 2017; Gregianin et al., 2016; Luty et al., 
2010; Ullah et al., 2015) and polymorphisms in IP3R have been linked to ALS in patients 
(van Es et al., 2007). The gene encoding Sigma1R resides on chromosome 9, and as 
such it has been suggested that the mutations found to cause ALS may be linked to 
C9ORF72, also found on chromosome 9 (Belzil et al., 2013), but recent studies have 
confirmed the role of Sigma1R mutations in ALS and identified reduced ER-mitochondria 
signalling (Bernard-Marissal et al., 2015; Gregianin et al., 2016; Watanabe et al., 2016).  
 
Mutations in the SOD1 gene were the first to be identified as a cause of familial ALS. 
ALS-mutant SOD1 also disrupts ER-mitochondria signalling (Watanabe et al., 2016), 
although the mechanisms by which this occurs are as yet unclear. However, ALS-mutant 
SOD1 is thought to interact with VDAC1 and affect its ability to act as a channel for the 
transfer of molecules such as ATP and calcium across the mitochondrial membrane 
(Israelson et al., 2010). Similarly, mutant SOD1 has been shown to cause loss of 
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Sigma1R at ER-mitochondria contacts, affecting ER-mitochondria signalling (Watanabe 
et al., 2016).  
 
This body of evidence indicates ER-mitochondria contacts as a potential therapeutic 
target for ALS. However, ER-mitochondria contacts have yet to be investigated in human 
ALS patients, and the mechanisms by which ER-mitochondria contacts are disrupted in 
ALS are yet to be elucidated.  
 
1.3 Hypothesis and study aims 
As detailed above, ER-mitochondria signalling regulates many of the functions which are 
damaged in ALS. Much evidence shows that these ER-mitochondria contacts, and the 
tethering interaction between VAPB and PTPIP51, are themselves disrupted in ALS. To 
date, this evidence only exists in animal and cell models of the disease. GSK-3β has 
been identified as a mediator of VAPB-PTPIP51 binding but the full mechanism by which 
VAPB-PTPIP51 binding is damaged in ALS is yet to be elucidated. As such, there are 
two hypotheses underlying this thesis; firstly, that ER-mitochondria contacts are 
disrupted in humans with ALS and secondly that VAPB-PTPIP51 binding is regulated by 
phosphorylation including via GSK-3β.  
 
There are many studies in cell and transgenic animal models of ALS including TDP-43, 
FUS and SOD1 models, in which ER-mitochondria signalling is linked to familial ALS 
(Bernard-Marissal et al., 2015; Israelson et al., 2010; Stoica et al., 2014; Stoica et al., 
2016; Watanabe et al., 2016). This body of evidence suggests that ER-mitochondria 
contacts are a potential therapeutic target for disease. However, ER-mitochondria 
signalling is yet to be studied in human versions of the disease and there is a particular 
lack of information about the approximately 90-95 % of ALS cases which are not familial. 
Therefore, the first hypothesis of this thesis was that ER-mitochondria contacts, as 
mediated by VAPB-PTPIP51 binding, are disrupted in human ALS.  
 
Firstly, this hypothesis was addressed by measuring the expression and binding of VAPB 
and PTPIP51 in post-mortem spinal cord samples from sporadic ALS patients and 
control donors. VAPB and PTPIP51 protein levels and binding were measured by 
immunoblotting and PLAs. Secondly, to test this hypothesis in familial ALS, motor 
neurons derived from iPSCs (iPSC-MNs) from control donors and two ALS patients 
carrying TDP-43 mutations were investigated.  
 
Studies of ER-mitochondria contacts in TDP-43 and FUS models of ALS have found that 
VAPB-PTPIP51 binding is disrupted by TDP-43 and FUS via activation of GSK-3β 
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(Stoica et al., 2014; Stoica et al., 2016). The mechanism by which GSK-3β reduces 
VAPB-PTPIP51 binding is as yet unknown. However, as GSK-3β is a ubiquitously 
expressed kinase and phosphorylation is a common regulator of protein-protein 
interactions. The second hypothesis of this thesis was therefore that GSK-3β 
phosphorylates either VAPB or PTPIP51 to disrupt their binding affinity. 
 
To test this hypothesis, firstly recombinant VAPB and PTPIP51 were incubated with 
GSK-3β and analysed for phosphorylation sites by mass spectrometry. Secondly, to 
identify phosphorylation in cells, VAPB and PTPIP51 isolated from cells overexpressing 
GSK-3β were analysed for phosphorylation sites by mass spectrometry.  
 
The overall aims of this study were to support the idea that correcting damaged ER-
mitochondria contacts is a novel therapeutic target for ALS and to begin to identify the 





























Unless otherwise stated, chemicals were purchased from Sigma Aldrich (Dorset, UK), 
cell culture reagents were purchased from ThermoFisher Scientific (Loughborough, UK) 
and cell culture plates and flasks were from Corning (Amsterdam, The Netherlands). 
Ultrapure water used in solutions and buffers was from a Milli-Q purification system 
(Merck Millipore; Watford, UK). Sterilisation of solutions for molecular biology and cell 
culture was carried out by autoclaving at 121 °C and 101 kPa for 20 min.   
 
2.1.1 Antibodies 
Antibodies were purchased from Cell Signalling Technology (Leiden, The Netherlands), 
Sigma Aldrich, Dako (Cambridge, UK), Jackson Immunoresearch (Ely, UK), Merck 
Millipore (Watford, UK), Abcam (Cambridge, UK), Santa Cruz (Heidelberg, Germany), 
ThermoFisher Scientific, Atlas (Bromma, Sweden), Synaptic Systems (Goettingen, 
Germany) and Gentex (Hsinchu City, Taiwan) and are detailed in Table 2.1. Primary 
antibodies against VAPB and PTPIP51 made “in house” were raised in rabbits or rats by 
immunization with glutathione S-transferase (GST)-VAPB(1-220) and GST-PTPIP51(36-
470), respectively as previously described (De Vos et al., 2012). 
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Mouse IgG Dako Rabbit 1:5000 HRP 0447 
 
Rabbit IgG Dako 
Polyclonal 
Goat 
1:5000 HRP 0448 
 


























    
Antibody  Supplier Cat no. 
   






Conjugated to PLA 
Probe-maker PLUS  
712-005-153 
































Conjugated to Rat IgG 
 
DUO92009 




E-Coli expression vectors pET28A-His-VAPB(1-220) and pGEX5X-PTPIP51(36-
470) used to produce recombinant protein were as previously described (Stoica et al., 
2014). Mammalian expression vectors were pCIneo control vector from Addgene 
(Massachusetts, USA) and amino-terminal myc-tagged VAPB (myc-VAPB) and carboxy-
terminal HA-tagged PTPIP51 (HA-PTPIP51) in pCIneo as previously described (De Vos 
et al., 2012).  
 
Mammalian expression vectors expressing full length GAL4 (pSG4+), GAL4-DNA 
binding domain (DBD, pM1) and VP16 DNA trans-activation domain (pVP16) were 
generated by Dr. Sarah Müller using vectors previously described (Sadowski et al., 
1992; Sadowski et al., 1988). Renilla luciferase pRL-CMV and firefly luciferase pG5-luc 
vectors were from Promega (Hampshire, UK). Expression vectors for GAL4 DBD-
VAPB(1-220) (pM1-VAPB(1-220)) and VP16-PTPIP51(36-470) were produced by Dr. 
Sarah Müller (unpublished work) using previously described plasmids (De Vos et al., 
2012). pCDNA3.1 was from ThermoFisher and pCDNA3.1-GSK-3β-WT was from 
Addgene (Massachusetts, USA). 
 
2.1.3 Human cells and tissue 
 2.1.3.1 Post-mortem tissue 
Post-mortem spinal cord tissue for human studies was provided by the Medical Research 
Council Neurodegenerative Disease Brain Bank at King’s College London. All tissue 
collection and processing were carried out under the regulations and licensing of the 
Human Tissue Authority, and in accordance with the Human Tissue Act, 2004. Human 
spinal cord tissue from 17 ALS and 17 control donors were provided (Table 2.2). All but 
three samples, which came from thoracic spinal cord, were from the lumbar region of the 
spinal cord. Patients were clinically diagnosed with ALS and diagnoses were confirmed 
by the brain bank by post-mortem identification of TDP-43 pathology. With the exception 
of two patients, who harboured a C9ORF72 repeat expansion, ALS-causing mutations 
were not reported in any other cases. Controls were age-matched and free of the clinical 
symptoms of ALS at time of death. One control donor was found to have TDP-43 
inclusions in their amygdala and hippocampus, but not in motor neurons in spinal cord. 
Aside from this, TDP-43 pathology was not reported in any control tissue. Two control 
donors displayed stage III Braak pathology, twelve displayed stage I-II, and three were 




For proximity ligation assays, 7 μm paraffin wax embedded sections of post-mortem 
lumbar or thoracic spinal cord were provided. For immunoblotting, frozen spinal cord 
tissue from the same donors were provided.  
 






Post-mortem Delay  
(hrs) Group 
Control C1 M 105 25 
Control C2 F 73 27 
Control C3 F 77 21 
Control C4 M 84 53 
Control C5 M 65 26 
Control C6 M 85 55 
Control C7 M 63 23 
Control C8 F 99 32 
Control C9 M 78 24 
Control C10 M 82 24 
Control C11 F 92 9 
Control C12 M 97 44 
Control C13 F 84 34 
Control C14 F 92 22.5 
Control C15 F 89 41 
Control *C16 M 81 18 
Control *C17 M 79 47 
ALS A1 M 68 78 
ALS **A2 M 57 94 
ALS A3 M 69 52.5 
ALS A4 M 76 51 
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ALS A5 M 68 73 
ALS *A6 F 73 70 
ALS A7 F 90 34 
ALS **A8 F 59 74 
ALS A9 F 72 53 
ALS A10 M 54 69 
ALS A11 M 77 66 
ALS A12 F 86 77 
ALS A13 F 80 36.5 
ALS A14 M 73 41.5 
ALS A15 F 69 64 
ALS A16 M 74 70 
ALS A17 M 71 58 




Motor neurons differentiated from patient iPSCs from two control donor and two ALS 
donor cell lines were kindly provided by the laboratory of Professor Chris Shaw (King’s 
College London), who originally received both ALS patient cell lines and one control cell 
line (33D6) from Professor Siddharthan Chandran (University of Edinburgh) and the 
other control line (M135) from Professor Jack Price (King’s College London). Patient 
cells were from two unrelated males, one aged 52 and harbouring the M337V mutation 
in TDP-43 and the other aged 64 and harbouring the G298S mutation. Control cells were 
from two unrelated males, one (33D6) aged 56 and the other (M135) in his 40s.  
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2.1.4 Immunostaining and Assays 
Duolink in situ proximity ligation assay kits (brightfield and orange) including in situ wash 
buffers, ligase and polymerase enzymes and buffers, blocking solutions and antibody 
diluents, Duolink PLA probes, and Mayer’s Haematoxylin were all purchased from 
Sigma-Aldrich. Xylene and ethanol were from VWR (Lutterworth, UK). NOVA red 
peroxidase substrate kit and ABC Vectastain were from VECTOR (Peterborough, UK) 
Clearvue mountant XYL, for mounting tissue sections, was from ThermoFisher Scientific. 
Fluorescence mountant, for mounting cells, was from Dako. Dual Glo Luciferase Assay 
System, including lysis buffer, luciferase substrates and luciferase inhibitor solution, was 
from Promega.  
 
2.1.5 Cell culture  
2.1.5.1 Stem cell culture and differentiation into iPSC-MNs 
Geltrex, Essential 8 Flex Medium (E8 Flex), Rho-associated protein kinase (ROCK) 
inhibitor Revitacell (100x), StemPro Accutase Cell Dissociation Reagent, Dulbecco’s 
Modified Eagle Medium (DMEM) / F12 with GlutaMAX, Neurobasal medium, N2 
supplement (10x), B27 supplement (10x), β-mercaptoethanol (0.01%) and Retinoic Acid 
(RA) were from ThermoFisher Scientific. SB431542 Activin Inhibitor (SB) and 
CHIR99021 GSK3 inhibitor (CHIR) were from Cambridge Biosciences (Cambridge, UK). 
Dorsomorphin AMPK inhibitor (Dorso) and Smoothened Agonist (SAG) were from Merck, 
ROCK inhibitor (Ri) Y-27632 was from Stem Cell Technologies and DAPT from Cell 
Guidance Systems (Cambridge, UK). Recombinant human Brain-Derived Neurotrophic 
Factor (BDNF), Glial cell line-Derived Neurotrophic Factor (GDNF) and Insulin-like 
Growth Factor (IGF) were from Peptrotech (London, UK). Versene 
(Ethylenediaminetetraacetic acid (EDTA) in phosphate buffered saline (PBS)) was from 
Lonza (Basel, Switzerland). Laminin isolated from Engelbreth-Holm-Swarm murine 
sarcoma (basement membrane), L-Ascorbic Acid 2-Phosphate (AA2P), Poly-L-ornithine 
(0.01 %) and Puromycin were from Sigma Aldrich. 
 
2.1.5.2 Cell line culture  
DMEM containing 4.5 g/l glucose and 1mM sodium pyruvate, Trypsin-EDTA solution 
(0.05 % (v/v)/ 0.02 % (v/v) in PBS) and Opti-MEM reduced serum medium were from 
Life Technologies. Fetal Bovine Serum (FBS) and L-glutamine (200 mM) were from GE 
Healthcare (Buckinghamshire, UK). Fugene 6 transfection reagent was from Promega. 




2.1.6 Molecular biology  
2.1.6.1 Immunoblotting and immunoprecipitation 
BCA protein assay kit was from Bio-Rad (Watford, UK). cOmplete protease inhibitor 
cocktail (EDTA free) and phosphatase inhibitor cocktail (PhosStop) were both from 
Roche (Welwyn Garden City, UK). Novex 4 – 12 % Tris-Glycine gels and nitrocellulose 
membranes were from ThermoFisher Scientific. For casting “home-made” gels, Mini-
PROTEAN Tetra Cell Casting set was from Bio-Rad and 30 % Acrylamide-bis-
acrylamide 37:5:1 stabilised solution was from Geneflow (Litchfield, UK). Molecular 
weight marker used was PageRuler Plus Prestained Protein Ladder 10 to 250 kDa from 
ThermoFisher Scientific. Dried milk powder and Bovine Serum Albumin (BSA) were from 
Sigma Aldrich. Enhanced chemiluminescent blotting reagent and Protein G Sepharose 
Fast Flow beads were from GE healthcare. The ChemiDoc XRS+ imaging system used 
to visualise immunoblots was from Bio-Rad.  
 
 2.1.6.2 Plasmid production and mutagenesis   
Luria-Bertani (LB) agar, LB broth, nuclease free water and the NanoDrop 1000 
Spectrophotometer used for measuring DNA concentration were from ThermoFisher 
Scientific. HiSpeed plasmid purification midi kits were from Qiagen (Manchester, UK). 
Quick change XL site directed mutagenesis kit and XL-Blue E.coli were from Agilent 
Technologies (Cheshire, UK). Library efficiency E.coli DH5α were from Thermofisher 
Scientific.  
 
 2.1.6.3 Protein purification, recombinant protein and cell treatments  
E.coli BL21 (DE3) were from Agilent. GraviTrap nickel column and Glutathione 
Sepharose 4B beads were from GE healthcare. Spectrophotometer was a Jenway 6300. 
Recombinant GSK-3β (P6040S) was from New England Biolabs and AMPK activator A-
769662 was from Cell Guidance Systems.  
 
2.1.7 Mass Spectrometry  
EASY NanoLC system for liquid chromatography (LC) and Orbitrap Velos Pro for 





For mutagenesis of pCIneo-myc-VAPB and pM1-VAPB(1-220) the following primers 











Forward: AATAAAATTATATCCACAACTGCATCAAAGGCAGAAACACCAATAGTG  
Reverse: CACTATTGGTGTTTCTGTCTTTGATGCAGTTGCGGATATAATTTTATT 
 
pCIneo-myc-/pM1- VAPB-T148D  
Forward: AATAAAATTATATCCACAACTGCATCAAAGGACGAAACACCAATAGTG  
Reverse: CACTATTGGTGTTTCTGTCTTTGATGCAGTGTCGGATATAATTTTATT  
 
 
2.1.9 Common reagents  
Phosphate Buffered Saline  
0.01 M phosphate buffer 
0.0027 M KCl  
0.137 M NaCl 
pH 7.4 
 
Tris Buffered Saline 
50 mM Tris-HCL 






50 mM Tris-HCl 
150 mM NaCl 
1 mM EDTA 
1 % (v/v) Triton X-100 
0.5 % (w/v) sodium deoxycholate 
0.1 % (w/v) sodium dodecyl sulfate (SDS) 
pH 7.4 
cOmplete protease inhibitor cocktail  
Phosphatase inhibitor (PhosStop) 
 
5x Lamelli Sample Buffer 
62.5 mM Tris-HCl (pH6.8) 
2 % (w/v) SDS 
5 % (v/v) β-mercaptoethanol 
10 % (v/v) Glycerol  
Touch bromophenol blue 
 
Resolving Gels 
Resolving master mix: 500 mM Tris pH 8.8, 1.5 % SDS in ultrapure H2O 
Table 2.3 Polyacrylamide resolving gel recipes for SDS-PAGE 
Component 8 % Gel 10 % Gel 12 % Gel 
Resolving master mix 6 ml 6 ml 6 ml 
30 % (v/v) Acrylamide-bis-acrylamide 2.4 ml 3 ml 3.6 ml 
10 % (w/v) Ammonium persulfate (APS) 90 μl 90 μl 90 μl 
N,N,N`,N`-Tetramethyl ethylenediamine (TEMED) 3.6 μl 3.6 μl 3.6 μl 
RO water 0.6 ml N/A N/A 





3.75 ml stacking master mix (150 mM Tris pH 6.8, 1.2 % SDS in ultrapure H2O) 
0.75 ml 30 % (v/v) Acrylamide-bis-acrylamide 
45 μl 10 % (w/v) APS  
4.5 μl TEMED 
 
SDS-PAGE Running Buffer 1L  
3 g Tris 
13 g Glycine 
10 ml 10 % (w/v) SDS 
in ultrapure H2O 
Buffered to pH 8.3 
 
SDS-PAGE Transfer Buffer 1L 
3 g Tris 
13 g Glycine 
200 ml methanol  
in ultrapure H2O 
 
Stripping Buffer 500 ml 
7.5 g Glycine 
0.5 g SDS 
5 ml Tween 20 
in ultrapure H2O 




2.2.1 Preparation of frozen human spinal cord tissue   
Frozen post-mortem spinal cord tissue was homogenized at 100 mg/ml in RIPA buffer 
using a Bio-Gen PRO200 rotor-stator homogeniser (Pro Scientific, Connecticut, USA) 
for 20 sec, with samples maintained on ice throughout. Tissue was sonicated 3 times for 
3 sec (Output 3, 10 sec on a Sonics Vibra Cells (Jencons PLS, East Grinstead, UK)) and 
returned to ice between each sonication. After sonication, samples were centrifuged for 
13 000 x g with an Eppendorf 5415R desktop centrifuge (Eppendorf, Hamburg, 
Germany) at 4 oC for 20 min and supernatant collected in fresh tubes. The protein 
concentration of each sample was determined as described in section 2.2.2. RIPA buffer 
was used to normalise the protein concentration of samples and 5x lamelli sample buffer 
was added to each sample to bring it to a final concentration of 2.5 mg/ml. 
 
2.2.2 Determining protein concentrations 
Protein concentrations were determined using a Promega BCA assay kit. Briefly, BSA 
was diluted in RIPA buffer to produce eights standards of concentration range 0-2 mg/ml. 
Samples were diluted 1:1 in RIPA buffer. 10 μl of sample or standard was added per well 
to a 96-well plate (ThermoNunc, Roskilde, Denmark) in triplicate. As per manufacturer’s 
instructions, BCA Reagents A and B were diluted 50:1 A:B and 200 µL was added to 
each well, prior to incubation for 30 min at 37 oC in the dark. The absorbance of the 
purple reaction product at 562 nm was determined with a PHERAstar microplate reader. 
Absorbance of each protein standard was plotted against concentration to create a 
standard curve. The protein concentration of each sample was determined using the line 
equation of the standard curve, y=mx+b, where y is absorbance, m is line gradient, b is 
the intersect on the y axis and x is protein concentration. 
 
2.2.3 Production of plasmid DNA  
LB agar (32 g/l) and LB broth (20 g/l) were sterilised by autoclaving and ~10 ml LB agar 
containing 100 μg/ml filter-sterilised ampicillin (LB-amp) for selection of plasmid vectors, 
was poured into sterile petri dishes and allowed to set. Plates were stored at 4 oC until 
use and for no more than one month.  
 
DH5α E.coli were transformed with plasmid DNA for expression and purification as 
follows. 50 μl aliquots of Library Efficiency DH5α E.coli cells were thawed on ice, mixed 
gently and transferred to 1.5 ml Eppendorf tubes. ~5 ng plasmid DNA was added and 
tubes incubated on ice for 30 min before a 45 sec heat shock in a water bath at 42 oC. 
Eppendorfs were incubated on ice for a further 2 min before the addition of 950 μl pre-
warmed LB broth and incubation at 37 oC for 1 hr with shaking at 225 rpm on a rotary 
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shaker. 20 - 200 μl LB containing transformed cells was streaked on LB-amp plates and 
bacteria were grown overnight at 37 oC. 5 ml LB broth containing 100 μg/ml filter-
sterilised ampicillin was inoculated with a single bacterial colony from LB-amp plates and 
incubated at 37 oC for 8 hrs with shaking at 225 rpm. 1 ml of this starter culture was used 
to inoculate 50 ml LB broth containing 100 μg/ml filter-sterilised ampicillin and these 
cultures were grown overnight at 37 oC. At this stage, in order to make stable stocks of 
cells expressing plasmids of interest, 0.75 ml 50 % glycerol was added to 0.75 ml 
overnight culture containing E.coli DH5α expressing the plasmid, and these were snap 
frozen and stored at -80 oC as a glycerol stock. These stocks could be streaked onto LB 
agar plates each time more of the plasmid was needed.  
 
Plasmid purification was carried out using a HiSpeed plasmid purification midi kit 
(Qiagen) as per the manufacturers’ instructions. 50 ml overnight culture was centrifuged 
at 4 300 x g for 30 min in a Beckman Allegra centrifuge (Beckman Coulter, Indianapolis, 
USA). Supernatant was removed and the bacterial pellet resuspended in 3 ml 
resuspension buffer. 3 ml lysis buffer was added and tubes were gently mix by repeated 
inversion prior to addition of 5 ml neutralisation buffer. Samples were centrifuged at 4 
300 x g for 30 min and the supernatant was applied to the binding column provided with 
the kit, to which DNA binds. Vacuum suction was applied to empty the column. The 
columns were washed by adding 5 ml wash buffer followed by vacuum suction, and then 
20 ml wash buffer, followed by vacuum suction. Bound DNA was eluted in 500 μl DNAse 
free water. The concentration of plasmid DNA was quantified by measuring absorbance 
at 260 nm using a NanoDrop 1000 spectrophotometer. The 260/280 nm absorbance 
ratio was used to determine DNA purity: pure DNA has a ratio of 1.8. Plasmid DNA was 
stored at -20 °C until required. 
 
2.2.4 Mutagenesis  
Site directed mutagenesis was carried out using the QuikChange II Site-Directed 
Mutagenesis Kit (Qiagen) as per manufacturer’s instructions. Briefly, reactions were set 
up to undergo PCR as follows; 50 ng of WT plasmid DNA to be mutated, 125 ng of 
forward and reverse primers (as per 2.1.8), 1 μl of dNTP, 5 μl of reaction buffer provided 
with the kit, nuclease free water to a total of 50 μl and 1 μl of PfuUltra High Fidelity DNA 
polymerase. PCR was carried out beginning with a 95 oC 30 sec step, followed by 18 
amplification cycles of the following: 
95 oC for 30 sec 
55 oC for 1 min 
68 oC for 6 min 
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1 μl Dpn I restriction enzyme was added to each reaction for 1 hr at 37 oC. XL-1 Blue 
Competent E.coli were transformed with 1μl of the PCR reaction as described in section 
2.2.3 for DH5α E.coli. 20 - 200 μl LB containing transformed cells was streaked on LB-
amp plates and bacteria were grown overnight at 37 oC. Multiple lots of 5 ml LB broth 
containing 100 μg/ml filter-sterilised ampicillin were inoculated with single bacterial 
colonies from the LB-amp plate and incubated at 37 oC for 8 hrs with shaking at 225 rpm. 
Plasmids were extracted from these cultures using the Qiagen HiSpeed plasmid 
purification kit as described in section 2.2.3. Plasmids were sequenced by 
SourceBioscience (Nottingham, UK) and this sequence was aligned with the wild type 
sequence to identify colonies containing the correct mutation. 
 
2.2.5 Cell culture 
Cell culture was carried out under sterile conditions in a class II microbiological hood and 
cells were cultured in a humidified incubator at 37 oC with 5 % CO2.  
 
2.2.5.1 iPSC culture and iPSC-MN differentiation  
Stem cell culture and differentiation was carried out by Dr. Jenny Greig. iPSCs were 
grown in E8 Flex medium with Revitacell (1/100) on 6-well plates coated with Geltrex. 
Cells were passaged 1 in 6 or as appropriate twice each week and media was typically 
replaced a minimum of twice each week or as required. For passaging, media was 
aspirated, cells were washed in PBS and 1 ml versene was applied to each well until 
cells detached from each other, but not fully from the well. Versene was carefully 
removed and cells washed with PBS very gently so as not to detach cells from the well. 
E8 flex with Revitacell was then used to wash cells, remove them from the surface of the 
well and resuspend for replating. Media was replaced with E8 Flex without Revitacell 24 
hrs after passaging.  
 
iPSCs from two healthy controls and two ALS cases, with either a M337V or G298S 
mutation in TDP-43 were differentiated into motor neurons by Dr. Jenny Greig, following 
a protocol adapted from Maury et al. (2015), briefly as follows and in Figure 2.1. The 
differentiation protocol was started when iPSCs reached ~ 70 % confluency. Cells were 
first washed with PBS and then detached from the well using 1 ml Accutase + 20 μM Ri. 
Cells were resuspended in E8 Flex with Revitacell, counted using a Nucelocounter NC-
3000 and briefly centrifuged. The cell pellet was resuspended in base media (1:1 
DMEM/F12 + GlutaMAX : Neurobasal with 1 % (v/v) N2, 1 % (v/v) B27, 0.01 % (v/v) β-
mercaptoethanol, 0.5 μM AA2P) containing 40 μM SB, 2 μM Dorso, 1 μM CHIR and 5 
μM Ri and cells were plated in 96-well plates at 1x105 cells per well. Plates were 
centrifuged at 200 x g in a Universal 320R centrifuge (Hettich, Massachusetts, USA) for 
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4 min with low brake and incubated overnight to allow the formation of embryoid bodies 
(EBs). EBs were transferred to 6-well plates in fresh base media containing SB, Dorso, 
CHIR and Ri as before and this was considered Day 0. After 48 hrs (Day 2), media was 
replaced with fresh base media containing SB, Dorso, CHIR, Ri, 1μM RA and 0.5 mM 
SAG. This media was replaced every 48 hrs or as required. On Day 7, media was 
replaced with base media containing only 1 μM RA and 0.5 mM SAG and on Day 9, 
media was replaced with base media containing 10 μM DAPT.  
 
On Day 11, EBs were dissociated by transferring to a 15 ml falcon tube, removal of 
supernatant, washing with PBS and addition of 1 ml pre-warmed Accutase. Cells were 
warmed at 37 oC for 5 – 10 min, resuspended in base media, centrifuged and the cell 
pellet re-suspended in base media + 20 ng/ml BDNF, GDNF, IGF and 10 μM DAPT 
(maturation media). Cells were transferred in maturation media to 24-well plates 
containing 13 mm coverslips which had previously been coated with 50 μg/ml poly-L-
ornithine in PBS for 1 hr at 37 oC followed by 40 μg/ml laminin in DMEM/F12 for 3 hrs at 
37 oC. Half of the media in each well was replaced every 48 hrs or more often as 
necessary. iPSC-MNs were fixed 22 days after EB formation by the addition of 16 % 
(w/v) paraformaldehyde (PFA) (Sigma Aldrich, Dorset, UK) to media to allow a final 
concentration of 4 % PFA. Media was then gently removed and replaced with fresh 4 % 
PFA in PBS, in which cells were incubated for 15 min. PFA was removed and cells were 
stored in PBS at 4 oC until use in proximity ligation assays.  
 
 
Figure 2.1: Diagram of iPSC-MN differentiation timeline 
Day 0 Day 22 






1:1 DMEM/F12 + GlutaMAX : Neurobasal 
1 % (v/v) N2
1 % (v/v) B27 































 2.2.5.2 Cell line culture   
HEK-293 cells were cultured in 75cm2 flasks in DMEM containing 4.5 g/l glucose and 
1mM sodium pyruvate, supplemented with 10 % (v/v) FBS and 1 % (v/v) glutaMAX. Cells 
were passaged every 3 or 4 days as appropriate, at ~ 80 % confluency. For passaging, 
media was aspirated and cells were washed with PBS before pre-warmed Trypsin-EDTA 
solution (0.05 % (v/v)/ 0.02 % (v/v) in phosphate buffered saline; PBS)  was added in a 
volume sufficient to cover the base of the flask for ~3 min until cells detached from the 
flask. Pre-warmed culture media was added to dilute trypsin to 1/10, solution was 
triturated to produce a single cell suspension and the appropriate amount of cell 
suspension, usually containing 1/6 of the starting cell number, was transferred to a new 
flask. Cells were plated in 24-well plates or 100 mm dishes and cells were harvested on 
ice by removal of media and scraping in appropriate lysis buffer.    
 
 2.2.5.3 Cell line transfection and treatment with compounds 
Cells were transfected using Opti-MEM and Fugene 6. For each well of a 24-well plate, 
2 μl Fugene 6 was added to 50 μl Opti-MEM and, separately, plasmid DNA totalling 1 μg 
was added to 50 μl Opti-MEM. Opti-MEM containing DNA and Fugene 6 were incubated 
separately for 5 min before being mixed and incubated for 20 min. The DNA-transfection 
reagent complexes were added to each well, and cells were lysed or fixed as appropriate 
24 hrs after transfection.  
 
AMPK inhibitors 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) and A-
769662 were made to stock concentrations of 10 mM in Dimethyl sulfoxide (DMSO), 
which were stored for up to 1 month at -20 oC and were diluted 1:100 to 100 mM in fresh 
cell culture media when required. The same volume of the vehicle control (DMSO) was 
diluted in cell culture media. Media was aspirated from cells and replaced with media 
containing either AICAR, A-769662 or DMSO for 2 hrs before cells were collected for 
analysis.   
 
2.2.6 SDS-PAGE and Immunoblotting  
Samples were boiled for 5 min at 98 oC using a digital DM-100 dry bath (Jencons PLS, 
East Grinstead, UK) and centrifuged at 31 400 x g for 60 sec with a Spectrafuge 24D 
centrifuge (Jencons PLS) before separation. 8, 10 or 12 % (v/v) polyacrylamide resolving 
gels were made as per Table 2.3 in Mini-PROTEAN Tetra Cell Casting sets, with 
isopropanol added on top to prevent drying. Once resolving gel was set, isopropanol was 
removed and stacking gel was added with a well comb in place and allowed to set. 
Samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 
“home-made” polyacrylamide gels alongside a PageRuler Plus Prestained Protein 
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Ladder to allow determination of protein size. Post-mortem human spinal cord samples 
were separated by SDS-PAGE using Novex 4-12 % Tris-glycine gels. Running buffer 
was the same for both commercial and “home-made” gels and was made as detailed in 
section 2.1.9. Proteins were electrophoresed at 120 V for 1.5 – 2 hrs, until the dye front 
reached the bottom of the gel.  
 
After separation by SDS-PAGE, proteins were transferred to Protran nitrocellulose 
membranes (0.45 μm pore; G.E. Healthcare) using a Bio-Rad Transblot system (for 
“home-made”) or Invitrogen X-Cell blot II (for precast gels) transfer systems. Transfers 
were carried out at 120 V for 1.5 hrs or at 30 V overnight to improve transfer efficiency 
when of large proteins, such as IP3R. After transfer, non-specific antibody binding was 
reduced by incubating membranes in blocking solution. Blocking solution was Tris–HCl-
buffered saline (TBS, pH 7.3) and 0.1 % (v/v) Tween-20 containing either 5 % (w/v) BSA 
(for probing for TOM20, IP3R3, GSK-3β and AMPK) or 5 % (w/v) non-fat dried milk 
powder (for probing all other proteins), for 1 hr at room temperature. Membranes were 
incubated with primary antibodies in blocking buffer overnight at 4 oC with rocking. After 
washing three times for 5-10 min with TBS containing 0.1 % Tween-20 (TBS-T), 
membranes were incubated with appropriate secondary antibodies diluted in blocking 
buffer for 1 hr at room temperature with rocking. After washing again three times in TBS-
T, membranes were processed for chemiluminescent detection. Membranes were 
incubated for 5 min in either a 1:1 dilution of ECL blotting reagents 1 and 2 (GE 
Healthcare) or Luminata Forte detection reagent (ThermoFisher). Chemiluminescent 
signals were detected with a Bio-Rad ChemiDoc imaging system. With the exception of 
western blots of immunoprecipitated protein, a housekeeping protein was also 
immunoblotted to allow for normalisation of protein loading in each well. Where the 
housekeeping protein is of a similar molecular weight to the protein of interest (for 
example, PDI and NSE), antibodies were stripped from the membrane after detection of 
bands for the protein of interest by incubation in stripping buffer for 10 min followed by 3 
x 10 min washes in PBS. The immunoblot process was then repeated from the stage of 
blocking with antibodies for the housekeeping protein. For proteins of sufficiently different 
sizes (for example TOM20 and PTPIP51), membranes were cut between these sizes to 
allow incubation of the same membrane in different antibodies. Optical density (OD) of 
each band was measured using ImageJ. For each sample, the OD of the band of the 
protein of interest was normalised to the OD for the loading control. A mean OD value 
for the control samples was calculated and OD values for each sample were then 




2.2.7 Immunostaining  
Wax was removed from embedded tissue sections by heating at 60 oC for 20 min in an 
oven followed by 2 x 2 min washes in xylene. A re-hydration series of 2 x 2 min 
immersions in 99 % (v/v) ethanol and 1 x 2 min wash in 95 % (v/v) ethanol was performed 
followed by 10 min immersion in running tap water. Antigen retrieval was carried out 
using 10 mM sodium citrate, pH 6.0, in RO water by heating sections in antigen retrieval 
solution to boiling and then simmering in a microwave. The time and power taken to 
reach and maintain boiling varies dependant on microwave and volume of buffer, but for 
2 – 4 sections in ~100 ml buffer, high power (in an 800W machine) was used for 6 min, 
followed by medium power for 12 min. Sections were washed in running tap water for 5 
min. At this stage, a hydrophobic pen was used to encircle the tissue so that minimal 
amounts of reagent were required to sufficiently cover the tissue. Endogenous 
peroxidase activity was blocked using 2.5 % (v/v) hydrogen peroxide in methanol for 5 
min at room temperature. Non-specific antibody binding was blocked by incubating 
sections in blocking buffer (TBS, pH 7.6, containing 1 % (v/v) donkey serum, 0.15 % (v/v) 
Tween-20) for 1 hr at room temperature. 
  
Sections were then incubated with primary antibody diluted in blocking buffer (TBS pH 
7.6, 1 % (v/v) donkey serum, 0.15 % (v/v) Tween-20) overnight at 4 oC. Sections were 
washed three times with PBS before the addition of appropriate secondary antibodies, 
also diluted in blocking buffer (TBS pH 7.6, 1 % (v/v) donkey serum, 0.15 % (v/v) Tween-
20) for 1 hr at room temperature. Sections were again washed three times in PBS and 
biotinylated secondary antibody were bound by avidin/biotinylated enzyme complexes 
using ABC vector kits (Vector labs, Peterborough, UK) as per the manufacturer’s 
instructions. To detect the signal, 0.5 mg/mL 3,3′- diaminobenzidine (DAB) in TBS 
containing 0.05 % (v/v) H2O2 was applied for 2 min. Sections were washed in PBS before 
Mayer’s Haematoxylin was used for 2 min to counterstain nuclei and sections were 
transferred to tap water to remove remaining solutions. After 10 min in running tap water, 
sections were de-hydrated by immersion for 1 x 2 min in 95 % (v/v) ethanol, 2 x 2 min in 
99 % (v/v) ethanol, 1 x 10 min in xylene, and glass coverslips were mounted using 
ClearVue XYL mounting media. 
 
2.2.8 Proximity ligation assay  
2.2.8.1 Post-mortem spinal cord sections   
Wax removal, re-hydration, antigen retrieval and peroxidase blocking steps were carried 
out as for immunostaining with the exception that the antigen retrieval step was longer 
due to the increased volume of buffer needed for a larger number of slides; for 2 x ~300 
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ml buffer (2 containers each holding 17 sections), high power in an 800 W machine was 
used for 6 min, followed by medium power for 15 min.  
 
Proximity ligation assays were performed using Duolink In Situ Brightfield detection 
reagents (Sigma-Aldrich), essentially as described by the manufacturer. As for 
immunostaining, a hydrophobic pen was used to encircle the tissue and minimise the 
amount of reagent required. After peroxidase blocking as above, sections were washed 
for 2 x 5 min in PLA wash buffer A before blocking for 1 hr at 37 oC in 1 drop of PLA 
blocking buffer. All steps at 37 oC were performed in a humidified slide chamber. After 
blocking, sections were incubated with 50 μl of both primary antibodies in PLA antibody 
diluent for 1 hr at 4 oC. Sections were washed twice for 5 min in PLA wash buffer A, 
followed by incubation for 1 hr at 37 oC in 50 μl PLA probe diluent containing PLA probes 
corresponding to each primary antibody and conjugated to complimentary 
oligonucleotides (one PLUS and one MINUS, both Duolink). Sections were washed twice 
for 5 min in PLA wash buffer A followed by incubation for 30 min at 37 oC with the ligase 
provided, diluted 1:40 in 1 x PLA ligase buffer in nuclease free water. Sections were 
washed twice for 5 min in PLA wash buffer A followed by incubation for 2 hrs at 37 oC 
with polymerase diluted 1:80 in 1 x amplification buffer in nuclease free water. Sections 
were washed twice for 2 min in wash buffer A followed by incubation with 1 x brightfield 
detection reagent in nuclease free water. Sections were washed twice for 2 min in wash 
buffer A before development of the PLA signal. NOVA red substrate kit reagents 1, 2, 3, 
4 were diluted 1/62, 1/100, 1/100, 1/62 respectively, mixed, and applied to the tissue for 
2 min. Sections were washed two more times for 2 min in buffer A and then 
counterstained in Mayer’s Haematoxylin for 2 min and washed in running tap water for 
10 min. De-hydration and mounting of sections was carried out as described for 
immunostaining; 95 % ethanol, 99 % ethanol and xylene immersions followed by 
mounting of glass coverslips using ClearVue XYL.  
 
Sections were imaged using an Olympus slide scanner VS120 with Brightfield mode, 
generating an automated maximal projection of 11 z planes through the depth of the 
tissue with a 40 x lens and 0.95 numerical aperture. Motor neurons were identified by 
eye based on their distinct morphology; large, round nuclei only found in the ventral horn 
grey matter of the spinal cord. PLA signals were quantified as the number of dots per 
motor neuron. Using Visopharm (v2018.4) software each motor neuron was manually 
outlined and an APP was created using the Author module to automatically detect and 
count the number of PLA dots within outlined areas. Raw PLA signals were plotted and 
PLA signals for each individual were also plotted against the normalised VAPB protein 





Cells were fixed in 4 % (v/v) PFA in PBS for 15 min at room temperature, quenched of 
autofluorescence using 0.05 M NH4Cl in PBS for 15 min and permeabilised using 0.2 % 
Triton-X in PBS for 3 min. Proximity ligation was performed using Duolink In Situ Orange 
detection reagents following the same protocol as for post-mortem tissue sections, with 
the exception that incubation with polymerase and amplification buffer was performed 
for 100 min. Coverslips were incubated in the humidified chamber cell side down onto 
~40 μl of each reagent spotted on parafilm. After amplification, all steps were carried out 
protected from light to prevent any loss of fluorescent signal. Cells were washed 1 x 10 
min in wash buffer B, 1 x 10 min in 0.1 wash buffer B and 1 x 10 min in PBS before 
counterstaining and mounting on to slides using fluorescent mountant (Dako).  
 
Counterstaining for ChAT in iPSC-MNs was performed at the end of the protocol by 
incubation with anti-ChAT in PBS overnight at 4 oC, followed by three washes in PBS 
and incubation in secondary antibody in PBS at room temperature for 1 hr. After 
counterstaining, coverslips were incubated with 4,6-diamidine-2-phenylindole (DAPI) 
followed by two washes in PBS and were mounted onto slides with fluorescent mounting 
medium. Images were taken at multiple depths through each ChAT-positive iPSC-MN 
on a Leica light microscope with Leica CTR500 camera using a 40 x objective or a Nikon 
A1R confocal microscope with Nikon A1 plus camera using a 60 x objective and 1.4 
numerical aperture (Nikon A1R images presented). Maximum intensity projections of 
image stacks were generated using the stack focuser plugin of ImageJ (for Leica images) 
or NIS Elements software (for Nikon A1R images) and proximity ligation signals, counted 
as the number of dots per cell soma, were quantified using the Particle Analysis function 
of ImageJ.  
 
2.2.9 Luciferase assay 
For luciferase experiments, HEK-293 cells were transfected in 24 well plates as 
described in section 2.2.5.3 with plasmid DNA totalling 1 μg per well; 0.3 μg firefly 
luciferase, 0.3 μg VP16-PTPIP51(36-470) and 0.3 μg pM1-VAPB(1-220) WT or mutant. 
In addition, renilla was transfected at 0.1 μg per well due to the strength of its signal. 
Luciferase assays were performed 24 hrs after transfection using the Dual-Glo 
Luciferase Assay System (Promega) as per the manufacturers’ instructions. Briefly, for 
a 24 well plate, cell media was aspirated, and cells were lysed in 50 μl Dual-Glo 
Luciferase assay reagent, made by diluting Dual-Glo Luciferase Substrate in Dual-Glo 
Luciferase Buffer, for 10 min at room temperature. Cell lysate was transferred to an 
opaque 96-well plate and firefly luminescence signal was measured using a PHERAstar 
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plate reader at 560 nm. 25 μl Dual-Glo Stop & Glo assay reagent, made by diluting Dual-
Glo Stop & Glo Substrate 1:100 in Dual-Glo Stop & Glo Buffer, was added to each well 
to inhibit firefly luminescence signal and after 10 min renilla signal was measured using 
a PHERAstar plate reader at 480 nm. Firefly luciferase signals were normalised to the 
signal given by the transfection control renilla and were compared to the control WT 




For the analysis of VAPB and PTPIP51 phosphorylation in cells, VAPB and PTPIP51 
were immunoprecipitated from HEK293 cells by Dr. Gábor Mórotz. HEK-293 cells were 
plated in 100 mm dishes and transfected at ~70 % confluency as described in section 
2.2.5.2 with 4 μg pCIneo-Myc-VAPB or pCIneo-HA-PTPIP51 and 4 μg control vector or 
pCDNA3.1- GSK-3β per well. 24 hrs after transfection, cells were lysed in 500 μl cold 
PBS containing 1 % (v/v) Triton-X 100 and protease inhibitors and incubated at 4 oC for 
1 hr on a rotary shaker. Cell lysate was then centrifuged at 6 100 x g for 1 min and 20 μl 
supernatant was taken as “input” of the immunoprecipitation. The remaining lysate was 
incubated with 2 μl Myc (for VAPB immunoprecipitation) or HA (for PTPIP51 
immunoprecipitation) antibody on a rotary shaker at 4 oC overnight. Protein-G-sepharose 
beads (Sigma Aldrich) were washed by suspending in 10 ml PBS, centrifuging at 3000 x 
g for 1 min and replacing PBS. After three washes, PBS was removed and to generate 
a 50 % slurry of beads 384 μl PBS containing 0.1 % (v/v) Triton X-100 was added for 
every 500 μl of beads. Antibodies were allowed to bind the beads by the addition of 25 
μl of this 50 % Protein-G-sepharose bead slurry to each 500 μl lysate/antibody mixture 
for 2 hrs at 4 oC on a rotary shaker. Following three x washes in PBS containing 0.1 % 
(v/v) Triton X-100, centrifuging at 3000 x g for 1 min between each wash to remove 
unbound proteins, the supernatant was discarded and the immunoprecipitated proteins 
were prepared for SDS–PAGE by eluting them from sepharose beads by the addition of 
laemmli sample buffer and heating at 98 °C for 5 min. Immunoprecipitated proteins were 
separated by SDS–PAGE as described in section 2.2.6, on 10 or 12 % acrylamide gels 
depending on the size of the protein to be resolved and were processed for mass 
spectrometry as described below (section 2.2.12).  
 
2.2.11 Production of recombinant protein and in vitro phosphorylation 
Recombinant VAPB and PTPIP51 were produced for incubation with recombinant kinase 
and subsequent analysis by mass spectrometry. Recombinant histidine tagged VAPB(1-
220) was prepared by Dr. Sébastien Paillusson by expression of pET28A-His-VAPB(1-
220) in E.coli BL21 (DE3) according to the manufacturers’ instructions, with the exception 
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that expression was induced with 0.4 mM Isopropyl β- D -1-thiogalactopyranoside (IPTG) 
for 3 hrs at 37 oC. Recombinant protein was purified on a GraviTrap nickel column and 
eluted with 500mM imidazole.  
 
GST-PTPIP51(36-470) was expressed in E.Coli DH5α because PTPIP51 was found to 
degrade less in these cells than in E.Coli BL21 (DE3). E.Coli DH5α cells were 
transformed with pGEX51, encoding GST, or pGEX51-PTPIP51(36-470) as described in 
section 2.2.3 and grown overnight. 5 ml of overnight cultures were used to inoculate 100 
ml LB broth. These 100 ml cultures were grown at 37 oC until they reached an optical 
density of 0.6‐0.8. Cultures were then induced to express the protein using 1 mM IPTG 
and incubated at 18 oC overnight. This lower temperature was used to further minimize 
degradation. An uninduced control culture was also grown at 18 oC overnight. Bacterial 
cultures were centrifuged at 4 oC at 4 300 x g for 30 min and the pellet was resuspended 
in lysis buffer (50 mM Tris pH 7.7, 150 mM KCl, 0.1 % Triton X 100 with 1 mM 
dithiothreitol (DTT, added fresh just before use). After 30 min incubation on ice, cell 
lysates were sonicated using 2, 20 sec pulses at 40 % duty cycle, with 60 sec on ice 
between each pulse to cool down the sample. After sonication, 1 ml of both induced and 
uninduced lysate was centrifuged at 31 400 x g for 1 min, supernatant was removed, and 
the cell pellet lysed in 1 x laemmli sample buffer ready for separation by SDS-PAGE. 
The remainder of the lysate was centrifuged at 4 oC at 4 000 x g for 20 min and 
supernatant collected.  
 
For each sample (GST and GST-PTPIP51(36-470)), 200 μl glutathione sepharose beads 
were washed by suspending in 10 ml PBS, centrifuging at 750 x g for 3 min and replacing 
PBS. After three washes, beads were re-suspended in 200 μl PBS. 400 μl glutathione-
sepharose beads in PBS were added to the supernatant of each bacterial cell lysate and 
incubated at 4 oC for 90 min on a rotary shaker. Beads were then washed as previously, 
three times with PBS, and re-suspended in 200 μl PBS. 20 μl of these GST-bound 
glutathione beads were diluted with 20 μl 2 x laemmli sample buffer ready for separation 
by SDS-PAGE. The remaining beads were centrifuged (750 x g, 3 min) and resuspended 
in glutathione buffer (25 mM glutathione, 50 mM Tris, 200 mM NaCl) for 1 hr at 4 oC to 
elute the recombinant protein from the beads. Purified recombinant protein was stored 
at -80 oC until required.  
 
The approximate concentration of recombinant protein was determined by running 
samples alongside BSA standards of known concentrations (1 – 10 μg) on an SDS-
PAGE gel. After separation, the gel was fixed for 1 hr in 50 % (v/v) methanol and 10 % 
(v/v) glacial acetic acid, and stained for 2 hrs in 50 % (v/v) methanol, 1 % (v/v) glacial 
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acetic acid and 0.1 % (w/v) Coomassie Brilliant Blue. Gels were de-stained in ultrapure 
H2O overnight. Protein concentrations were determined by matching band intensities of 
recombinant protein to BSA bands. Once an approximate concentration of purified 
protein was determined, 6 μg His-VAPB(1-220) or GST-PTPIP51(36-470) were 
incubated for 16 hrs at 30 oC with 1 μl (500 units) commercial recombinant rabbit GSK-
3β in the buffer provided, supplemented with 200 μM ATP. The phosphorylation reaction 
was stopped by the addition of laemmli sample buffer. Samples were separated by SDS-
PAGE as described in section 2.2.6, on 10 or 12 % acrylamide gels depending on the 
size of the protein to be resolved and were processed for mass spectrometry as 
described below (section 2.2.12).  
 
2.2.12 Mass spectrometry  
Recombinant or in vitro proteins to undergo mass spectrometry were separated by SDS–
PAGE on 10 or 12 % acrylamide gels, as described in section 2.2.6.  Proteins were fixed 
in the gel by incubation in fixing buffer containing 50 % (v/v) methanol and 10 % (v/v) 
glacial acetic acid for 1 hr at room temperature. Proteins were then stained by incubation 
in imperial protein stain for 2 hrs at room temperature and de-stained in ultrapure H2O 
overnight, also at room temperature. Proteins bands were excised and stored in ultrapure 
H2O at 4 oC until further processing.  
 
Peptide processing and subsequent liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) were carried out by Mr. Steven Lynham at the KCL 
Proteomics Facility. Peptide processing was carried out on proteins whilst they remained 
in the gel and three bands of each protein were pooled for analysis. Briefly, after 
removing water in which they were stored, gel pieces were washed for 10 min in a 
sufficient amount of 100 mM Ammonium Bicarbonate (Ambic) to cover them. Gel pieces 
were then washed twice in acetonitrile and dried for 5 min in a SpeedVac. Gel pieces 
were rehydrated in 1 mM DTT (1 mM DTT in 100 mM Ambic) at 56 oC for 30 min to 
chemically block cysteine residues by reduction. Gel pieces were again washed with 
acetonitrile, followed by incubation in 55 mM Iodoacetamide (IAA, 55 mM in 100 mM 
Ambic) in the dark for 20 min at room temperature to form stable carbamidomethyl 
derivatives. Following a further two washes in acetonitrile to completely destain and 
dehydrate, gel pieces were dried in a SpeedVac for 10 min. Gel pieces were rehydrated 
with trypsin (30 μl Trypsin in 0.1 % (v/v) trifluoracetic acid diluted in 200 μl 50 mM Ambic) 
for 20 min at 4 oC. Unabsorbed trypsin was removed and replaced with 50 mM Ambic to 
maintain hydration of gel pieces, which were incubated for 2 hrs at 37 oC and then at 
room temperature overnight. After digestion, peptides were extracted from the gel by 
three 5 min washes at 37 oC with 50 mM Ambic followed by acetonitrile. Peptides were 
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dried in a SpeedVac and re-suspended in 10 μL of 50 mM ammonium bicarbonate for 
analysis. 
 
Peptides were separated by liquid chromatography on an EASY NanoLC system, 
using reversed phase chromatography on a 75 μm C18 column and eluted at a flow rate 
of 300 nl/min over 60 min in a linear gradient of acetonitrile in 0.1 % formic acid. The 
eluate was ionized by electrospray ionization, ions were fragmented by collision induced 
fragmentation and the mass to charge ratio of fragment ions was detected using a linear 
trap quadrupole. This ionisation, fragmentation and detection were carried out in an 
Orbitrap Velos Pro. Raw data was processed in Proteome Discoverer (v1.4) and an in-
house database containing VAPB or PTPIP51 as appropriate was used to assign peptide 
spectra in Mascot software. Spectra were visualised in Scaffold 4 (v4.7.2). Analysis of b- 
and y- ion series was performed manually to confirm or reject assignment of 
phosphorylation sites. b- and y- series ions are created by fragmentation of peptides at 
the peptide bond between amino acids; b-ions are generated when the ion is retained on 
the N-terminal fragment and y-ions are generated when the ion is retained on the C-
terminal fragment. Correct assignment of phosphorylation was confirmed where there 
was sufficient coverage of b- and y- ions and loss of phosphoric acid (mass loss of 98, 
indicative of phosphorylation) was found on specific b- and y- ions such that there was 
only one possible position of phosphorylation in the full peptide.  
 
2.2.13 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism. Data was tested for normal 
distribution using D’Agostino & Pearson normality test and p > 0.05 was considered to 
represent normally distributed data. Non-parametric tests were used where data was not 
normally distributed (p < 0.05). Raw data for post-mortem delay (PMD) and age and 
normalised data western blots and PLA were plotted for control and ALS cases. Normally 
distributed data were analysed by unpaired two-tailed t-test and data which was not 
normally distributed were analysed by the non-parametric alternative Mann-Whitney test. 
PLA data and VAPB protein amounts for each individual were also plotted against each 
other and against raw PMD and age data for each individual. These data were analysed 
by Pearson’s correlation. Luciferase data was analysed by ANOVA and Tukey post-hoc 


















3.1.1. ER-mitochondria signalling in animal and cell models of ALS  
As detailed in chapter 1, signalling between ER and mitochondria facilitates a number of 
the cellular processes that are damaged in neurodegenerative diseases including 
calcium exchange and ATP production, and correcting ER-mitochondria interactions 
may therefore represent a therapeutic target. Signalling between these organelles is 
mediated by tethering between the ER membrane protein VAPB and mitochondrial 
membrane protein PTPIP51 (Lau et al., 2018).  
 
The VAPB-PTPIP51 interaction is disrupted in animal and cell models of ALS. 
Expression of WT or ALS-causing mutant forms of either TDP-43 or FUS reduce VAPB-
PTPIP51 interactions in cultured cells and this reduction is also seen in transgenic mouse 
models expressing WT and mutant forms of TDP-43 and FUS (Stoica et al., 2014; Stoica 
et al., 2016). As a result, disrupted ER-mitochondria contacts, reduced calcium exchange 
between ER and mitochondria and reduced ATP production are also observed in these 
models (Stoica et al., 2014; Stoica et al., 2016). However, neither ER-mitochondrial 
signalling nor VAPB-PTPIP51 binding has yet been investigated in ALS in humans.  
 
3.1.2 Measuring ER-mitochondria contacts in ALS donor tissues 
Human diseases of the central nervous system (CNS) present a major challenge to 
investigate because the affected tissues are largely inaccessible in humans. CNS tissues 
obtained post-mortem and peripheral cells re-programmed to neuronal lineages provide 
two potential solutions to this challenge.  
 
3.1.2.1 Post-mortem spinal cord tissues 
Studies of human neurodegenerative diseases using post-mortem CNS tissue have 
identified pathological hallmarks of diseases such as ALS. For example, TDP-43 was 
identified as the ubiquitinated disease protein that accumulates in affected neurons in 
both ALS and FTD (Neumann et al., 2006) prior to discovery of disease-causing 
mutations in the TARDBP gene that encodes TDP-43 (Sreedharan et al., 2008). This 
can be considered evidence that post-mortem disease tissue is a valuable resource for 
investigating disease mechanisms. For the studies described in this Chapter, the London 
Medical Research Council Neurodegenerative Diseases Brain Bank provided post-





3.1.2.2 Induced pluripotent stem cell-derived motor neurons  
Differentiated patient-derived iPSCs are now relatively well characterised as in vitro 
models of disease (Egawa et al., 2012; Ghaffari et al., 2018; Guo et al., 2017), and this 
approach allows the study of various different cell types, including neurons which cannot 
be directly sampled from patients. Cells derived from iPSC retain the exact genetic 
identity of donors, potentially including as yet unidentified variants that contribute to 
disease.  
 
In this Chapter, VAPB-PTPIP51 interactions were examined in motor neurons 
differentiated from human iPSCs (iPSC-MNs), from control donors and from donors with 
ALS-causing mutations. The two ALS donors had familial forms of ALS, rather than the 
more common sporadic type of disease represented in our post-mortem tissue samples. 
Both donors harbour ALS-causing mutations in the TARDP gene that lead to single 
amino acid substitutions in the TDP-43 protein, M337V (Corrado et al., 2009; Rutherford 
et al., 2008; Sreedharan et al., 2008) and G298S (Nozaki et al., 2010; Van Deerlin et al., 
2008). Both of these mutations are found in exon 6 of TARDP, which codes a glycine 
rich domain and a C-terminal domain (Pesiridis et al., 2009). The G298S mutation 
resides in the glycine rich domain of TDP-43, which is responsible for alternative splicing 
regulation (Van Deerlin et al., 2008). The M337V mutation resides in the C-terminal 
domain and is reported to promote increased fragmentation of TDP-43 to produce C-
terminally truncated TDP-43 fragments (Sreedharan et al., 2008). The protein region 
coded by Exon 6 is also known to be important for mediating the interactions of TDP-43 
with other RNA binding proteins (Berning and Walker, 2019). iPSC-MNs harbouring the 
M337 or G298S mutations in TDP-43 have previously been investigated. These studies 
found that M337V and G298S iPSC-MNs display reduced neurite length as well as 
increased amounts of insoluble TDP-43 relative to control lines (Bilican et al., 2012; 
Egawa et al., 2012). The latter findings are in-line with the accumulations of TDP-43 
found in the post-mortem tissues of a majority of ALS patients (Ling et al., 2013; Van 
Deerlin et al., 2008), while the former suggest that these TDP-43 mutations are 
damaging to motor neuron health. 
 
Dr. Jenny Greig, a collaborator on this project, differentiated iPSCs generated from 
patient and control donor fibroblasts into motor neurons. For this study, an adapted 
protocol was used which promotes maturation of iPSCs into motor neurons as 
determined by electrophysiological activity and expression of choline acetyl transferase 
(ChAT), the enzyme responsible for the synthesis of the neurotransmitter acetylcholine. 
In iPSC-derived motor neuron cells, an immature action potential can be stimulated at 
17 days in vitro and ChAT expression and mature action potential firing are observed at 
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31 days of culture (Maury et al., 2015). In the studies described in this Chapter, iPSC-
motor neurons were grown to 22 days in vitro at which point ChAT is expressed in 65 – 
80 % of cells (unpublished data, Jenny Greig e-thesis). In our hands, this timepoint gave 
the best compromise between maturity of motor neurons and their in vitro survival. Dr. 
Greig previously characterised the M337V and G298S iPSC-MNs used here and found 
in both lines that localisation of TDP-43 is unaltered, but TDP-43 levels are increased 
compared to that in iPSC-MNs from control donors (unpublished data, Jenny Greig e-
thesis). 
 
3.1.2.3 Proximity ligation assays  
To investigate ER-mitochondria contacts in post-mortem spinal cord and iPSC-MNs from 
humans with ALS, this study uses proximity ligation assays to detect VAPB-PTPIP51 
interactions. Proximity ligation assays detect two proteins of interest that are in close 
proximity, between 10 and 40 nm (Alam, 2018; Soderberg et al., 2006). Briefly, primary 
antibodies to the two proteins of interest, raised in different host species, are applied to 
the cells or tissue. In this case in-house rabbit VAPB and in-house rat PTPIP51 
antibodies are used. Species-specific secondary antibodies conjugated to 
complimentary oligonucleotides are then applied and these two oligonucleotides are 
ligated when proteins of interest are sufficiently close to each other. For Brightfield PLA, 
as used for tissue sections, rolling amplification using the ligated oligonucleotides as a 
primer is followed by addition of detection reagents containing horse radish peroxidase-
linked nucleotides which hybridize to the amplification product. These oligonucleotides 
enzymatically convert NOVA red substrate to produce visible red-brown dots at areas of 
interaction between proteins of interest. PLAs were used in their brightfield format in 
human tissue because, in our hands, this generates the strongest signal-background 
and a nuclear counterstain is sufficient to identify motor neurons on the basis of their 
morphology. For fluorescent detection, as used on iPSC-MNs, the rolling amplification 
occurs with fluorescently labelled nucleotides and no extra detection step is required. In 
this case, a fluorescent dot indicates an interaction between the two proteins. PLAs were 
used in their fluorescent format for iPSC-MN studies to enable both nuclear and ChAT 
counterstaining to ensure that analysis was specific to cells that had been successfully 
differentiated into motor neurons. 
 
PLAs have previously been used by our group to examine VAPB-PTPIP51 interactions 
in neuronal cell lines, rodent primary neurons, mouse brain, and iPSC-neurons (Gomez-
Suaga et al., 2017b; Gomez-Suaga et al., 2019; Paillusson et al., 2017; Stoica et al., 




3.1.3 Aims of this chapter 
The aim of this chapter was to investigate the hypothesis that ER-mitochondria contacts 
are disrupted in human ALS. Evidence from human tissues is critical to support the idea 
that strategies which correct ER-mitochondria contacts will have benefit for the treatment 
of ALS.  
 
Firstly, VAPB and PTPIP51 protein amounts were measured in post-mortem spinal cord 
tissue by immunoblotting for VAPB and PTPIP51. Motor neurons in post-mortem spinal 
cord tissue from the same donors were assessed by PLA to allow measurement of 
interactions between the ER-mitochondria tethers VAPB and PTPIP51. Secondly, 
VAPB-PTPIP51 interactions were measured by PLA in iPSC-MNs harbouring ALS-
causative M337V or G298S mutations in comparison to unrelated control iPSC-MNs. 
 
3.2 Results 
3.2.1 VAPB levels are reduced in ALS donor tissue 
Previous studies have found that VAPB-PTPIP51 binding is disrupted in animal and cell 
models of ALS, and that this reduction in tethering is not caused by a reduction in the 
protein levels of either VAPB or PTPIP51 (Stoica et al., 2014; Stoica et al., 2016). 
However, there are reports that VAPB protein levels are reduced in sporadic ALS spinal 
cord relative to controls (Anagnostou et al., 2010) and that iPSC-MNs carrying ALS-
causing mutant forms of VAPB show reduced levels of VAPB protein relative to iPSC-
MNs from non-affected siblings (Mitne-Neto et al., 2011). This study therefore first 
investigated VAPB and PTPIP51 protein expression in our samples of post-mortem 
spinal cord by immunoblotting. Samples were homogenised in RIPA buffer, sonicated, 
centrifuged and protein concentration was measured by BCA assay as described in 2.2.1 
and 2.2.2. Protein concentration was normalised to 2.5 mg/ml protein in Laemmli sample 
buffer before boiling for 5 min.  
 
It was first important to identify primary antibodies with sufficient specificity. Several 
antibodies against VAPB and PTPIP51 were tested in a small set of three control and 
three ALS samples (Figure 3.1). VAPB was detected by an “in house” anti-VAPB, 
produced as described (De Vos et al., 2012) and a commercial anti-VAPB antibody from 
Abcam. Two different anti-PTPIP51 antibodies were tested: one sourced from Gentex 
and the other from Atlas. The molecular mass of VAPB is 33 kDa and it is predicted to 
display a single band at this molecular weight (MW) on immunoblot. The molecular mass 
of PTPIP51 is 51 kDa but it is predicted to display a single band closer to 70 kDa on 
immunoblot. Neuron specific enolase (NSE) was used as a loading control and has a 




The in-house VAPB antibody produced a single band at the expected MW of 33 kDa 
(Figure 3.1A). The VAPB antibody from Abcam produced a doublet at approximately 33 
kDa as well as non-specific bands at 37 kDa, 55 kDa and 70 kDa (Figure 3.1B). The in-
house VAPB antibody is therefore used throughout the rest of this work. The anti-
PTPIP51 antibody sourced from Gentex produced the expected band at just below 70 
kDa but also some strong non-specific bands at 35kDa (Figure 3.1C). The anti-PTPIP51 
antibody sourced from Atlas also produced the expected band at 70 kDa and only faint 
non-specific bands at 35 kDa (Figure 3.1D) and is therefore used throughout the rest of 





Figure 3.1: Antibody optimisation for VAPB and PTPIP51 antibodies. Immunoblots 
of human spinal cord homogenate probed with A) In-house VAPB antibody, B) VAPB 
antibody sourced from Abcam, C) PTPIP51 antibody sourced from Gentex and D) 
PTPIP51 antibody sourced from Atlas. Corresponding NSE blots for A) and C) (bottom 
left panel) and B) and D) (bottom right panel) are shown. N=1 experiment, 3 control and 




Having selected primary antibodies against VAPB and PTPIP51, post-mortem spinal 
cord samples from 17 control and 17 ALS donors, prepared as described above, were 
immunoblotted. All but three samples, which came from thoracic spinal cord, were from 
the lumbar region of the spinal cord. Samples from the thoracic spinal cord are indicated 
in results. Clinical ALS diagnosis was confirmed by the Brain Bank through 
histopathological identification of TDP-43 pathology in motor neurons in all but one case. 
The cases did not include any that showed FUS or SOD1 pathology. Two ALS cases 
were subsequently found to have repeat expansions in C9ORF72 and are indicated in 
results, but no other donor carried additional ALS-causing mutations. One control donor 
displayed TDP-43 inclusions in the hippocampal formation and amygdala, but all control 
donors were confirmed as suitable for this study by both a lack of clinical ALS diagnosis 
and the absence of TDP-43, FUS, SOD1 or C9ORF72 pathology in motor neurons.  
 
Summary demographics of the cases are displayed in Table 3.1. Samples were selected 
by the Brain Bank based on the best possible match between gender, age, and post-
mortem delay (PMD) between control and ALS samples. However, some differences in 
these parameters were subsequently found. Samples are well-matched based on sex. 
There was however a significant difference in PMD: the average PMD for control 
samples was 30.91 (+/- 12.89) hrs compared to an average of 62.44 (+/-16.06) hrs for 
ALS samples (Figure 3.2A). Control samples came from significantly older donors with 
an average age of 83.82 (+/- 11.28) years compared to an average age in ALS cases of 
73.12 (+/- 8.96) years (Figure 3.2B). Age and PMD are therefore assessed in relation to 





Table 3.1: Summary demographics of post-mortem spinal cord tissue donors 
 Control ALS 
Number of cases 17 17 
Male  10 10 
Female 7 7 
Age (years) 63 - 105 56 - 90 
Average Post-mortem Delay 
(Hrs) 
9 - 55 34 - 94 
   






Figure 3.2: Differences in age and post-mortem delay between control and ALS 
cases. A) Hrs of post-mortem delay and B) age in years are plotted for each control and 
ALS donor from which post-mortem spinal cord tissue samples were obtained. N = 17 
control and 17 ALS cases. Age and post-mortem delay were normally distributed as 
tested using D’Agostino & Pearson normality test, p > 0.05. As such, data were analysed 




VAPB and PTPIP51 protein levels were measured in control and ALS donor samples by 
immunoblotting. One ALS sample consistently showed bands at higher than expected 
molecular weights for each protein and was therefore excluded from all analyses. One 
control sample showed no PTPIP51 band and was therefore also excluded. Loss of 
neurons occurs in the spinal cord of ALS patients (Rosler et al., 2000) and therefore a 
general loss of neuronal proteins may also be expected in spinal cord lysates. To account 
for this, the neuronal protein NSE was measured in all samples and amount of protein of 
interest was normalised to NSE level in the same sample. Samples were run across two 
gels, with 8 control and 8 ALS samples on one gel, and 9 control and 9 ALS samples on 
the other. Samples were loaded alternating between control and ALS to reduce the risk 
of any potential uneven antibody exposure. For figures 3.3 and 3.4, representative 
samples, 7 control and 7 ALS, were chosen and the centre 5 control and 5 ALS samples 
on the immunoblot are shown. A single blot was cut to probe for PTPIP51 and TOM20, 
followed by stripping and re-probing for NSE. VAPB and PDI were probed on separate 
blots but also stripped and re-probed for NSE since they are of similar molecular weight. 
 
VAPB levels were found to be significantly reduced in ALS spinal cord compared to that 
in control spinal cord (Figure 3.3A). In contrast, there was no change in the levels of 
PTPIP51 in spinal cord tissue between ALS and control spinal cord samples (Figure 
3.3B). To determine if this reduction in the amount of VAPB is specific or results from 
loss of total ER in ALS spinal cord, the expression of an ER marker, protein disulfide 
isomerase (PDI), was measured by immunoblotting in the same samples. PDI has a 
predicted molecular mass of 57kDa. Similarly, the expression of a 20kDa mitochondrial 
marker, translocase of outer mitochondrial membrane 20 (TOM20), was measured to 
indicate whether the amount of mitochondria is altered in ALS samples. One control 
sample showed no TOM20 band and was therefore excluded from the analysis. The 
protein levels of PDI and TOM20 were also normalised to that of NSE for each sample. 
There was no change in the amount of the ER marker PDI (Figure 3.3C), suggesting that 
the amount of ER, and therefore other ER proteins, is maintained in the ALS tissues. 
Overall, these data suggest a selective loss of VAPB in sporadic ALS spinal cord, in 
agreement with Anagnostou et al. (2010). Interestingly, levels of the mitochondrial 
marker TOM20 were found to be increased in ALS samples relative to controls (Figure 
3.3D), which suggests that there is an increase in either mitochondrial number or 
mitochondrial protein content in ALS spinal cord. 
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Figure 3.3: Levels of ER and mitochondrial proteins in post-mortem spinal cord 
tissue from control and ALS donors. Representative immunoblots of NSE and A) 
VAPB, B) PTPIP51, C) PDI and D) TOM20 in control and ALS spinal cord. Graphs show 
quantification of MAM-related protein levels in the different samples following 
normalisation to NSE levels. Thoracic spinal cord samples are indicated in green and 
C9ORF72 cases are indicated in red. The levels of each protein in control and ALS data 
sets were normally distributed as tested using D’Agostino & Pearson normality test, p > 
0.05. As such, data were analysed by the parametric unpaired two-tailed t-test. N=16-
17, error bars are s.e.m., *p<0.05. 
79 
 
3.2.2 Levels of IP3R, VDAC and Sigma1R are unaltered in ALS donor tissue 
In addition to VAPB and PTPIP51, which represent structural tethers between ER and 
mitochondria, this study investigated interacting pairs of proteins at ER-mitochondria 
contact sites that are proposed to have important functional roles in this location, but that 
may not have a direct role in tethering ER and mitochondria (Lau et al., 2018). One of 
the major functions facilitated by ER-mitochondria contacts is the transfer of calcium from 
the ER, where it is stored, into the mitochondria where it is used in the production of ATP 
(Paillusson et al., 2016). IP3R-VDAC interactions via Grp75 mediate this exchange of 
calcium between the two organelles: calcium is released from the ER via IP3R and enters 
the mitochondria via VDAC (Paillusson et al., 2016; Szabadkai et al., 2006). There are 
three isoforms of IP3R that interact with VDAC to form contacts between the ER and 
mitochondria, IP3R1 and IP3R3 being the most well studied in this respect (Ivanova et 
al., 2014). Unpublished data from our lab investigating IP3R1 and IP3R3 showed that 
IP3R1 was most abundant in the brain and IP3R3 was most abundant in the spinal cord, 
and as such, IP3R3 was studied. The Sigma1R, an ER protein enriched in MAM, binds 
to IP3Rs in the membrane of the ER and is thought to mediate IP3R clustering in the 
membrane to facilitate IP3R-mediated delivery of calcium from ER stores to 
mitochondria. Interestingly, loss-of-function mutations in Sigma1R are linked with familial 
ALS and FTD (Al-Saif et al., 2011; Belzil et al., 2013; Bernard-Marissal et al., 2015; Luty 
et al., 2010) and Sigma1R agonists have shown benefits in mouse models of ALS/FTD 
(Mancuso et al., 2012; Ono et al., 2014; Ryskamp et al., 2019). Calcium exchange is not 
only one of the major functions of ER-mitochondrial signalling but is also known to be 
disrupted in a number of neurodegenerative diseases (Bernard-Marissal et al., 2018; Cali 
et al., 2013a; Krols et al., 2016). We therefore chose to investigate whether IP3R, VDAC 
or Sigma1R protein levels are altered in human ALS donor spinal cord. 
 
IP3R3, VDAC and Sigma1R levels were measured in control and ALS spinal cord 
samples by immunoblotting and protein amounts were normalised to NSE, as described 
above. Sigma1R was probed on the same blot as VAPB, above, by cutting the 
membrane to probe with separate antibodies. NSE was probed on the same section as 
VAPB, after stripping. IP3R and VDAC were probed on separate blots, and the VDAC 
blot was stripped and re-probed for NSE. IP3R3 has a calculated molecular weight of 
304 kDa but is expected to produce a band at 260 kDa. VDAC and Sigma1R have 
molecular weights of 31 and 25 kDa, respectively. Quantification of this data showed that 
there was no significant difference in the levels of IP3R3, VDAC or Sigma1R in ALS 






Figure 3.4: Levels of MAM related proteins in post-mortem spinal cord tissue from 
control and ALS donors. Representative immunoblots of NSE and A) IP3R3, B) VDAC 
and C) Sigma1R in control and ALS spinal cord. Graphs show quantification of MAM-
related protein levels in the different samples following normalisation to NSE levels. Tho-
racic spinal cord samples are indicated in green and C9ORF72 cases are indicated in 
red. The levels of VDAC in control and ALS data sets were normally distributed as tested 
using D’Agostino & Pearson normality test, p > 0.05 and were therefore analysed by 
unpaired two-tailed t test. The levels of IP3R and Sigma1R in Control and ALS data sets 
were not normally distributed as tested using D’Agostino & Pearson normality test, p < 





3.2.3 VAPB-PTPIP51 interactions are reduced in ALS donor tissue 
Having confirmed that there is a loss of VAPB, but not general ER proteins, and an 
increase in some mitochondrial proteins (but not PTPIP51) in human ALS donor tissue, 
the next aim in this study was to determine if the tethering between VAPB and PTPIP51, 
which mediates ER-mitochondrial signalling, is disrupted in ALS donor tissue. Previous 
studies have shown a reduction in the binding between VAPB and PTPIP51 in cell and 
animal models of ALS (Stoica et al., 2014; Stoica et al., 2016), and so it was 
hypothesised that this tethering interaction would be reduced in ALS spinal cord motor 
neurons relative to controls. In order to investigate this, PLAs, as previously described 
(Stoica et al., 2016), were used to measure VAPB-PTPIP51 interactions in spinal cord 
sections from the same control and ALS cases used for immunoblotting. 
 
In the first instance, immunohistochemistry was performed on spinal cord tissue with in-
house VAPB and PTPIP51 antibodies as previously used on tissue sections (Stoica et 
al., 2016). Each antibody was used at concentrations of 1/200, 1/800 and 1/3200 to 
identify a suitable concentration for use in proximity ligation assays on tissue sections. 
The anti-VAPB antibody showed strong labelling at a concentration of 1/200, weak 
labelling at 1/800 and no labelling was apparent when used at 1/3200 (Figure 3.5A). The 
anti-PTPIP51 antibody showed strong immunolabelling when used at concentrations of 
1/200 and 1/800 and weak labelling at 1/3200 (Figure 3.5B). Therefore, antibodies were 
used in PLA experiments at concentrations of 1/200 for VAPB and PTPIP51. 
 
PLAs using the VAPB and PTPIP51 antibodies used in this study have previously been 
published (Stoica et al., 2014; Stoica et al., 2016). To confirm the specificity of the 
technique in human spinal cord tissue, control PLA experiments were carried out. This 
involved conditions in which neither or only a single primary antibody was applied, in 
order to detect any non-specific binding of either primary antibody to other proteins in 
the tissue, and to test the specificity of the PLA signals. Sections were therefore 
incubated with all reagents required for successful PLA and either both primary 
antibodies, neither primary antibody, VAPB primary antibody only, or PTPIP51 antibody 
only (Figure 3.6). PLA signal (red dots) was only detected in the condition in which both 
antibodies were applied, confirming that the signal is specific and is able to identify 






Figure 3.5: Determining optimum antibody concentrations for immunolabelling in 
spinal cord. VAPB (A) and PTPIP51 (B) antibodies were used to immunolabel human 
spinal cord tissue sections at concentrations of 1:200, 1:800 and 1:3200. Examples of 





Figure 3.6: Control experiments demonstrating the specificity of VAPB-PTPIP51 
PLAs in post-mortem spinal cord sections. Controls involved omission of VAPB 
(PTPIP51 only), PTPIP51 (VAPB only), or both VAPB and PTPIP51 primary antibodies 
(no primary Ab). Graph shows PLA signals per motor neuron in the different conditions. 





Having established the optimum concentration of VAPB and PTPIP51 antibodies for use 
in PLAs on spinal cord sections, and demonstrated that the PLA signals are specific, 
VAPB-PTPIP51 PLAs were then carried out on spinal cord sections from the 17 ALS and 
17 control cases used above for immunoblotting. Sections were also stained with 
haematoxylin to detect nuclei. One control and one ALS section showed no PLA signal, 
and one ALS tissue section did not display discernible motor neurons, so quantification 
of PLA signals was conducted on the remaining 16 control and 15 ALS sections. Motor 
neurons were identified in the ventral horn on the basis of their size and morphology as 
in other studies (Arai et al., 2006; Vance et al., 2009) and the number of PLA dots per 
motor neuron was counted. Plasticity in the size of motor neurons has previously been 
reported, with an increase in soma size in affected regions of ALS mice in early disease, 
and a decrease in soma size at end stage disease, compared to that of healthy control 
mice (Dukkipati et al., 2018). However, no difference in size was found between the 
soma of healthy and ALS motor neurons in humans, likely given that the size of a motor 
neuron soma can vary greatly (Toft et al., 2005). To account for possible variations in 
soma size, the number of PLA signals in each motor neuron soma was normalised to its 
size. The number of PLA dots per cell area was significantly reduced in motor neurons 
of ALS spinal cord compared to those in the motor neurons of control sections (Control 
100 % +/- 4.7; ALS 83 % +/- 6.4. Raw data are PLA dots per cell: Control 240 +/- 24; 
ALS 174 +/- 15) (Figure 3.7) as determined by a two-tailed t-test (p = 0.026). These data 
indicate that the number of VAPB-PTPIP51 interactions is reduced in ALS spinal cord, 






Figure 3.7: VAPB-PTPIP51 interactions are reduced in ALS spinal cord motor 
neurons. Representative images of VAPB-PTPIP51 PLAs in motor neurons of control 
and ALS donor spinal cord sections are shown. Top panel shows low magnification and 
bottom panel shows higher magnification insets of the areas indicated by dotted lines. 
VAPB-PTPIP51 signal numbers were normalised to the size of each cell to correct for 
any shrinkage of neurons in the ALS cases. Data was then normalised to controls. Graph 
shows mean number of VAPB-PTPIP51 PLA signals per area of motor neuron for each 
case as a percentage of the mean for control cases. Thoracic spinal cord samples are 
indicated in green and C9ORF72 cases are indicated in red. There was an average of 
240 signals per cell in controls and 174 signals per cell in ALS tissue. n = 16 control, n = 
15 ALS: 20 – 208 motor neurons per case. The number of PLA signals were normally 
distributed as tested using D’Agostino & Pearson normality test, p > 0.05 and were 
therefore analysed by unpaired two-tailed t-test, error bars are s.e.m., *p=0.037. Scale 










































3.2.4 VAPB level does not correlate with VAPB-PTPIP51 interactions 
Given that VAPB protein is reduced in ALS spinal cord tissue, it is possible that the 
reduction of VAPB-PTPIP51 interactions seen in ALS donor tissue is caused by lower 
VAPB protein amounts in the same tissue. In order to investigate this hypothesis, the 
level of VAPB protein was correlated with VAPB-PTPIP51 PLA signal in sections from 
the same case (Figure 3.8). If the interaction between VAPB and PTPIP51 were altered 
based on changes in VAPB protein amount alone, a strong positive correlation would be 
expected. However, there was no significant correlation between protein levels of VAPB 
and PLA signal number (r = -0.106, p=0.58) (Figure 3.8A). Similarly, there was no 
correlation between VAPB amounts and VAPB-PTPIP51 PLA signals when ALS or 
control groups were examined alone (ALS r = 0.045, p=0.11; control r = -0.444, p=0.87) 
(Figure 3.8A where black dots represent control and red dots ALS cases). This suggests 
that changes in VAPB protein amounts alone are not sufficient to cause the reduction in 
VAPB-PTPIP51 interactions identified in ALS spinal cord. 
 
As there were significant differences in age and post-mortem delay between the post-
mortem ALS and control spinal cord tissue samples used in this study, these factors 
were also investigated in relation to VAPB protein amounts and VAPB-PTPIP51 PLAs. 
As mentioned above, should either age or PMD affect levels of VAPB protein or VAPB-
PTPIP51 interactions, a correlation with levels of VAPB or PLA signal would be expected. 
In fact, neither age nor PMD delay correlated with levels of VAPB protein or PLA signal 
and this remained the case whether groups were considered individually or as a whole 
(Figure 3.8B-E where black dots represent control and red dots represent ALS cases, 
summarised in Table 3.2). These results suggest that regardless of age or PMD, the 
amount of VAPB protein is reduced in ALS donor spinal cord and that, independently of 
the levels of VAPB, the interaction between VAPB and PTPIP51 is disrupted in ALS 
donor spinal cords. Taken together these data are strongly indicative that ER-






Figure 3.8: VAPB protein levels, age and PMD do not correlate with PLA signal. A) 
VAPB protein levels normalised to NSE for each individual were plotted against the mean 
number of VAPB-PTPIP51 PLA signals per cell for each individual. The mean number of 
VAPB-PTPIP51 PLA signals per cell were plotted against B) Age and C) PMD. VAPB 
protein levels normalised to NSE were also plotted against D) Age and E) PMD. Data 
was analysed by Pearson’s correlation. R values, calculated for control and ALS 




Table 3.2: Correlation coefficients for donor post-mortem spinal cord tissues 
 
  VAPB level VAPB level PLA Signal PLA Signal VAPB level  
  Age PMD Age PMD PLA Signal  
Control -0.102 0.294 -0.102 0.495 -0.444  
ALS 0.125 -0.190 -0.218 0.218 0.045  
All cases 0.014 -0.008 -0.316 -0.061 -0.106  
      
p>0.05 for all correlations     
 
 
3.2.5 VAPB-PTPIP51 interactions are reduced in iPSC-MNs from ALS donors 
harbouring mutations in TDP-43 
Having confirmed that VAPB-PTPIP51 interactions are reduced in post-mortem ALS 
spinal cord compared to control tissues, this work next aimed to investigate the VAPB-
PTPIP51 interaction in a second model with direct relevance to human disease. 
Therefore, VAPB-PTPIP51 interactions were studied in iPSC-MNs derived from two ALS 
patients harbouring either the M337V or G298S ALS-causative mutation in TDP-43, and 
two unrelated control donors.  
 
Firstly, the specificity of the PLA method in control iPSC-MNs was investigated (Figure 
3.9). ChAT is a marker for motor neurons (Maury et al., 2015; Oda, 1999) and so cultured 
cells were counter stained for ChAT (green) to confirm differentiation of iPSCs into motor 
neurons. ChAT staining was strong and diffuse in cell soma, with some small puncta, as 
seen in Figures 3.9 – 3.11. As expected, ChAT also clearly stained cell processes, 
thought this staining was less strong than in the cell soma. The percentage of ChAT 
stained cells was not quantified in these experiments but was deemed to be similar to 
previous experiments by our collaborator, Jenny Greig who reported 65 – 80 % ChAT 
staining (Jenny Greig e-thesis). Controls were carried out as before, including neither 
primary antibody, VAPB primary antibody only, PTPIP51 antibody only or both primary 
antibodies (Figure 3.9). No PLA signal (red dots) was detected when no primary 
antibodies were applied (not shown) or when only a single antibody was used. PLA signal 
was only detected in the condition in which both antibodies were applied, showing that 
the signal is specific to points of interaction between the VAPB and PTPIP51 proteins in 
iPSC-MNs. Coverslips showing populations of cells with very large soma, indicating glia 
cell populations, were excluded since it was considered that this might affect VAPB-
PTPIP51 binding and introduce a variable other than patient versus control cells. These 





Figure 3.9: Control experiments demonstrating the specificity of VAPB-PTPIP51 
PLAs in iPSC-MNs. Controls involved omission of VAPB (PTPIP51 only), PTPIP51 
(VAPB only), or both VAPB and PTPIP51 primary antibodies (not shown). Cells were 
immunolabelled with an antibody against choline acetyl transferase (ChAT) to identify 
cells that had differentiated into motor neurons. Panels show DAPI (blue), ChAT (green), 
PLA (red) and Merge from left to right, respectively. Graph shows VAPB-PTPIP51 PLA 
signals per iPSC-MN in the different conditions. N=1 experiment, 20-96 cells per 
































































To determine whether the VAPB–PTPIP51 interaction is disrupted in ALS patient 
material, proximity ligation assays were used to examine the VAPB-PTPIP51 interaction 
in iPSC-MNs from ALS patients with either M337V or G298S point mutations in TDP-43, 
and unrelated controls without ALS.  
 
Firstly, iPSC-MNs from an ALS patient donor harbouring an M337V mutation in TDP-43 
were investigated in comparison to iPSC-MNs from an unrelated healthy donor. VAPB-
PTPIP51 PLA was carried out as above and PLA signals were quantified specifically in 
motor neurons that display ChAT immunolabelling. PLA signals were quantified per 
motor neuron and normalised to the surface area of the motor neuron soma to account 
for any differences in cell size. PLA signals per area of motor neuron were found to be 
significantly reduced in ALS patient iPSC-MNs as compared to control iPSC-MNs 
(p<0.0001) (Figure 3.10). PLA signal in iPSC-MNs from TDP-43-M337V ALS donors was 
on average 49 % lower than PLA signal in iPSC-MNs from control donors (Figure 3.10). 
 
Next, iPSC-MNs from an ALS patient donor harbouring a G298S mutation in TDP-43 
were investigated compared to iPSC-MNs from another unrelated control donor. VAPB-
PTPIP51 PLA and quantification was carried out as described above. PLA signals were 
found to be significantly reduced in TDP-43-G298S iPSC-MNs ALS in comparison to 
those in control iPSC-MNs (p=0.0011) (Figure 3.11). PLA signal in iPSC-MNs from TDP-
43-G298S ALS donors was on average 40 % lower than PLA signal in iPSC-MNs from 
control donors (Figure 3.11). Taken together these data indicate a disruption of VAPB-
PTPIP51 binding in ALS patient material, further indicating that ER-mitochondria 








Figure 3.10: The VAPB-PTPIP51 interaction is reduced in iPSC-MNs derived from 
ALS patients harbouring the TDP-43 M337V mutation. Representative images of 
VAPB-PTPIP51 PLAs in iPSC-MNs derived from a control donor and an ALS patient 
harbouring a TDP-43 M337V mutation are shown. Cells were also immunolabelled using 
an antibody against choline acetyl transferase (ChAT) to identify motor neurons. Panels 
show DAPI (blue), ChAT (green), PLA (red) and Merge from left to right, respectively. 
Graph shows mean number of VAPB-PTPIP51 PLA signals per area of motor neuron as 
a percentage of control. The number of neurons analysed were N=3 biological replicates, 
including 13 – 53 cells from each experiment. PLA signals in ALS samples were not 
normally distributed as tested using D’Agostino & Pearson normality test, p < 0.05 and 
data was therefore analysed by the non-parametric Mann-Whitney test, error bars are 
















































Figure 3.11: The VAPB-PTPIP51 interaction is reduced in iPSC-MNs derived from 
ALS patients harbouring the TDP-43 G298S mutation. Representative images of 
VAPB-PTPIP51 PLAs in iPSC-MNs derived from control donors and ALS patients har-
bouring a TDP-43 G298S mutation are shown. Cells were counter-stained for choline 
acetyl transferase (ChAT) to identify motor neurons. Panels show DAPI (blue), ChAT 
(green), PLA (red) and Merge from left to right, respectively. Graph shows mean number 
of VAPB-PTPIP51 PLA signals per area of motor neuron as a percentage of control. The 
numbers of neurons analysed were N= 3 biological replicates, 10 – 32 cells from each 
experiment. PLA signals in ALS samples were not normally distributed as tested using 
D’Agostino & Pearson normality test, p < 0.05 and data was therefore analysed by the 















































3.3.1 Summary of results 
In line with the hypothesis of this chapter, this work has found that the interaction 
between VAPB and PTPIP51 is reduced in motor neurons in human ALS spinal cord 
tissues and iPSC-MNs compared to controls. VAPB protein amounts are reduced in ALS 
spinal cord but did not correlate with disrupted VAPB-PTPIP51 interactions in these 
samples. The amount of the ER marker PDI was unchanged from controls indicating that 
the change in VAPB is not solely a result of ER loss. No change in the protein amount of 
PTPIP51 was detected between ALS and control spinal cord tissue, but levels of the 
mitochondrial marker TOM20 were increased in ALS tissue. There was no change in the 
levels of other ER-mitochondria associated proteins, namely IP3R, VDAC or Sigma1R 
in ALS donor tissue compared to controls. These results strongly indicate that the 
reduced interactions between VAPB-PTPIP51 observed in these samples is specific and 
indicates disrupted ER-mitochondria interactions in ALS.  
 
3.3.2 ER protein levels in post-mortem ALS spinal cord 
The finding in this work that VAPB protein levels are reduced in the spinal cord of ALS 
donors complements previously published data (Anagnostou et al., 2010). This finding 
also fits with reports that expression of the P56S ALS-causing mutation in VAPB reduces 
VAPB protein levels and loss of VAPB function (Kanekura et al., 2006; Mitne-Neto et al., 
2011), suggesting that reduced VAPB functionality is involved in ALS pathogenesis. 
Interestingly, in contrast to the findings in spinal cord, VAPB protein levels are reported 
to accumulate in denervated muscle tissue of ALS donors (Jesse et al., 2017). Taken 
together, these observations highlight cell-type differences in ALS and could indicate that 
gene therapy to upregulate VAPB in brain may not be a feasible strategy in ALS, unless 
we develop a better understanding of the causes of ALS up- and down-regulation in 
specific tissues. 
 
In the work presented here, the levels of other ER resident proteins, PDI and IP3R, were 
similar in control and ALS spinal cord tissues. This suggests that the change seen in 
VAPB protein is not due to a reduction in the overall amount of ER in ALS spinal cord. It 
has previously been reported that the amount of PDI, which is considered a marker of 
ER stress, is increased in ALS (Atkin et al., 2008; Ilieva et al., 2007). These published 
studies investigated only 5 – 8 individuals including some earlier onset ALS cases which 
may explain the differences between these studies and the work presented here. The 
average age of ALS donors in the previous reports was 59 and 63 years respectively, 
compared to an average age of 72 years in this study. Interestingly, Anagnostou et al. 
(2010) found that VAPB protein amounts are only significantly lower in ALS cases that 
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show rapid progession from diagnosis to death (1-3 years) and not in patients surviving 
4 – 20 years with ALS. These observations raise questions about the possibility that 
there are differing mechanisms in disease depending on age at disease onset, and the 
speed of progression. It would be interesting therefore to consider differences in VAPB, 
PDI, and other ER-stress markers in early- and late-onset ALS in which rate of disease 
progression is known, and also to compare sporadic and familial ALS cases.  
 
3.3.3 Mitochondrial protein levels in post-mortem ALS spinal cord  
TOM20 is a constituent member of a complex found in the outer membrane of 
mitochondria that is responsible for importing mitochondrial proteins from cytosol into the 
intermembrane space of mitochondria (Mori and Terada, 1998). It is used in this study 
as a mitochondrial marker and its protein levels were found to be increased in ALS spinal 
cord. It may be speculated that elevated TOM20 amounts indicates increased numbers 
of mitochondria or increased production of mitochondrial proteins. However, the levels 
of other mitochondrial proteins, PTPIP51 and VDAC, were found to be unchanged 
between control and ALS donors which argues against this conclusion. Therefore, the 
observed increase in TOM20 expression in ALS tissue is surprising, especially since 
mitochondrial dysfunction is heavily implicated in ALS (Jiang et al., 2015).  
 
A study of mitochondria in spinal cord from two ALS cases with SOD1 mutations also 
reported an increase in the amounts of TOM20, as well as an increase in the amounts 
of other mitochondrial import proteins (Li et al., 2010). A hypothesis to explain these 
observations, consistent with reports that mitochondria are defective in ALS, would be 
that enhanced expression of mitochondrial proteins represents a compensatory 
mechanism for dysfunctional mitochondria. This is supported by the finding of Li et al. 
(2010) in SOD1 transgenic mice, who showed that despite increased levels of TOM 
proteins generally, the import activity of mitochondria in the ALS model is reduced, 
suggesting dysfunction of the TOM complex. The hypothesis could be investigated by 
measuring import activity and mitochondrial protein amounts at various time points 
during ALS progression: if decreased import activity occurred first, it may indicate that 
increased protein expression is a compensatory response. Measuring whether or not 
experimental impairment of TOM20 activity, for example by genetic editing, results in 
increased mitochondrial protein levels would serve to show whether impaired TOM20 
activity alone is sufficient to drive an increase in protein levels. Although PTPIP51 and 
VDAC protein levels were not found to be higher in ALS than control tissues in this study, 
Li et al. (2010) also found increases in the amount of other mitochondrial proteins such 




There are also reports that mitophagy, the process by which mitochondria are degraded 
and recycled, is disrupted in ALS (Davis et al., 2018; Hong et al., 2012) and this is in-
keeping with findings of ALS-causing mutations in genes involved in autophagy such as 
TBK-1 and OPTN (Oakes et al., 2017). Dysfunctional mitophagy leads to aberrant 
accumulation of mitochondria (Evans and Holzbaur, 2019) and therefore mitophagy 
could also be investigated as a potential cause of increased TOM20 protein levels in 
ALS.  
 
3.3.4 Sigma1R protein levels in post-mortem ALS spinal cord 
This study also investigated the levels of proteins involved in calcium signalling between 
the ER and mitochondria. IP3R and VDAC interact at MAM to facilitate efficient exchange 
of calcium (Csordas et al., 2006; Rowland and Voeltz, 2012) and the Sigma 1R mediates 
the clustering of IP3Rs at MAM to generate localised high calcium concentrations 
(Hayashi and Su, 2007; Ryskamp et al., 2019). IP3R3, VDAC and Sigma1R protein 
levels in spinal cord were found to be unchanged between ALS and control tissues in 
this study. IP3R3 was investigated in this study due to its relative abundance in the spinal 
cord compared to the other well studied isoform, IP3R1. More recently however, isoform 
2 has been reported as the most efficient coupler for ER-mitochondria calcium transfer, 
although all three isoforms carry out this role (Bartok et al., 2019). It would therefore be 
worthwhile to investigate the protein levels of IP3R2, and its interaction with VDAC, in 
ALS spinal cord.  
 
ALS-causing mutations have been found in Sigma1R (Al-Saif et al., 2011; Luty et al., 
2010) but since these mutations are thought to be loss of function mutations (Bernard-
Marissal et al., 2015; Dreser et al., 2017; Gregianin et al., 2016), altered Sigma1R protein 
amounts are not necessarily expected. It has been reported that Sigma1R protein levels 
are increased in denervated muscle tissue of ALS donors (Jesse et al., 2017), as 
discussed previously for VAPB. Increased VAPB levels in denervated muscle tissue 
(Jesse et al., 2017) and decreased VAPB levels in spinal cord in ALS (Anagnostou et 
al., 2010) further indicates that there may be cell/tissue specific alterations in MAM 
proteins in ALS that are worthy of further investigation.  
 
3.3.5 Reduced VAPB-PTPIP51 interactions in post-mortem ALS spinal cord  
The finding in this chapter that VAPB-PTPIP51 interactions are reduced in human ALS 
spinal cord and iPSC-MNs provides valuable validation of previous studies showing 
reduced interactions between these proteins in animal and cell models of ALS (Stoica et 
al., 2014; Stoica et al., 2016). Previous studies have shown that reducing VAPB-
PTPIP51 interactions, by genetically ablating VAPB or PTPIP51 expression, reduces 
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ER-mitochondrial membrane contacts and subsequently ER-mitochondrial signalling (De 
Vos et al., 2012). The data therefore leads to the conclusion that ER-mitochondrial 
signalling is disrupted in ALS. To further confirm this conclusion, post-mortem tissue may 
be used in EM studies to measure ER and mitochondrial membrane contacts directly. 
The methods employed in this chapter could be used to investigate the interaction of 
IP3R and VDAC, which are responsible for the transfer of calcium at ER-mitochondria 
contact sites (Szabadkai et al., 2006), in ALS tissues. This could provide further 
confirmation that there is disruption of ER-mitochondrial signalling in ALS. 
 
It may be considered that reduced VAPB protein amounts explain the reduction in VAPB-
PTPIP51 interactions observed in ALS spinal cord. However, VAPB protein amounts did 
not correlate with number of VAPB-PTPIP51 PLA signals in the same samples. This 
suggests that levels of VAPB does not account entirely for the reduced VAPB-PTPIP51 
binding in ALS cells, and that another, as yet unknown, mechanism contributes to this 
reduced interaction. This is supported by findings in animal models in which VAPB-
PTPIP51 binding is decreased in ALS without any corresponding changes in VAPB 
protein (Stoica et al., 2014; Stoica et al., 2016). It may be hypothesised therefore that 
there is a change in the affinity of VAPB to PTPIP51 in ALS motor neurons. Previous 
studies have shown that TDP-43 and FUS reduce VAPB-PTPIP51 interaction via 
activation of the kinase GSK-3β (Stoica et al., 2014; Stoica et al., 2016). GSK-3β 
phosphorylates a wide range of proteins in the cell and as such it is possible that VAPB 
or PTPIP51 is a target, either directly or indirectly, of GSK-3β. Phosphorylation can act 
as a modulator of protein interactions and therefore it can be hypothesised that 
phosphorylation of either VAPB or PTPIP51 disrupts their interaction and therefore ER-
mitochondria contacts. This potential mechanism is investigated in the next chapter of 
this study.  
 
The majority of ALS cases investigated here were sporadic and had no identified ALS-
causing mutations. Two ALS cases had repeat expansions in C9ORF72. The amount of 
VAPB and PTPIP51 proteins and extent of VAPB-PTPIP51 interactions in these cases 
were not apparently different compared to the other ALS cases examined. Therefore, 
there was not sufficient justification to remove them from our data set. The ALS donors 
were significantly younger at death than non-disease controls, but samples from these 
cases were exposed to significantly longer post-mortem delays than control donors. 
These variables were correlated with VAPB protein amounts and PLA signal to gauge 
the extent that such variables might contribute to the results. No correlation was identified 
between either age or post-mortem delay with VAPB amounts or VAPB-PTPIP51 PLA 
signals. This does not completely rule out potential effects of age and post-mortem delay 
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on our investigations but does indicate that factors besides these two variables are 
involved in the differences in ER-mitochondria interactions observed between ALS and 
control donor tissues.  
 
Finally, post-mortem ALS tissues are generally collected at the very end stages of 
disease, with varying levels of post-mortem delay, which can cause variability in protein 
degradation and tissue integrity. Therefore, post-mortem tissues do not necessarily 
represent only tissue changes caused by disease. However, major pathological findings 
in post-mortem tissue have paved the way for the discovery of mutations which cause 
ALS. For tissues such as the CNS, post-mortem analyses remain one of the most 
accessible ways of measuring disease related changes in an inaccessible tissue. 
 
3.3.6 Reduced VAPB-PTPIP51 interactions in ALS patient-derived iPSC-MNs 
Measurement of PLA signal in iPSC-MNs allowed investigation of ALS in a human tissue 
model that is not subject to post-mortem stress and using cells from patients harbouring 
mutations in TDP-43 that cause familial forms of ALS. VAPB-PTPIP51 interactions were 
found to be reduced in iPSC-MNs derived from patients with two different TDP-43 
mutations (M337V and G298S), providing further support for the idea that disruption of 
VAPB-PTPIP51 binding reduces ER-mitochondria interactions in ALS.  
 
At 21 days of iPSC-MN differentiation, our collaborator on this work (Dr. Greig) reports 
increased TDP-43 levels in both M337V and G298S iPSC-MNs, and that formation of 
TDP-43 aggregates is found only in M337V cells at this timepoint (unpublished data,  
Jenny Greig e-thesis). Therefore, reduced VAPB-PTPIP51 interactions do not appear to 
be related to the emergence of TDP-43 aggregates since PLA signals were similarly 
reduced in both iPSC-MN lines. This might suggest that disrupted ER-mitochondria 
interactions occur early in disease development. End stage disease in humans shows 
reduced VAPB protein levels as well as reduced ER-mitochondria interactions, however, 
mouse studies find reduced ER-mitochondria but unaltered VAPB or PTPIP51 protein 
levels. This supports, but does not confirm, a hypothesis that ER-mitochondria contact 
is an early pathological disease mechanism. This hypothesis could be investigated 
effectively by studying transgenic mouse models of ALS at various time points before 
and after symptom onset. Parallel studies of iPSC-MNs differentiated for different lengths 
of time would also go some way to ascertaining the stage at which ER-mitochondria 
contacts are disrupted.  
 
Some criticisms have been made over the use of iPSC-derived cells, particularly in age-
related neurodegenerative diseases. For example, epigenetic profiles are usually 
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disrupted during the de-differentiation process and since epigenetic marks confer many 
age-related properties of cells (Guo et al., 2017), this is an issue when studying 
neurodegenerative diseases for which age is a risk factor. As for all cell culture studies, 
the surrounding environment of the cells does not recapitulate that of human brain, 
lacking other neural cell types and the many extracellular factors that can affect cell 
responses. In addition, this study compares just two patient iPSC lines as a result of 
availability, and so individual (within group) differences impact results very strongly and 
make comparisons with controls difficult. Isogenic control lines in which the ALS-causing 
mutation, in this case M337V or G298S in TDP-43, is edited to the wild-type sequence, 
would overcome some of these issues by enabling the comparison of cells from the same 
donor. Editing is carried out after de-differentiation to iPSCs, such that changes in 
epigenetic profiles during the de-differentiation process, although still disrupted, are 
consistent between cell lines (Ghaffari et al., 2018). Most importantly, isogenic cell lines 
eliminate individual genetic differences between control and mutant cells, besides the 
ALS-causing mutation (Guo et al., 2017). Moreover, motor neurons derived from patient 
iPSCs also enable the study of disease development and progression, unlike post-
mortem tissues. 
 
To further strengthen findings from human ALS tissues described here, VAPB-PTPIP51 
interactions could be studied in human material from more common familial forms of 
ALS, including those with disease-causing mutations in SOD1 and C9ORF72. 
Nevertheless, finding the same results in human tissues with sporadic and familial forms 
of ALS strongly supports the premise that disrupted ER-mitochondria contacts are a 
pathological feature of ALS. This is supported by the notion that ER-mitochondrial 
signalling mediates a number of common mechanisms disrupted in ALS and 
neurodegenerative disease more widely (Paillusson et al., 2016). In addition, our group 
have found reduced VAPB-PTPIP51 interactions in early Braak stage post-mortem AD 
brain (Lau et al., manuscript in submission) supporting the hypothesis that defective ER-
mitochondrial interactions occur early in different types of neurodegenerative diseases. 
Together these results suggest ER-mitochondria contacts should be considered as a 




















4.1.1. ER-mitochondrial signalling is disrupted by TDP-43 and FUS by GSK-3β 
activation 
The work in Chapter 3 showed that ER-mitochondria tethering by VAPB-PTPIP51 
binding is reduced in the motor neurons of human ALS patients. This work confirms 
previous studies suggesting that the VAPB-PTPIP51 interaction is a potential therapeutic 
target for the treatment of ALS.  
 
As discussed in detail in Chapter 1, VAPB-PTPIP51 binding is disrupted by ALS-related 
proteins TDP-43 and FUS. This disruption is mediated by activation of GSK-3β (Stoica 
et al., 2016; Stoica et al., 2014). Two small molecule inhibitors of GSK-3β, CHIR99021 
and AR-A014418, were used to study its role in ER-mitochondrial signalling and found 
that GSK-3β inhibition increases VAPB-PTPIP51 binding and rescues the effect of WT 
and ALS-mutant FUS on ER-mitochondria tethering and calcium signalling (Stoica et al., 
2016). This indicates a potential role for GSK-3β kinase activity in the disruption of ER-
mitochondria contact functions and in turn in the pathogenesis of ALS. However, the 
mechanism by which GSK-3β affects the binding of VAPB and PTPIP51 is yet to be 
established.  
 
4.1.2 GSK-3β is a serine/threonine kinase implicated in neurodegenerative disease 
GSK-3β is a serine/threonine kinase which phosphorylates a large number of substrates 
in the cell (Kaidanovich-Beilin and Woodgett, 2011). Phosphorylation is one of the 
primary post translational modifications known to alter protein-protein interactions within 
the cell. Phosphorylation also occurs dynamically, meaning that it can modulate 
interactions reversibly, as would be necessary in the case of regulating ER-mitochondria 
contacts which respond to dynamic cellular processes. The work in this chapter therefore 
hypothesises that GSK-3β disrupts VAPB-PTPIP51 binding by phosphorylating VAPB 
and/or PTPIP51.  
 
There are two isoforms of glycogen synthase kinase, GSK-3α and GSK-3β. Both 
isoforms are ubiquitous and highly expressed in the central nervous system. Both GSK-
3 isoforms are involved in a wide range of cellular processes including differentiation, 
proliferation and apoptosis and they signal in a variety of pathways, including Notch and 
Wnt signalling (Kaidanovich-Beilin and Woodgett, 2011). GSK-3 is one of few proteins 
with high basal activity, regulated by inhibitory phosphorylation. For GSK-3β, 
phosphorylation at tyrosine residue 216 is thought to enhance activity whilst inhibitory 
phosphorylation occurs primarily at residue serine 9, but can also occur at threonine 43, 
serine 389 and threonine 390 (Kaidanovich-Beilin and Woodgett, 2011). This regulation 
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occurs via a number of diverse pathways, including mitogen-activated protein kinase 
(MAPK) and Akt, but is also reported to occur by autophosphorylation. Additionally, GSK-
3β can be regulated by the formation of complexes, such as in the Wnt signalling 
pathway, or through localisation, although these are less fully understood. GSK-3β has 
numerous substrates in the cell. Mostly these substrates undergo priming 
phosphorylation prior to phosphorylation by GSK-3β, such that there is phosphorylation 
4 or 5 residues C-terminal to the GSK-3β target site (Doble and Woodgett, 2003; Forde 
and Dale, 2007; Kaidanovich-Beilin and Woodgett, 2011; Luo, 2012; Wu and Pan, 2010). 
 
GSK-3β is implicated in neurodegenerative diseases, for example in AD due to its activity 
as a tau kinase, and inhibition of the kinase has been found to be neuroprotective (Doble 
and Woodgett, 2003). In ALS, small molecule inhibitors of GSK-3β have been found to 
improve motor neuron survival and reduce symptoms in cell and animal models (Caldero 
et al., 2010; Feng et al., 2008; Fornai et al., 2008; Koh et al., 2007), though it should be 
noted that these results were not reproducible in female mice (Pizzasegola et al., 2009). 
Reduced activity of the GSK-3 inhibitor Akt (which phosphorylates GSK-3β on serine-9) 
has been reported in ALS patient tissue and prior to symptom onset in the SOD1 mutant 
mouse model of ALS. Overexpression of Akt in this model reduced motor neuron death 
(Dewil et al., 2007). Additionally, GSK-3 inhibitors were identified in a screen for kinase 
inhibitors which reduce the formation of TDP-43-positive stress granules (Moujalled et 
al., 2013). Despite efforts to inhibit GSK-3β in neurodegenerative disease treatment, 
trials have not yet been successful; perhaps due to the difficulty in targeting one isoform 
over another and the extent of pathways in which GSK-3β is a crucial component. 
Identifying a mechanism downstream of GSK-3β in ALS pathogenesis may therefore 
provide a drug target with greater selectivity.  
 
4.1.3 AMP-activated Kinase is a master regulator of cellular energy metabolism 
AMP-activated kinase (AMPK) has been shown to phosphorylate the ER protein VAPA, 
as identified in a study of cellular phospho-proteomic changes occurring during exercise 
(Hoffman et al., 2015). VAPA is a homologue of VAPB and unpublished work from our 
group shows that VAPA binds to PTPIP51. The protein sequences of VAPA and VAPB 
are highly conserved and the site phosphorylated by AMPK in VAPA, serine residue 164, 
is conserved in VAPB at serine residue 158 in humans and other species (Figure 4.1).  
 
AMPK is a major metabolic regulator of the cell. It is activated in response to reduced 
energy levels and phosphorylates substrates to stimulate processes which increase the 
production of ATP (Carling, 2017; Hardie et al., 2012). AMPK is a complex of three 
subunits. The α-subunit contains the protein’s catalytic kinase domain and is also the 
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site of activating phosphorylation, threonine residue 172. Thr172 is phosphorylated by 
Calcium/Calmodulin Dependent Protein Kinase Kinase 2 (CAMKK2), in response to high 
cellular calcium levels, activating AMPK. AMPK is also activated by low cellular energy 
levels, as indicated by high cellular levels of AMP as compared to that of ATP. The γ-
subunit binds to AMP, ADP or ATP and therefore senses the AMP/ADP:ATP ratio as a 
measure of cellular energy. The β-subunit contains a glycogen binding domain which is 
thought to act as another energy sensing mechanism. The β-subunit also completes the 
AMPK complex by interacting with both α- and γ- subunits (Carling, 2017; Hardie et al., 
2012).  
 
AMPK has also been linked to ALS, though the significance of this link is yet to be 
established. AMPK activity is reported to be upregulated in one model of ALS (Liu et al., 
2015), but this is a model using wild-type TDP-43 and in an ALS-causing mutant TDP-
43 model AMPK activity is reduced (Perera et al., 2014). Very little is known about the 
role of AMPK in ALS, but these studies suggest that dysregulation of AMPK activity may 
be involved in pathogenesis. Treatment with an AMPK activator, Latrepirdine, has been 
found to delay symptom onset in a SOD1 ALS mouse model when administered prior to 
the onset of symptoms (Coughlan et al., 2015). This AMPK activator has also been 
investigated in clinical trials for AD and other neurodegenerative disease but with mixed 
efficacy (Cano-Cuenca et al., 2014).  
 
Given that AMPK is activated in response to reduced cellular energy and increased 
cellular calcium levels, and that ER-mitochondria contacts facilitate mitochondrial 
calcium uptake and ATP production, it is possible to hypothesise that AMPK plays a role 
in the regulation of ER-mitochondria contacts. This chapter therefore also investigates 
the hypothesis that AMPK phosphorylates VAPB or PTPIP51 to modulate their tethering 
of ER-mitochondrial membranes. 
 
 
Figure 4.1: AMPK phosphorylation site in VAPA is conserved in VAPB in humans. 
Alignment of a section of the sequence of human VAPA, human VAPB and mouse 
VAPB. AMPK phosphorylation site is circled in red; it is conserved between VAPA and 





4.1.4 Aims of this chapter 
In order to investigate the hypothesis that GSK-3β phosphorylates VAPB or PTPIP51, 
this work first phosphorylated recombinant VAPB or PTPIP51 with GSK-3β in vitro. LC-
MS/MS was then used to identify GSK-3β phosphorylation sites in either protein.  
 
To confirm the presence of these in vitro sites in cells, and to identify novel sites of 
phosphorylation, VAPB and PTPIP51 were immunoprecipitated from cells and analysed 
by LC-MS/MS. Further, to enhance the likelihood of confirming target GSK-3β 
phosphorylation sites identified in vitro, VAPB and PTPIP51 were immunoprecipitated 
from cells transfected with GSK-3β, so as to increase its cellular activity. Finally, to 
enhance the likelihood of identifying the predicted AMPK phosphorylation site, or other 
potential AMPK target residues, VAPB and PTPIP51 were immunoprecipitated from cells 
treated with an AMPK activator and analysed by LC-MS/MS.  
 
4.2 Results 
4.2.1 Identification of GSK-3β phosphorylation sites in recombinant PTPIP51  
To investigate the hypothesis that GSK-3β disrupts VAPB-PTPIP51 binding by 
phosphorylation, this study sought to identify target sites in recombinant protein isolated 
from E.coli. First, PTPIP51 was to be incubated with recombinant GSK-3β in vitro to allow 
phosphorylation in an environment with no other kinases present.  
 
Recombinant PTPIP51 without the mitochondrial targeting transmembrane domain and 
fused to GST (GST-PTPIP51(36-470)) was produced as described in 2.2.11. To 
phosphorylate PTPIP51 with GSK-3β, 6 μg GST-PTPIP51(36-470) was incubated for 16 
hrs at 30 oC with commercially sourced recombinant GSK-3β and an excess of ATP. 
PTPIP51 without the transmembrane domain was used because membrane spanning 
domains are not expected to be phosphorylated as they reside in the membrane and are 
insoluble and therefore difficult to isolate from E.coli. Reactions containing either the 
buffer and ATP reaction mix (RM) alone, RM and GST-PTPIP51(36-470), RM and GSK-
3β or RM, GST-PTPIP51(36-470) and GSK-3β were performed. After 16 hrs, samples 
were separated using SDS-PAGE and stained with imperial protein stain as described in 
2.2.12 (Figure 4.2). GST-PTPIP51(36-470) has a molecular weight of approximately 75 
kDa and is expected to show a band at a slightly higher molecular weight, as PTPIP51 
itself does. GSK-3β has a predicted molecular weight of 47 kDa. Commercially sourced 
GSK-3β is expected to show a band at approximately 55 kDa and contains the E.coli 
protein GroE chaperone with a molecular weight of 90 kDa. Reactions containing RM, 
GST-PTPIP51(36-470) and GSK-3β were carried out in triplicate to ensure sufficient 




Recombinant protein corresponding to GST-PTPIP51(36-470) which had been 
incubated with GSK-3β was excised from the gel for mass spectrometric analysis. 
Although mass spectrometry is a sensitive technique, phosphorylation occurs reversibly 
and in small proportions. Therefore, to ensure that a sufficient amount of protein to 
enable the detection of phosphopeptides was generated, three bands of the protein were 
excised and pooled for processing and mass spectrometry. Recombinant protein was 
prepared for LC-MS/MS as detailed in 2.2.12. Briefly, the protein was digested with 
trypsin, cysteine residues were reduced and stabilised and peptides were then extracted 
for LC-MS/MS analyses.  
 
Peptides corresponding to recombinant PTPIP51(36-470) and providing sequence 
coverage of 79 % of the full-length human protein were identified by LC-MS/MS (Figure 
4.3). Only one site of phosphorylation was identified in PTPIP51. The fragmentation 
spectra of the corresponding phosphopeptide localized this phosphorylation to serine 
residue S77 (Figure 4.4). Phosphorylation at S77 has not been reported in any large-
scale mass spectrometry data curated in either of two online repositories, the database 
of Phospho-sites in Animals and Fungi (dbPAF) and Phosphosite (see 
http://www.phosphosite.org/home). Additionally, this serine residue at position 77 is not 
conserved between the human, mouse or rat protein, suggesting little likelihood of this 
residue having a regulatory function in such a fundamental cellular process as ER-












Figure 4.2: In vitro phosphorylation of GST-PTPIP51(36-470) by GSK-3β. GST-
PTPIP51(36-470) was incubated with commercial GSK-3β. Reactions containing RM 
alone, RM + GST-PTPIP51(36-470), RM + GSK-3β and RM + GSK-3β + GST-
PTPIP51(36-470) were incubated for 16 hrs at 30 0C. Proteins were separated by SDS-
PAGE and visualised using imperial protein stain. Reactions without recombinant 
PTPIP51 enabled distinction between PTPIP51 and proteins contained in the RM or 







Figure 4.3: PTPIP51 is phosphorylated by GSK-3β in vitro at residue S77. (A) 
Sequence of full length human PTPIP51 with the MS/MS sequence coverage of 79 %, 
obtained after trypsin digestion of GST-PTPIP51(36-470), shown as underlined. One in 
vitro GSK-3β phosphorylation site was identified (S77), shown in red. (B) PTPIP51 
phosphopeptide obtained by MS/MS sequencing with corresponding mass/charge (m/z) 
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Figure 4.4: Identification of PTPIP51 S77 as a potential GSK-3β phosphorylation 
site by LC-MS/MS. Tandem mass spectrometry spectrum of the PTPIP51 
phosphopeptide 68AVPGGAGDApSVLPSLPR84 (m/z 822.412+) fragment ion series after 
collision induced dissociation. The m/z of the ions is plotted against intensity and the 
detected ions of the b- (red) and y- (blue) ion collision series are indicated in the 
sequence of the peptide (top left). A loss of 98, indicating a constant neutral loss of 
phosphoric acid, from the parent ion is present at m/z 773.462+ and is indicative of either 
a serine or threonine phosphorylation on the peptide. Loss of phosphoric acid from b-12, 
b-14 and b-15 and y-9, y-10, y-11 and y-12 (indicated by arrows on the spectrum) localize 




4.2.2 Identification of GSK-3β phosphorylation sites in recombinant VAPB  
Having investigated phosphorylation of PTPIP51 by GSK-3β, this study next sought to 
identify GSK-3β target phosphorylation sites in recombinant VAPB. As above, VAPB was 
to be incubated with recombinant GSK-3β to allow phosphorylation in an environment 
with no other kinases present.  
 
Recombinant protein corresponding to the cytoplasmic domain of VAPB with a histidine 
tag (His-VAPB(1-220)) was produced as described in 2.2.11. To phosphorylate VAPB 
with GSK-3β, 6 μg His-VAPB(1-220) was incubated for 16 hrs at 30 oC with commercially 
sourced recombinant GSK-3β and an excess of ATP. Reactions containing either the 
buffer and ATP reaction mix (RM) alone, RM and His-VAPB(1-220), RM and GSK-3β or 
RM, His-VAPB(1-220) and GSK-3β were performed (Figure 4.5). After 16 hrs, samples 
were separated using SDS-PAGE and stained with imperial protein stain as described in 
2.2.12. VAPB has a predicted molecular weight of 33 kDa and, as in section 4.2.1, GSK-
3β was predicted to show a band at 55 kDa with GroE chaperone at 90 kDa. Reactions 
containing RM, His-VAPB(1-220) and GSK-3β were carried out in triplicate to ensure 
sufficient protein was available for mass spectrometry and to enable detection of 








Figure 4.5: In vitro phosphorylation of His-VAPB(1-220) by GSK-3β. His-VAPB(1-
220) was incubated with commercial GSK-3β. Reactions containing RM alone, RM + 
His-VAPB(1-220), RM + GSK-3β and RM + GSK-3β + His-VAPB(1-220) were incubated 
for 16 hrs at 30 0C. Proteins were separated by SDS-PAGE and visualised using imperial 
protein stain. Reactions without recombinant VAPB enabled distinction between VAPB 
and proteins contained in the RM or contaminants of commercial GSK-3β. Molecular 
mass markers are indicated on the right. 
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Peptides corresponding to recombinant His-VAPB(1-220) and providing sequence 
coverage of 85 % of the full-length human protein were identified by LC-MS/MS (Figure 
4.6). Three sites of phosphorylation were identified (Figure 4.6) in His-VAPB(1-220). 
Fragmentation spectra of the corresponding phosphopeptides localized phosphorylation 
to threonine residues T143, T148 and T150 (Figures 4.7, 4.8, 4.9 respectively). All three 
of these residues reside between the MSP domain and the coiled coil domain of VAPB.  
 
GSK-3β commonly targets proteins that are pre-phosphorylated at a priming residue 
located 4 or 5 residues C-terminal to the site of GSK-3β phosphorylation (Doble and 
Woodgett, 2003). Priming of GSK-3β substrates is usually carried out by a different 
kinase, therefore such priming is not replicated in these in vitro conditions and it is 
possible that some GSK-3β sites were not detected in this study. However, 
phosphorylation at residues T143 and T148 fit the consensus sequence for GSK-3β 
phosphorylation, with T148 potentially acting as a priming site for phosphorylation at 
T143. It is possible that the close proximity and high concentration of enzyme and 
substrate in these in vitro conditions, as well as the lack of any inhibitory regulation or 
alternative substrates, allows GSK-3β to phosphorylate residues which are susceptible 
to phosphorylation but might normally be phosphorylated by a different kinase in vivo. 
Large scale mass spectrometry data from four studies have reported phosphorylation at 
VAPB-T143, and one study has reported phosphorylation at VAPB-T148, as curated in 
the dbPAF, supporting the result that these residues undergo phosphorylation. T150 has 
also been found to be phosphorylated (see http://www.phosphosite.org/) but this site is 
not conserved between humans, mice and rats. As ER-mitochondrial signalling mediates 
many fundamental cellular functions and has been observed in experiments in mice, it 
would be considered that regulatory mechanisms are conserved between species. This 
project therefore focusses on residues T143 and T148, which are conserved, as the most 





Figure 4.6: VAPB is phosphorylated by GSK-3β in vitro at residues T143, T148 and 
T150. (A) Sequence of full length human VAPB with the MS/MS sequence coverage of 
85 %, obtained after trypsin digestion of His-VAPB(1-220), shown as underlined. Three 
in vitro GSK-3β phosphorylation sites were identified (T143, T148, T150), shown in red. 
(B) VAPB phosphopeptides obtained by MS/MS sequencing with their mass/charge 








Peptide Sequence                Peptide m/z Residue 
121CVFELPAENDKPHDVEINKIISpTTASKTETPIVSK155   998.504+ T143 
140IISTTASKpTETPIVSK155     585.983+ T148 
121CVFELPAENDKPHDVEINKIISTTASKTEpTPIVSK155   998.504+ T150 




Figure 4.7: Identification of VAPB T143 as a potential GSK-3β phosphorylation site 
by LC-MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
121CVFELPAENDKPHDVEINKIISpTTASKTETPIVSK155 (m/z 998.504+) fragment ion 
series after collision induced dissociation. The m/z of the ions is plotted against intensity 
and the detected ions of the b- (red) and y- (blue) ion collision series are indicated on 
the sequence of the peptide (top left). A constant neutral loss of 98, phosphoric acid, 
from the parent ion indicative of serine or threonine phosphorylation was not detected on 
the peptide. However, loss of phosphoric acid from y-13 and y-14, (indicated by arrows 







Figure 4.8: Identification of VAPB T148 as a potential GSK-3β phosphorylation site 
by LC-MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
140IISTTASKpTETPIVSK155 (m/z 585.983+) fragment ion series after collision induced 
dissociation. The m/z of the ions is plotted against intensity and the detected ions of the 
b- (red) and y- (blue) ion collision series are indicated on the sequence of the peptide 
(top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was present 
at m/z 553.263+ and is indicative of either a serine or threonine phosphorylation on the 
peptide. Loss of phosphoric acid from the doubly charged b-10, b-11 and y-9, y-10 ions 







Figure 4.9: Identification of VAPB T150 as a potential GSK-3β phosphorylation site 
by LC-MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
140IISTTASKTEpTPIVSK155 (m/z 878.462+) fragment ion series after collision induced 
dissociation. The m/z of the ions is plotted against intensity and the detected ions of the 
b- (red) and y- (blue) ion collision series are indicated on the sequence of the peptide 
(top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was present 
at m/z 829.652+ and is indicative of either a serine or threonine phosphorylation on the 
peptide. Loss of phosphoric acid from b-13 and y-6, y-7, y-9, y-10 and y-11 ions 







4.2.3 Modification of VAPB at GSK-3β phosphorylation sites affects VAPB-
PTPIP51 binding 
To determine whether phosphorylation by GSK-3β at T143 and T148 in VAPB affect its 
binding to PTPIP51, phosphomutants of VAPB were generated. T143 and T148 were 
mutated either to alanine, to prevent phosphorylation, or to aspartate, to mimic 
constitutive phosphorylation. This approach has been used in many studies (see for e.g. 
(Ackerley et al., 2003; Eidenmuller et al., 2001)). These mutations were introduced into 
a construct of VAPB for use in a mammalian GAL4 2-hybrid assay which measures the 
strength of interaction between VAPB and PTPIP51 using a luciferase readout. 
 
This assay uses a firefly luciferase reporter gene under the control of the upstream 
activating sequence (UAS) promoter, activated by GAL4. GAL4 comprises a DNA 
binding domain (DBD) and a trans-activating (TA) domain. The DBD and a viral protein 
which acts as a strong trans-activator, VP16, can be expressed separately and when 
coming into contact with each other will drive firefly luciferase expression. To facilitate 
the measurement of VAPB-PTPIP51 binding, this study used constructs expressing the 
cytoplasmic domains of VAPB and PTPIP51, VAPB(1-220) and PTPIP51(36-470), fused 
to the GAL4 DBD and VP16 trans-activator respectively to drive firefly luciferase 
expression upon binding (Figure 4.10). A construct expressing renilla luciferase under a 
constitutively active promoter was used as a transfection efficiency control. Renilla 
luciferase emits light at a different wavelength and in response to different substrates to 
firefly luciferase and the two signals can therefore be distinguished.  
 
In the first instance, to confirm the specificity of the GAL4 2-hybrid assay system for 
quantifying VAPB-PTPIP51 binding, the assay was performed with DBD-VAPB(1-220)-
WT and VP16-PTPIP51(36-470), with the positive control of full length GAL4 and several 
negative controls. Negative controls include DBD-VAPB(1-220) and VP16-PTPIP51(36-
470) transfected with the corresponding domains of GAL4 not conjugated to the 
corresponding VAPB or PTPIP51 protein to ensure that both constructs are required to 
induce firefly luciferase expression. 
 
HEK-293 cells were transfected with the GAL4-UAS-luciferase construct either alone or 
with DBD, VP16, DBD+VP16, DBD-VAPB(1-220)+VP16, VP16-PTPIP51(36-470)+DBD, 
DBD-VAPB(1-220)+VP16-PTPIP51(36-470) or full length GAL4 as a positive control. 
Cells were also transfected with the transfection control renilla luciferase. Expression of 
GAL4 or DBD-VAPB(1-220)+VP16-PTPIP51(36-470) induced strong firefly luciferase 
signals (Figure 4.11) compared to controls, demonstrating the validity of the assay for 
monitoring PTPIP51-VAPB binding. 
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Next, HEK-293 cells were transfected with constructs expressing renilla and firefly 
luciferase, VP16-PTPIP51(36-470) and either DBD-VAPB(1-220)-WT, DBD-VAPB(1-
220)-T143A, DBD-VAPB(1-220)-T143D, DBD-VAPB(1-220)-T148A or DBD-VAPB(1-
220)-T148D. After 24 hrs of transfection cells were lysed and firefly luciferase signals, 
followed by renilla signals, were assayed. Firefly luciferase signals were normalised to 
renilla signals and then to that of VAPB(1-220)-WT. VAPB(1-220)-T148D displayed 
significantly reduced binding to PTPIP51(36-470) when compared to WT-VAPB control 
(p=0.028) in these assays, suggesting that phosphorylation at this residue reduces the 







Figure 4.10: Diagram of the basis of the mammalian cell GAL4 2-hybrid assay 
system for quantifying VAPB-PTPIP51 binding. Luciferase expression is under the 
control of the GAL4-UAS promoter. Binding of VAPB(1-220), which is conjugated to the 
DNA binding domain of GAL4, to PTPIP51(36-470), which is conjugated to the trans-
activating protein VP16, brings VP16 into close proximity to the promoter enabling it to 
induce firefly luciferase expression. Measurement of the firefly luciferase signal enables 







Figure 4.11: Control experiment to demonstrate the validity of the mammalian cell 
GAL4 2-hybrid assay for monitoring the VAPB-PTPIP51 interaction. Cells were 
transfected with renilla and firefly luciferase with either control vector (Ctrl), GAL4-DBD, 
DBD, VP16, DBD+VP16, VP16 + DBD-VAPB(1-220), DBD+VP16-PTPIP51(36-470), 
DBD-VAPB+VP16-PTPIP51(36-470), or full length GAL4 as a positive control. Cells 
were lysed 24 hrs after transfection, luciferase signals were measured and firefly lucifer-
ase signal normalised to renilla signals. DBD-VAPB(1-220)+VP16-PTPIP51(36-470) and 
full length GAL4 induced firefly luciferase expression. N = 1 experiment, 4 replicates. 

























































































































Figure 4.12: Modification of T148D in VAPB reduces binding to PTPIP51 in the 
mammalian cell GAL4 2-hybrid assay. Cells were transfected with constructs of renilla 
and firefly luciferase, VP16-PTPIP51(36-470) and either DBD-VAPB(1-220) -WT, -
T143A, -T143D, -T148A or -T148D. Cells were lysed 24 hrs after transfection, luciferase 
signals were measured and firefly luciferase signal normalised to renilla. DBD-VAPB(1-
220)-T148D produced significantly lower luciferase signal as compared to DBD-VAPB-
WT control. Data analysed by one-way ANOVA and Tukey post hoc test. n = 3 biological 







































































4.2.4 Identification of phosphorylation sites in VAPB in cells in which GSK-3β is 
activated by overexpression 
The identification of phosphorylation sites in recombinant proteins as described above is 
useful to identify sites phosphorylated directly by GSK-3β. However, it is also important 
to confirm the presence of phosphorylation at these sites in cells, where the factors that 
affect phosphorylation in vivo, such as phosphatases and kinase inhibitors, are present. 
For this reason, phosphorylation of VAPB and PTPIP51 was studied by mass 
spectrometry of VAPB and PTPIP51 purified from transfected cells. VAPB and PTPIP51 
were purified by immunoprecipitation and SDS-PAGE. To maximise the likelihood of 
identifying GSK-3β phosphorylation target sites, VAPB and PTPIP51 were co-
transfected with either control vector or GSK-3β to increase kinase activity. 
 
Firstly, full length VAPB with an N-terminal myc tag was exogenously expressed in HEK-
293 cells with either control vector (Ctrl) or a construct expressing GSK-3β. Cells were 
lysed 24 hrs after transfection and a small sample was probed for GSK-3β to ensure 
over-expression in the GSK-3β transfected cells (Figure 4.13A) Endogenous GSK-3β 
has a predicted molecular weight of 47 kDa and bands were seen at this weight. Myc-
VAPB was immunoprecipitated from both samples via the myc tag and proteins were 
separated by SDS-PAGE. To maximise the amount of protein for analysis, the 
experiment was carried out in triplicate and myc-VAPB from all three samples for each 
condition was excised from the imperial stained SDS-PADE gel (Figure 4.13B) for mass 
spectrometric analysis. More myc-VAPB, as indicated by stronger bands at 33kDa, was 
found in cells over-expressing GSK-3β. This may be considered to indicate that GSK-3β 
increases levels of VAPB, increases global protein expression, or that there are more 
cells in the GSK-3β over-expression condition which may be caused by GSK-3β or may 
be an experimental difference. Increased global protein amounts are also seen in GSK-
3β over-expressing cells in Figure 2.24, though to a lesser extent. Western blot for VAPB 
with a loading control, or a cell count, could be used to identify the cause of this 
difference. Gels bands of myc-VAPB were prepared, including digestion of the protein 
with trypsin, for LC-MS/MS which was carried out at the King’s College London 










Figure 4.13: Overexpression of GSK-3β and purification of Myc-VAPB for LC-
MS/MS analysis of phosphorylation. HEK-293 cells were transfected with Myc-VAPB 
and either control vector or GSK-3β. Cells were lysed 24 hrs after transfection and a 
sample was probed for GSK-3β expression by immunoblot (A). Myc-VAPB was immuno-
precipitated using a Myc antibody, separated on an SDS-PAGE gel and stained with 
imperial protein stain (B). The positions of GSK-3β and VAPB are shown and molecular 




LC-MS/MS of myc-VAPB isolated from cells expressing only endogenous GSK-3β 
identified peptides corresponding to myc-VAPB and provided sequence coverage of 76 
% of the full-length human protein (Figure 4.14). Six individual sites of phosphorylation 
were identified and analysis of the corresponding fragmentation spectra of these 
phosphopeptides confirmed the localisation of phosphorylation to threonine reside T144 
and serine residues S154, S156, S158, S159 and S160. 
 
LC-MS/MS of myc-VAPB isolated from cells over-expressing exogenous GSK-3β 
identified peptides corresponding to myc-VAPB and provided sequence coverage of 86 
% of the full-length human protein (Figure 4.15). Five individual sites of phosphorylation 
were identified and analysis of the corresponding fragmentation spectra of these 
phosphopeptides confirmed the localisation of phosphorylation to threonine reside T150 
and serine residues S146, S156, S158 and S160. One doubly phosphorylated peptide 
was identified, with phosphorylation at both S156 and S160 residues.  
 
One representative fragmentation spectrum is shown for one phosphopeptide 
representing each phosphorylation site found in VAPB either from cells expressing only 
endogenous GSK-3β or from cells overexpressing GSK-3β. Spectra are shown for 
residues T144, S146, T150, S154, S156, S158, S159 and S160 in figures 4.16, 4.17, 
4.18, 4.19, 4.20, 4.21, 4.22 and 4.23 respectively.  
 
Phosphorylation at residues S146 and T150 was found in VAPB from cells over-
expressing GSK-3β but not in VAPB from control cells. VAPB residues T143 and T148, 
as identified in the recombinant experiments carried out earlier in the chapter, were not 
found to be phosphorylated in VAPB from cells. Whilst this does not rule out 
phosphorylation of these residues by GSK-3β, it does mean that more experiments 





Figure 4.14: Phosphorylation sites identified in VAPB isolated from cells 
expressing only endogenous GSK-3β. (A) Sequence of full length human VAPB with 
the MS/MS sequence coverage of 76 % shown as underlined. Six phosphorylation sites 
were identified (T144, S154, S156, S158, S159, S160), shown in red. (B) VAPB 
phosphopeptides obtained by MS/MS sequencing with their mass/charge (m/z) ratios. 







Peptide Sequence    Peptide m/z Phosphorylated Residue 
140IISTpTASKTETPIVSK155   878.462+ T144 
148TETPIVpSKSLSSSLDDTEVKK168  782.063+ S154 
140IISTTASKTETPIVSKpSLSSSLDDTEVK167 1006.513+ S156 
156SLpSSSLDDTEVKK168   744.852+ S158 
148TETPIVSKSLSpSSLDDTEVK167  1108.532+ S159 





Figure 4.15: Phosphorylation sites identified in VAPB isolated from cells 
overexpressing GSK-3β. (A) Sequence of full length human VAPB with the MS/MS 
sequence coverage of 86 % shown as underlined. Five phosphorylation sites were 
identified (S146, T150, S156, S158, S160), shown in red. (B) VAPB phosphopeptides 
obtained by MS/MS sequencing with their mass/charge (m/z) ratios. One doubly 
phosphorylated peptide was identified, with phosphorylation at both S156 and S160 








Peptide Sequence   Peptide m/z Phosphorylated Residue 
140IISTTApSKTETPIVSK155   878.462+ S146 
140IISTTASKTEpTPIVSK155   878.462+ T150 
148TETPIVSKpSLSSpSLDDTEVK167  1148.522+ S156, S160 
148TETPIVSKpSLSSSLDDTEVKK167  739.363+ S156 
156SLpSSSLDDTEVKK168   496.903+ S158 




Figure 4.16: Identification of VAPB T144 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
140IISTpTASKTETPIVSK155 (m/z 878.462+) fragment ion series after collision induced 
dissociation. The m/z of the fragment ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was 
present at m/z 829.902+ and is indicative of either a serine or threonine phosphorylation 
on the peptide. Loss of phosphoric acid from the b-5 and y-12 ions (indicated by arrows 




Figure 4.17: Identification of VAPB S146 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
140IISTTApSKTETPIVSK155 (m/z 878.462+) fragment ion series after collision induced 
dissociation. The m/z of the fragment ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was 
present at m/z 829.712+ and is indicative of either a serine or threonine phosphorylation 
on the peptide. Loss of phosphoric acid from the y-10 ion, the doubly charged y-13 and 
y-14 ions (indicated by arrows on the spectrum) and the b-8 and b-10 ions, localize this 





Figure 4.18: Identification of VAPB T150 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
140IISTTASKTEpTPIVSK155 (m/z 878.462+) fragment ion series after collision induced 
dissociation. The m/z of the fragment ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was 
present at m/z 830.202+ and is indicative of either a serine or threonine phosphorylation 
on the peptide. Loss of phosphoric acid was detected at the b-13 ion. Loss of phosphoric 
acid from the sequence tag y-6 to y-11 ions (indicated by arrows on the spectrum), but 





Figure 4.19: Identification of VAPB S154 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
148TETPIVpSKSLSSSLDDTEVKK168 (m/z 782.063+) fragment ion series after collision 
induced dissociation. The m/z of the ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was 
present at m/z 749.623+ and is indicative of either a serine or threonine phosphorylation 
on the peptide. Loss of phosphoric acid from doubly charged b-13 and y-15 ions 
(indicated by arrows on the spectrum), but not y-5 to y-10 or y-12, localize this 




Figure 4.20: Identification of VAPB S156 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
140IISTTASKTETPIVSKpSLSSSLDDTEVK167 (m/z 1006.513+) fragment ion series after 
collision induced dissociation. The m/z of the ions is plotted against intensity and the 
detected ions of the b- (red) and y- (blue) ion collision series are indicated on the 
sequence of the peptide (top left). A constant neutral loss of phosphoric acid, 98, from 
the parent ion was present at m/z 974.323+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from y-12 and y-14 but not y-11 
ions, and from doubly charged b-17 and b-18 ions, (indicated by arrows on the spectrum) 





Figure 4.21: Identification of VAPB S158 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
156SLpSSSLDDTEVKK168 (m/z 744.852+) fragment ion series after collision induced 
dissociation. The m/z of the ions is plotted against intensity and the detected ions of the 
b- (red) and y- (blue) ion collision series are indicated on the sequence of the peptide 
(top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was present 
at m/z 696.062+ and is indicative of either a serine or threonine phosphorylation on the 
peptide. Loss of phosphoric acid from b-3 and both singly and doubly charged y-11 ions, 





Figure 4.22: Identification of VAPB S159 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
148TETPIVSKSLSpSSLDDTEVK167 (m/z 1,108.532+) fragment ion series after collision 
induced dissociation. The m/z of the ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was 
present at m/z 1059.902+ and is indicative of either a serine or threonine phosphorylation 
on the peptide. Loss of phosphoric acid from b-12, but not b-5 to b-11 ions, and from y-






Figure 4.23: Identification of VAPB S160 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
156SLSSpSLDDTEVKK168 (m/z 744.852+) fragment ion series after collision induced 
dissociation. The m/z of the ions is plotted against intensity and the detected ions of the 
b- (red) and y- (blue) ion collision series are indicated on the sequence of the peptide 
(top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was present 
at m/z 696.132+ and is indicative of either a serine or threonine phosphorylation on the 
peptide. Loss of phosphoric acid from singly charged b-8 and doubly charged b-9 and b-
10 ions, and from y-9 to y-11 ions, (indicated by arrows on the spectrum) localize this 





4.2.5 Identification of phosphorylation sites in PTPIP51 in cells in which GSK-3β 
is activated by overexpression 
In a similar fashion to the experiments described above for VAPB, cellular 
phosphorylation of PTPIP51 was studied to identify phosphorylation sites in cells. Full 
length PTPIP51 with a C-terminal HA tag was exogenously expressed in HEK-293 cells 
with either control vector (Ctrl) or vector expressing GSK-3β: overexpression of GSK-3β 
was conducted to increase the possibility of identifying GSK-3β phosphorylation sites. 
Cells were lysed 24 hrs after transfection and a small sample was probed for GSK-3β by 
immunoblot to check for over-expression in the GSK-3β transfected cells (Figure 4.24). 
GSK-3β expression was detected in cells overexpressing GSK-3β, but endogenous 
GSK-3β was not detected. This is likely due to the small amount of cell lysis sample used 
to check for GSK-3β. PTPIP51-HA was immunoprecipitated from both samples via the 
HA tag and proteins were separated by SDS-PAGE and stained with imperial protein 
stain (Figure 4.24). As above, the experiment was carried out in triplicate and PTPIP51-
HA bands from all three samples were excised for mass spectrometric analysis. Gel 
bands of isolated PTPIP51-HA were prepared, including digestion of the protein with 
trypsin, as detailed in 2.2.12 for LC-MS/MS which was carried out at the King’s College 








Figure 4.24: Overexpression of GSK-3β and purification of PTPIP51-HA for LC-
MS/MS analysis of phosphorylation. HEK-293 cells were transfected with PTPIP51-
HA and either control vector or GSK-3β. Cells were lysed 24 hrs after transfection and a 
sample was probed for GSK-3β expression by immunoblot (A). PTPIP51-HA was im-
munoprecipitated using a HA antibody, separated on an SDS-PAGE gel, and stained 
with imperial protein stain (B). The positions of GSK-3β, PTPIP51 and Immunoglobulin 




LC-MS/MS of PTPIP51-HA isolated from cells expressing only endogenous GSK-3β 
identified peptides corresponding to PTPIP51-HA and provided sequence coverage of 
82 % of the full-length human protein (Figure 4.25). Twelve individual sites of 
phosphorylation were identified and analysis of the corresponding fragmentation spectra 
of these phosphopeptides confirmed the localisation of phosphorylation to threonine 
resides T54 and T56 and serine residues S44, S46, S50, S57, S77, S81, S193, S225, 
S272 and S285. Doubly phosphorylated peptides were identified, corresponding to 
phosphorylation at S44 and S46, S44 and S50, S46 and S57, S46 and S50. 
 
LC-MS/MS of PTPIP51-HA isolated from cells over-expressing exogenous GSK-3β 
identified peptides corresponding to PTPIP51-HA and provided sequence coverage of 
83 % of the full-length human protein (Figure 4.26). Ten individual sites of 
phosphorylation were identified and analysis of the corresponding fragmentation spectra 
of these phosphopeptides confirmed the localisation of phosphorylation to serine 
residues S44, S46, S50, S57, S77, S81, S193, S212, S285 and to tyrosine residue Y284. 
Doubly phosphorylated peptides were identified, corresponding to phosphorylation at 
S44 and S50, S46 and S57, S46 and S50. One triply phosphorylated peptide was 
identified, with phosphorylation at residues S44, S46, S50. Phosphorylation at residue 
S212 was found in PTPIP51 from cells over-expressing GSK-3β but not in PTPIP51 from 
control cells.  
 
One representative fragmentation spectrum is shown for one phosphopeptide 
representing each phosphorylation site found in PTPIP51, either from cells expressing 
only endogenous GSK-3β or from cells overexpressing GSK-3β. Spectra are shown for 
residues S44, S46, S50, T54, T56, S57, S77, S81, S193, S212, S225, Y284, S285 in 





Figure 4.25: Phosphorylation sites identified in PTPIP51 isolated from cells 
expressing endogenous GSK-3β. (A) Sequence of full length human PTPIP51 with the 
MS/MS sequence coverage of 82 % shown as underlined. Twelve phosphorylation sites 
were identified, shown red and detailed in B) under “Modification”. (B) PTPIP51 
phosphopeptides obtained by MS/MS sequencing with their mass/charge (m/z) ratios 











Peptide Sequence      Peptide m/z  Modification 
41HGRpSQpSLPNSLDYTQTSDPGR61    826.013+ S44, S46 
41HGRpSQSLPNSLDYTQTSDPGR61    799.363+ S44 
41HGRpSQSLPNpSLDYTQTSDPGR61    1238.522+ S44, S50 
41HGRSQpSLPNSLDYTQTSDPGR61    1198.542+ S46 
44SQpSLPNSLDYTQTpSDPGR61    1063.432+ S46, S57 
44SQSLPNpSLDYTQTSDPGR61      1023.452+ S50 
44SQSLPNSLDYTQpTSDPGR61      1023.452+ T56 
44SQpSLPNpSLDYTQTSDPGR61    1063.432+ S46, S50 
44SQSLPNSLDYpTQTSDPGR61      683.633+ T54 
68AVPGGAGDApSVLPSLPR84     822.412+ S77 
68AVPGGAGDASVLPpSLPR84     822.412+ S81 
188DSDKEpSEDGEDEVSCETVK206    1119.422+ S193 
210KDSLDLEEEAASGASpSALEAGGSSGLEDVLPLLQQADELHR250   1430.013+ S225 
268LVYGpSRQDFLWR279     810.392+ S272 





Figure 4.26: Phosphorylation sites identified in PTPIP51 isolated from cells 
overexpressing exogenous GSK-3β. (A) Sequence of full length human PTPIP51 with 
the MS/MS sequence coverage of 83 % shown as underlined. Ten phosphorylation sites 
were identified, shown red and detailed in B) under “Modification”. (B) PTPIP51 
phosphopeptides obtained by MS/MS sequencing with their mass/charge (m/z) ratios 













Peptide Sequence      Peptide m/z  Modification 
41HGRpSQSLPNSLDYTQTSDPGR61    799.363+ S44 
41HGRpSQSLPNpSLDYTQTSDPGR61    826.023+ S44, S50 
41HGRpSQpSLPNpSLDYTQTSDPGR61    1278.502+ S44, S46, S50 
41HGRSQpSLPNSLDYTQTSDPGR61    1198.532+ S46 
44SQpSLPNSLDYTQTpSDPGR61    1063.432+ S46, S57 
44SQSLPNpSLDYTQTSDPGR61      1023.452+ S50 
44SQSLPNSLDYTQTpSDPGR61      1023.452+ S57 
44SQpSLPNpSLDYTQTSDPGR61    1063.432+ S46, S50 
68AVPGGAGDApSVLPSLPR84     822.412+ S77 
68AVPGGAGDASVLPpSLPR84     822.412+ S81 
188DSDKEpSEDGEDEVSCETVK206    1119.422+ S193 
210KDpSLDLEEEAASGASSALEAGGSSGLEDVLPLLQQADELHR250   1430.013+ S212 
283ApYSDMCELTEEVSEK297     907.352+ Y284 




Figure 4.27: Identification of PTPIP51 S44 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
41HGRpSQSLPNSLDYTQTSDPGR61 (m/z 799.363+) fragment ion series after collision 
induced dissociation. The m/z of the ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated in the sequence of the 
peptide (top left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from 
the parent ion is present at m/z 767.123+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from b-5 and b-7 ions, and from 
doubly charged y-18 and y-20 ions (indicated by arrows on the spectrum), localize this 











Figure 4.28: Identification of PTPIP51 S46 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
41HGRSQpSLPNSLDYTQTSDPGR61 (m/z 1198.532+) fragment ion series after collision 
induced dissociation. The m/z of the ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated in the sequence of the 
peptide (top left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from 
the parent ion is present at m/z 1149.892+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from the doubly charged y-19 
ion and from b-6 and b-7 ions, but not from the b-5 ion, (indicated by arrows on the 











Figure 4.29: Identification of PTPIP51 S50 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
44SQSLPNpSLDYTQTSDPGR61 (m/z 1023.452+) fragment ion series after collision in-
duced dissociation. The m/z of the ions is plotted against intensity and the detected ions 
of the b- (red) and y- (blue) ion collision series are indicated in the sequence of the pep-
tide (top left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from the 
parent ion is present at m/z 974.652+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from b-7 and b-8 ions, but not 
from the b-1, b-2 or b3 ions, and from y-12 but not y-16 ions (indicated by arrows on the 











Figure 4.30: Identification of PTPIP51 T54 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
44SQSLPNSLDYpTQTSDPGR61 (m/z 682.633+) fragment ion series after collision in-
duced dissociation. The m/z of the ions is plotted against intensity and the detected ions 
of the b- (red) and y- (blue) ion collision series are indicated in the sequence of the pep-
tide (top left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from the 
parent ion is present at m/z 650.253+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from doubly charged b-11 and 
doubly charged y-9 and y-10 ions (indicated by arrows on the spectrum), localize this 











Figure 4.31: Identification of PTPIP51 T56 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
44SQSLPNSLDYTQpTSDPGR61 (m/z 1023.452+) fragment ion series after collision in-
duced dissociation. The m/z of the ions is plotted against intensity and the detected ions 
of the b- (red) and y- (blue) ion collision series are indicated in the sequence of the pep-
tide (top left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from the 
parent ion is present at m/z 965.752+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from b-13 and y-6 ions (indi-
cated by arrows on the spectrum), localize this phosphorylation to T56 (highlighted red 











Figure 4.32: Identification of PTPIP51 S57 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
44SQSLPNSLDYTQTpSDPGR61 (m/z 1023.452+) fragment ion series after collision in-
duced dissociation. The m/z of the ions is plotted against intensity and the detected ions 
of the b- (red) and y- (blue) ion collision series are indicated in the sequence of the pep-
tide (top left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from the 
parent ion is present at m/z 974.802+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from y-6 and doubly charged b-
15 and b-16 ions, but not from b-4 to b-12 ions (indicated by arrows on the spectrum), 











Figure 4.33: Identification of PTPIP51 S77 as phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
68AVPGGAGDApSVLPSLPR84 (m/z 822.412+) fragment ion series after collision induced 
dissociation. The m/z of the ions is plotted against intensity and the detected ions of the 
b- (red) and y- (blue) ion collision series are indicated in the sequence of the peptide (top 
left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from the parent 
ion is present at m/z 773.562+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from b-12 and y-9 ions 
(indicated by arrows on the spectrum), localize this phosphorylation to S77 (highlighted 











Figure 4.34: Identification of PTPIP51 S81 as phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
68AVPGGAGDASVLPpSLPR84 (m/z 822.412+) fragment ion series after collision induced 
dissociation. The m/z of the ions is plotted against intensity and the detected ions of the 
b- (red) and y- (blue) ion collision series are indicated in the sequence of the peptide (top 
left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from the parent 
ion is present at m/z 773.572+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from b-15 and y-4 and y-6 ions 
(indicated by arrows on the spectrum), localize this phosphorylation to S81 (highlighted 












Figure 4.35: Identification of PTPIP51 S193 as phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the PTPIP51 phosphopeptide 
188DSDKEpSEDGEDEVScETVK206 (m/z 1119.422+) fragment ion series after collision in-
duced dissociation. The m/z of the ions is plotted against intensity and the detected ions 
of the b- (red) and y- (blue) ion collision series are indicated in the sequence of the pep-
tide (top left). A loss of 98, indicating a constant neutral loss of phosphoric acid, from the 
parent ion is present at m/z 1070.762+ and is indicative of either a serine or threonine 
phosphorylation on the peptide. Loss of phosphoric acid from b-7 and b-8, y-14 and y-
15 ions (indicated by arrows on the spectrum), localize this phosphorylation to S193 




Figure 4.36: Identification of PTPIP51 S212 as a phosphorylation site by LC-
MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
210KDpSLDLEEEAASGASSALEAGGSSGLEDVLPLLQQADELHR250 (m/z 1430.013+) 
fragment ion series after collision induced dissociation. The m/z of the fragment ions is 
plotted against intensity and the detected ions of the b- (red) and y- (blue) ion collision 
series are indicated on the sequence of the peptide (top left). A constant neutral loss of 
phosphoric acid, 98, from the parent ion was present at m/z 1398.273+ and is indicative 
of either a serine or threonine phosphorylation on the peptide. Loss of phosphoric acid 








Figure 4.37: Identification of PTPIP51 S225 as a phosphorylation site by LC-
MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
210KDSLDLEEEAASGASpSALEAGGSSGLEDVLPLLQQADELHR250 (m/z 1430.013+) 
fragment ion series after collision induced dissociation. The m/z of the fragment ions is 
plotted against intensity and the detected ions of the b- (red) and y- (blue) ion collision 
series are indicated on the sequence of the peptide (top left). A constant neutral loss of 
phosphoric acid, 98, from the parent ion was present at m/z 1398.073+ and is indicative 
of either a serine or threonine phosphorylation on the peptide. Loss of phosphoric acid 
at the doubly charged y-26 ion and the b-16, b-18 and b-19 ions (indicated by arrows on 













Figure 4.38: Identification of PTPIP51 S272 as a phosphorylation site by LC-
MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
268LVYGpSRQDFLWR279 (m/z 810.392+) fragment ion series after collision induced dis-
sociation. The m/z of the fragment ions is plotted against intensity and the detected ions 
of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was 
present at m/z 761.602+ and is indicative of either a serine or threonine phosphorylation 
on the peptide. Loss of phosphoric acid at the doubly charged y-10 ion and the b-5 and 












Figure 4.39: Identification of PTPIP51 Y284 as a phosphorylation site by LC-
MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
283ApYSDMCELTEEVSEK297 (m/z 907.352+) fragment ion series after collision induced 
dissociation. The m/z of the fragment ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). No constant neutral loss from the parent ion was detected, implying 
that neither serine nor threonine phosphorylation was present on the peptide. Good frag-
mentation coverage of the peptide sequence provides weak confirmation of phosphory-












Figure 4.40: Identification of PTPIP51 S285 as a phosphorylation site by LC-
MS/MS. Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
283AYpSDMCELTEEVSEK297 (m/z 907.352+) fragment ion series after collision induced 
dissociation. The m/z of the fragment ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss was not detected at the parent ion. However, 
good fragmentation coverage of the peptide sequence and loss of phosphoric acid at the 
doubly charged y-13 ion and the b-8 ion (indicated by arrows on the spectrum), localizes 

















4.2.6 Identification of phosphorylation sites in VAPB in cells in which AMPK is 
activated 
As detailed above, there is the possibility that AMPK phosphorylates serine 158 in VAPB, 
based on the corresponding site in VAPA which is phosphorylated by AMPK. Given this 
evidence and the proposed role of dysregulated AMPK activity in ALS, this study next 
investigated whether AMPK phosphorylated either VAPB or PTPIP51.  
 
A number of chemical activators of AMPK have been reported, AICAR and A-769662 
are two such activators. A-769662 is reported to act more specifically (Vincent et al., 
2014) and studies were therefore conducted to investigate the effect of A-769662 in 
comparison to AICAR on AMPK activity. To do this, HEK-293 cells were treated with 
either vehicle (DMSO), AICAR, or A-769662 for 2 hrs. AMPK is activated either by 
nucleoside binding or by phosphorylation at T172. One of the most abundant targets of 
activated AMPK is Acetyl-CoA Carboxylase (ACC) which is primarily phosphorylated at 
serine 79. As such, lysates were probed on immunoblots with antibodies to total AMPK 
and total ACC and phospho-specific antibodies to AMPK T172 (P-AMPK) and ACC S79 
(P-ACC) (Figure 4.41). AMPK has a predicted molecular weight of 63 kDa and ACC has 
a predicted molecular weight of 265 kDa. Neither treatment affected the expression of 
total AMPK or ACC. Both AICAR and A-769662 increased the phosphorylation of AMPK, 
but only A-769662 appeared to increased phosphorylation of ACC. For both its reported 
selectivity and its demonstrated activity in these experiments, A-769662 was used to 
enhance AMPK activity in cells in order to investigate AMPK phosphorylation of VAPB 
and PTPIP51. 
 
Full length, myc-tagged VAPB was exogenously expressed in HEK-293 cells and cells 
were subsequently treated with either DMSO (vehicle) or A-769662 for 2 hrs. A sample 
of cell lysate was probed by immunoblot to confirm VAPB expression (Figure 4.42A). 
Myc-VAPB was immunoprecipitated from both samples via the myc tag and proteins 
were separated by SDS-PAGE and stained with imperial protein stain (Figure 4.42B). In 
this experiment, VAPB was immunoprecipitated at a higher yield from cells treated with 
A-769662 as can be seen by the more intense band on the SDS-PAGE gel in the A-
769662 treated cells (Figure 4.42B). Although there is a low yield of VAPB from DMSO 
treated cells, as in 4.2.5, the experiment was carried out in triplicate and all three bands 
were excised to ensure sufficient material for mass spectrometric analysis. Gel bands of 
isolated Myc-VAPB were prepared, including digestion with trypsin, as detailed in 2.2.12 






Figure 4.41: Activation of AMPK using AICAR and A-769662. HEK-293 cells were 
treated for 2 hrs with either DMSO vehicle control, AICAR or A-769662 (A769). Cells 
were lysed and probed on immunoblots for total AMPK and ACC, AMPK phosphorylated 
at T172 (P-AMPK) and ACC phosphorylated at S79 (P-ACC). The positions of proteins 











Figure 4.42: Overexpression and purification of Myc-VAPB for LC-MS/MS analysis 
of phosphorylation. HEK-293 cells were transfected with Myc-VAPB for 22 hrs and then 
treated with either DMSO vehicle control or A-769662 (A769). Cells were lysed 24 hrs 
after transfection and a sample was probed for VAPB expression on immunoblots (A). 
Myc-VAPB was immunoprecipitated using a Myc antibody, separated on an SDS-PAGE 
gel and stained with imperial protein stain (B). The position of VAPB is shown and mo-




LC-MS/MS of myc-VAPB isolated from cells treated with vehicle control DMSO, identified 
peptides corresponding to myc-VAPB and provided sequence coverage of 76 % of the 
full-length human protein (Figure 4.43). Eight individual sites of phosphorylation were 
identified and analysis of the corresponding fragmentation spectra of these 
phosphopeptides confirmed the localisation of phosphorylation to threonine residue 
T143, T144, T148, T150, and serine residues S156, S158 and S159. One doubly 
phosphorylated peptide was identified, with phosphorylation at both S156 and S158 
residues.  
 
LC-MS/MS of myc-VAPB isolated from cells treated with the AMPK activator A-769662 
identified peptides corresponding to myc-VAPB and provided sequence coverage of 72 
% of the full-length human protein (Figure 4.44). Four individual sites of phosphorylation 
were identified and analysis of the corresponding fragmentation spectra of these 
phosphopeptides confirmed the localisation of phosphorylation to threonine residue 
T150 and serine residues S156, S158 and S159. One doubly phosphorylated peptide 
was identified, with phosphorylation at both S158 and S159 residues.  
 
No phosphorylation sites were found in VAPB from cells treated with A-769662 that were 
not also found in VAPB from control cells. However, residues T143, T144 and T146 were 
found to be phosphorylated in VAPB from control cells but not in VAPB from cells treated 
with A-769662. The predicted AMPK phosphorylation site, S158 was found to be 
phosphorylated in VAPB from both samples. 
 
One representative phosphopeptide fragmentation spectrum is shown for each of the 
phosphorylation sites found in VAPB from cells either treated with DMSO or A-769662 
that have not yet been found in cells in this work. Representative fragmentation spectra 
for phosphorylation residues T144, T150, S156, S158 and S159 are shown in section 
4.2.4. Representative fragmentation spectra for phosphorylation residues T143 and 






Figure 4.43: Phosphorylation sites identified in VAPB isolated from cells treated 
with DMSO vehicle control. (A) Sequence of full length human VAPB with the MS/MS 
sequence coverage of 76 % shown as underlined. Seven phosphorylation sites were 
identified (T143, T144, T148, T150, S156, S158, S159), shown in red. (B) VAPB 
phosphopeptides obtained by MS/MS sequencing with their mass/charge (m/z) ratios. 







Peptide Sequence     Peptide m/z Modification 
140IISpTTASKTETPIVSK155    585.983+ T143 
140IISTpTASKTETPIVSK155    878.462+ T144 
140IISTTASKpTETPIVSK155    585.983+ T148 
140IISTTASKTEpTPIVSK155    878.462+ T150 
140IISTTASKTETPIVSKpSLSSSLDDTEVK167  1006.513+ S156 
140IISTTASKTETPIVSKpSLpSSSLDDTEVK167  1148.513+ S156, S158 
156SLpSSSLDDTEVKK168    744.852+ S158 





Figure 4.44: Phosphorylation sites identified in VAPB isolated from cells treated 
with AMPK activator A-769662. (A) Sequence of full length human VAPB with the 
MS/MS sequence coverage of 72 % shown as underlined. Four sites were identified 
(T150, S156, S158, S159), shown in red. (B) VAPB phosphopeptides obtained by 
MS/MS sequencing with their mass/charge (m/z) ratios. Phosphorylated residues shown 













Peptide Sequence    Peptide m/z Modification 
140IISTTASKTEpTPIVSK155   878.462+ T150 
148TETPIVSKSLpSpSSLDDTEVK167  1148.522+ S158, S159 
148TETPIVSKpSLSSSLDDTEVKK167  1108.543+ S156 




Figure 4.45: Identification of VAPB T143 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 
140IISpTTASKTETPIVSK155 (m/z 585.983+) fragment ion series after collision induced 
dissociation. The m/z of the fragment ions is plotted against intensity and the detected 
ions of the b- (red) and y- (blue) ion collision series are indicated on the sequence of the 
peptide (top left). A constant neutral loss of phosphoric acid, 98, from the parent ion was 
present at m/z 553.373+ and is indicative of either a serine or threonine phosphorylation 
on the peptide. Loss of phosphoric acid from the b-4 ion and the doubly charged y-13 













Figure 4.46: Identification of VAPB T148 as a phosphorylation site by LC-MS/MS. 
Tandem mass spectrometry spectrum of the VAPB phosphopeptide 140IIST-
TASKpTETPIVSK155 (m/z 585.983+) fragment ion series after collision induced dissocia-
tion. The m/z of the fragment ions is plotted against intensity and the detected ions of the 
b- (red) and y- (blue) ion collision series are indicated on the sequence of the peptide 
(top left). A constant neutral loss from the parent ion was found. However, a constant 
neutral loss of phosphoric acid, 98, indicative of either a serine or threonine phosphory-
lation on the peptide from the doubly charged b-10 and y-8 ions, localize this phosphor-




4.2.7 Identification of phosphorylation sites in PTPIP51 in cells in which AMPK is 
activated 
A similar study to that described above for VAPB was then conducted with PTPIP51. 
PTPIP51 was immunoprecipitated from HEK-293 cells in which AMPK was activated 
using A-769662. For comparison, cells were treated also with DMSO vehicle.  
 
Full length, HA-tagged PTPIP51 was exogenously expressed in HEK-293 cells and cells 
were subsequently treated with either DMSO vehicle or A-769662 for 2 hrs. Cells were 
lysed and a small sample was probed by immunoblot for PTPIP51-HA (Figure 4.47). 
PTPIP51-HA was immunoprecipitated from both samples via the HA tag and proteins 
were separated by SDS-PAGE and stained with imperial protein stain (Figure 4.47). 
PTPIP51 was immunoprecipitated at a higher yield from cells treated with A-769662 as 
can be seen by the more intense PTPIP51 band on the gel (Figure 4.47) in the A-769662 
condition. Although there is a low yield of PTPIP51 from DMSO treated cells, as in 4.2.6, 
the experiment was carried out in triplicate and all three gel bands were excised to ensure 
sufficient material for mass spectrometric analysis. Gel bands of isolated PTPIP51-HA 
was prepared, including digestion with trypsin, as detailed in 2.2.12 for LC-MS/MS which 








Figure 4.47: Overexpression and purification of PTPIP51-HA for LC-MS/MS analy-
sis of phosphorylation. HEK-293 cells were transfected with PTPIP51-HA for 22 hrs 
and then treated with either DMSO vehicle control or A-769662 (A769). Cells were lysed 
24 hrs after transfection and a sample was probed on immunoblots for PTPIP51-HA ex-
pression with HA antibody (A). PTPIP51-HA was immunoprecipitated using a HA anti-
body, separated on an SDS-PAGE gel and stained with imperial protein stain (B). The 
position of PTPIP51 and immunoglobulin heavy chain (Ig) is shown and molecular mass 




LC-MS/MS of PTPIP51-HA isolated from cells treated with vehicle control DMSO, 
identified peptides corresponding to PTPIP51-HA and provided sequence coverage of 
61 % of the full-length human protein (Figure 4.48). Six individual sites of phosphorylation 
were identified and analysis of the corresponding fragmentation spectra of these 
phosphopeptides confirmed the localisation of phosphorylation to serine residues S44, 
S46, S50, S57, S77, S81. Doubly phosphorylated peptides were identified, 
corresponding to phosphorylation at S44 and S46, S46 and S50. Two triply 
phosphorylated peptides were identified, corresponding to phosphorylation at serine 
residues S44, S46 and S50, and S46, S50 and S57.  
 
LC-MS/MS of PTPIP51-HA isolated from cells treated with the AMPK activator A-
769662, identified peptides corresponding to PTPIP51-HA and provided sequence 
coverage of 72 % of the full-length human protein (Figure 4.49). Six individual sites of 
phosphorylation were identified and analysis of the corresponding fragmentation spectra 
of these phosphopeptides confirmed the localisation of phosphorylation to serine 
residues S44, S46, S50, S77, S81 and S212. A doubly phosphorylated peptide was 
identified, corresponding to phosphorylation at S46 and S50. One triply phosphorylated 
peptide was identified, with phosphorylation at residues S44, S46, S50. Phosphorylation 
at residue S212 was found in PTPIP51 from cells treated with A-769662 but not in 
PTPIP51 from control cells.  
 
All of the phosphorylation sites identified in PTPIP51 from cells treated with either DMSO 
or A-769662 were identified in 4.2.5 of this chapter. As such, representative 
fragmentation spectra for each phosphorylation residue are not repeated here but 
instead can be found in section 4.2.5. A summary table of the phosphorylation sites 
which were found under each set of experimental conditions is included in the discussion 
of this chapter (Figure 4.50 for VAPB phosphorylation sites, Figure 4.51 for PTPIP51 





Figure 4.48: Phosphorylation sites identified in PTPIP51 isolated from cells treated 
with DMSO vehicle control. (A) Sequence of full length human PTPIP51 with the 
MS/MS sequence coverage of 61 % shown as underlined. Six phosphorylation sites were 
identified (S44, S46, S50, S57, S77, S81), shown in red. (B) PTPIP51 phosphopeptides 
obtained by MS/MS sequencing with their mass/charge (m/z) ratios. Phosphorylated 












Peptide Sequence     Peptide m/z  Modification 
41HGRpSQpSLPNSLDYTQTSDPGR61   826.013+ S44, S46 
41HGRpSQpSLPNpSLDYTQTSDPGR61   852.673+ S44, S46, S50 
41HGRpSQSLPNSLDYTQTSDPGR61   799.363+ S44 
44SQpSLPNSLDYTQTSDPGR61    1023.442+ S46 
44SQpSLPNpSLDYTQTpSDPGR61   1103.412+ S46, S50, S57 
44SQSLPNpSLDYTQTSDPGR61     1023.442+ S50 
44SQpSLPNpSLDYTQTSDPGR61   1063.432+ S46, S50 
68AVPGGAGDApSVLPSLPR84    822.412+ S77 




Figure 4.49: Phosphorylation sites identified in PTPIP51 isolated from cells treated 
with AMPK activator A-769662. (A) Sequence of full length human VAPB with the 
MS/MS sequence coverage of 72 % shown as underlined. Six phosphorylation sites were 
identified (S44, S46, S50, S77, S81, S212), shown in red. (B) PTPIP51 phosphopeptides 
obtained by MS/MS sequencing with their mass/charge (m/z) ratios. Phosphorylated 













Peptide Sequence      Peptide m/z  Modification                            
41HGRpSQSLPNSLDYTQTSDPGR61    799.363+ S44 
44SQpSLPNpSLDYTQTSDPGR61    1063.432+ S46, S50 
41HGRpSQpSLPNpSLDYTQTSDPGR61    825.673+ S44,S46,S50 
44SQpSLPNSLDYTQTSDPGR61     1023.442+ S46 
44SQSLPNpSLDYTQTSDPGR61      1023.452+ S50 
68AVPGGAGDApSVLPSLPR84     822.412+ S77 
68AVPGGAGDASVLPpSLPR84     822.412+ S81 




4.3.1 Summary of results 
In this chapter, phosphorylation of VAPB and PTPIP51, specifically in conditions of GSK-
3β and AMPK activity were investigated by mass spectrometry. In the case of GSK-3β, 
recombinant protein was incubated with the kinase in vitro to identify potential sites of 
direct phosphorylation. VAPB and PTPIP51 isolated from cells were also analysed to 
identify phosphorylation sites in cells. Over-expression of GSK-3β and pharmacological 
activation of AMPK were used to indicate the phosphorylation of VAPB and PTPIP51 in 
response to activation of these kinases.  
 
This work identified novel potential GSK-3β phosphorylation sites in both VAPB and 
PTPIP51. VAPB residues T143, T148, T150 and PTPIP51 residue S77 were found to be 
phosphorylated by recombinant GSK-3β. Mutation of VAPB at residues T143 and T148 
to mimic or preclude phosphorylation indicated that modification at T148 reduces the 
binding of VAPB to PTPIP51. VAPB residue T150, but not residues T143 and T148, was 
found to be phosphorylated in cells over-expressing GSK-3β. However, VAPB residues 
T143, T148 and T150 were found to be phosphorylated in control cells. PTPIP51 S77 
was also found to be phosphorylated in cells in all of the conditions tested.  
 
A number of phosphorylation sites were found in VAPB and PTPIP51 
immunoprecipitated from cells. A summary of the sites found to be phosphorylated in 
VAPB and PTPIP51 from each condition, and a diagram of their position in the protein 
are shown in figures 4.50 and 4.51 for VAPB and PTPIP51, respectively. VAPB S146 
was the only residue identified only in cells overexpressing GSK-3β. The predicted 
AMPK phosphorylation site in VAPB, residue S158, was found to be phosphorylated in 
all cellular conditions. A majority of PTPIP51 phosphorylation sites were found in all 
cellular conditions. PTPIP51 Y284 was only found to be phosphorylated in PTPIP51 from 
cells overexpressing GSK-3β. PTPIP51 residue S212 was phosphorylated in PTPIP51 
from cells treated with AMPK activator A-769662 and in cells over-expressing GSK-3β 
but not in control cells. Doubly phosphorylated peptides, indicating that two residues are 
phosphorylated at the same time in the protein, were also found. Of these doubly 
phosphorylated peptides, one in each protein fits the described GSK-3β motif of priming 
phosphorylation 4 or 5 residues upstream of target phosphorylation (Doble and 









Figure 4.50: Summary of phosphorylation sites found in VAPB. Table shows the 
phosphorylation sites found in recombinant VAPB after incubation with GSK-3β 
(Recombinant protein), VAPB immunoprecipitated from cells which were transfected with 
control vector (Control) or GSK-3β and VAPB immunoprecipitated from cells treated with 
vehicle (DMSO) or A-769662. Diagram shows the position of identified phosphorylation 
sites on the structure of VAPB. MSP, motile sperm domain. CC, coiled coil domain, TM, 
transmembrane domain.    
 
VAPB PTPIP51
Control GSK-3β DMSO A769662 Control GSK-3β DMSO A769662
T143 x x S44 x x x x
T144 x x S46 x x x x
S146 x S50 x x x x
T148 x x T54 x
T150 x x x x T56 x
S154 x S57 x x x
S156 x x x x S77 x x x x x
S158 x x x x S81 x x x x
S159 x x x S193 x x





T143 Recombinant, DMSO S44 Control, GSK-3β, DMSO, A769662
T144 Recombinant, Conrol, DMSO S46 Control, GSK-3β, DMSO, A769662
S146 GSK-3β S50 Control, GSK-3β, DMSO, A769662
T148 Recombi ant, DMSO T54 Control
T150 Recombinant, GSK-3β, DMSO, A769662 T56 Control
S154 Control S57 Control, GSK-3β, DMSO
S156 Control, GSK-3β, DMSO, A769662 S77 Recombinant, Control, GSK-3β, DMSO, A769662
S158 Control, GSK-3β, DMSO, A769662 S81 Control, GSK-3β, DMSO, A769662
S159 Control, DMSO, A769662 S193 Control, GSK-3β






















Figure 4.51: Summary of phosphorylation sites found in PTPIP51. Table shows the 
phosphorylation sites found in either recombinant PTPIP51 after incubation with GSK-
3β (Recombinant protein), PTPIP51 immunoprecipitated from cells transfected with 
control vector (Control) or GSK-3β or treated with vehicle (DMSO) or A-769662. Diagram 
shows the position of identified phosphorylation sites on the structure of PTPIP51. TM, 





4.3.2 Identification of phosphorylation sites in VAPB and PTPIP51   
The study of kinases using recombinant protein is useful to identify the direct 
phosphorylation of a substrate, in the absence of other downstream kinases. However, 
this method also removes the natural modulation of kinase activity that is present in the 
cell, potentially leading to both false negatives and false positives. For example, false 
positives may arise due to the lack of competing natural kinase substrates and false 
negatives may arise because E.coli produced recombinant proteins may not fold 
correctly. To determine if the phosphorylation sites identified in recombinant protein in 
this study were false positives, VAPB and PTPIP51 from cells were also analysed. Since 
phosphorylation occurs dynamically in the cell, GSK-3β over-expression was used to 
enhance the chances of identifying phosphorylation at those residues found in 
recombinant experiments. Similarly, A-769662 was used to activate AMPK and increase 
the likelihood of identifying novel sites of phosphorylation that may be a result of AMPK 
activity.  
 
Phosphorylation sites that were not identified in VAPB or PTPIP51 from control cells but 
were identified in protein from GSK-3β over-expressing cells or A-769662 treated cells 
may be deemed more likely to be targets of GSK-3β or AMPK. Quantitative mass 
spectrometry which compared the amounts of phosphorylation of VAPB or PTPIP51 on 
particular sites in control cells, or cells in which GSK-3β or AMPK were activated, would 
be required to demonstrate cellular targets for the two kinases. Quantitative mass 
spectrometry was out of the scope of this work and therefore the phosphorylation sites 
found are not confirmed kinase targets but instead provide direction for further 
investigation into the functional effects of modification on VAPB-PTPIP51 binding and 
ER-mitochondria signalling.  
 
PTPIP51 residue S212 was found to be phosphorylated only in PTPIP51 from cells 
expressing GSK-3β or in which AMPK was activated, though it should be noted that this 
site was not covered in mass spectrometric analysis of PTPIP51 from DMSO treated 
cells. PTPIP51 S212 lies outside the core residues of PTPIP51 found to be necessary 
for binding to VAPB (De Vos et al., 2012) and modification at this site is therefore unlikely 
to alter its ability to bind to VAPB. The potential AMPK target phosphorylation site in 
VAPB, S158, which is the conserved residue corresponding to the AMPK target 
phosphorylation site in VAPA (Hoffman et al., 2015), was found to be phosphorylated in 
VAPB from all cellular samples. This would be a sensible next candidate for investigation 
for altering binding affinity to PTPIP51, and incubation of recombinant VAPB with active 




In both VAPB and PTPIP51, a cluster of phosphorylation sites in a particular area of the 
protein were identified. The structure of VAPB consists of an MSP domain, a coiled coil 
domain, and a transmembrane domain, with unstructured regions between the main 
domains. The ALS-causing mutation in VAPB, P56S, is reported to reduce VAPB 
solubility by altering folding within the MSP domain (Shi et al., 2010). The two residues 
of VAPB investigated in this work, T143 and T148, reside in an unstructured region 
between the MSP and coiled coil domains. Indeed, all of the phosphorylation sites 
identified in VAPB, recombinantly and from control, GSK-3β over-expressing and A-
769662 treated cells, reside in this region. It may be speculated that the multiple 
phosphorylation sites found in this region indicate a role for this region in modulating the 
structure of function of the protein. Similarly, a cluster of phosphorylation sites in 
PTPIP51 were found close to the transmembrane domain of the protein. The structure 
of PTPIP51 is yet to be reported and although the MSP domain of VAPB has been 
crystallised and the structure identified (Shi et al., 2010), the structure of the rest of the 
protein remains unsolved. Structural studies of VAPB and PTPIP51, such as NMR or 
crystallography investigations, particularly of VAPB in complex with PTPIP51, would 
enable modelling of the effect of the post translational modifications found in this study. 
Structural information would also provide the basis for development of molecules able to 
stabilise the interaction.  
 
4.3.3 The effect of VAPB phosphorylation on binding to PTPIP51 
GSK-3β target sites for phosphorylation are reported to have a priming site located 4 or 
5 residues upstream of the main target site (Doble and Woodgett, 2003). VAPB T143 
and T148 both fit this reported phosphorylation motif and are conserved across different 
species, as would be expected of residues able to regulate a prominent cellular process 
such as ER-mitochondrial signalling. Conversely, PTPIP51 S77 and VAPB T150 
residues are not conserved between animals. As such, VAPB T143 and VAPB T148 
were investigated for a potential role in regulating the binding of VAPB to PTPIP51.  
 
Mutation of VAPB T143 or T148 indicated that T143 alone had no effect on binding to 
PTPIP51 but that phosphorylation of T148 may reduce the affinity of VAPB to PTPIP51. 
In the GAL4 2-hybrid luciferase studies there was a modest but significant decreasing in 
binding between VAPB-T148D and PTPIP51 compared to that of WT VAPB. Preventing 
phosphorylation at VAPB T148 had no effect on binding. This may be due to the majority 
of VAPB in the cell being non-phosphorylated at this residue. Whilst the GAL4 2-hybrid 
luciferase assay is a useful first indicator of protein binding, the interactions involved take 
place in the nucleus, requiring the removal of the transmembrane domains of VAPB and 
PTPIP51, and their interaction away from their natural cellular locations. Further 
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investigation into the binding of VAPB and PTPIP51 should include immunoprecipitation 
experiments in which full length proteins can be investigated in their correct locations 
within the cell.  
 
In order to confer the importance of VAPB T148 in ALS, the extent of phosphorylation at 
this residue should be measured in ALS cell and transgenic models and in human ALS 
tissues. This could be performed as in this study by mass spectrometry. Quantitative 
mass spectrometry would allow comparison between VAPB from ALS and control tissue. 
Alternatively, a phospho-antibody to VAPB-T148 could be produced and used to quantify 
differences in the amount of phosphorylation at this specific residue between control and 
ALS tissue.  
 
4.3.4 Implications for therapeutic potential  
There is much evidence indicating a role for dysregulated ER-mitochondria contacts in 
ALS (discussed in detail in chapter 1, for review see Lau et al., 2018) and GSK-3β has 
been shown to mediate this dysregulation (Stoica et al., 2016; Stoica et al., 2014). GSK-
3β, ER-mitochondrial signalling and VAPB-PTPIP51 binding are therefore potential 
therapeutic targets for ALS.  
 
Kinases are attractive therapeutic targets because it is known that they can be modulated 
by small molecule drugs. GSK-3β itself has been targeted for the treatment of 
neurodegenerative disease (discussed in detail in chapter 1) (Ahn et al., 2012; Cohen 
and Goedert, 2004; Feng et al., 2008; Koh et al., 2007) with little success due to its wide-
ranging roles within the cell. Therefore, there is a need to understand the mechanisms 
by which GSK-3β exerts its effects in ALS to identify downstream targets for therapy. 
There is also evidence linking AMPK to ALS (discussed in 4.1) and the phosphorylation 
of VAP proteins (Hoffman et al., 2015). Identification of either a GSK-3β or AMPK 
phosphorylation site in VAPB or PTPIP51 which disrupts ER-mitochondrial signalling 
would shed light on the role of GSK-3β or AMPK in ALS and enable investigation into 




















5.1 The role of VAPB-PTPIP51 interactions in ALS 
The studies described in Chapter 3 investigated a number of ER-mitochondria signalling 
proteins and used PLAs to quantify the VAPB-PTPIP51 interaction in post-mortem spinal 
cord tissue and iPSC-MNs from ALS donors. These studies found that VAPB-PTPIP51 
interactions are significantly reduced in ALS patients. This finding is in line with evidence 
in animal and cell models of ALS (Stoica et al., 2014; Stoica et al., 2016) and 
demonstrates for the first time that defective ER-mitochondria contacts are a feature of 
human ALS. A decrease in VAPB protein levels was also identified in ALS post-mortem 
spinal cord, in agreement with published studies (Anagnostou et al., 2010). VAPB protein 
level and PLA signal did not correlate, suggesting that VAPB amount did not necessarily 
account for the variation in VAPB-PTPIP51 interaction. TOM20 protein amounts were 
increased in ALS tissue, as reported in animal studies (Li et al., 2010) but no change in 
the levels of other mitochondrial or ER proteins was found. Together these findings 
reveal ER-mitochondria contacts and the VAPB-PTPIP51 tethers as a novel feature of 
human ALS and a potential therapeutic target.  
 
5.1.1 Broken ER-mitochondria contacts: cause or consequence of cell damage? 
In confirming the disruption of ER-mitochondria contacts as a feature of human ALS, this 
work identifies VAPB and PTPIP51 tethers as specific targets for studies aiming to 
rescue ER-mitochondria signalling in ALS. Chapter 3 describes a VAPB-PTPIP51 
binding assay, the GAL4 2-hybrid luciferase reporter assay which presents the 
opportunity to screen for small molecule drugs capable of rescuing ER-mitochondria 
contacts.  
 
In order to determine if such drugs would act therapeutically, future studies should seek 
to identify whether disruption to ER-mitochondria contacts occurs as an early ALS 
pathology which leads to cell damage or as a consequence of ALS-related cell damage. 
TDP-43 and FUS both disrupt ER-mitochondria contacts via activation of GSK-3β (Stoica 
et al., 2014; Stoica et al., 2016), but the mechanism by which this occurs is as yet 
unknown, and the possibility that it happens as a consequence of ALS-related cell 
damage as opposed to an early pathology should be ruled out if it is to be targeted 
therapeutically. This could be addressed by determining if disruption to ER-mitochondria 
contacts occurs early in disease, for example by measuring temporal changes in ER-
mitochondria contacts in ALS transgenic mice, identifying whether they occur before the 
onset of symptoms. In support of the idea that disruption to MAM occurs early in disease, 
ER-mitochondria contacts are reported to be broken in TDP-43 and FUS transgenic mice 
without any change in VAPB protein levels (Stoica et al., 2014; Stoica et al., 2016), whilst 
VAPB protein levels are decreased at the end stage of the disease in humans, as found 
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in this study and by Anagnostou et al., (2010). Future studies may therefore want to 
measure both ER-mitochondria contacts and VAPB proteins levels in pre-symptomatic, 
symptomatic, and end-stage ALS transgenic animals. iPSC-MNs derived from ALS 
patients show increased levels of insoluble TDP-43 when matured in vitro (Bilican et al., 
2012; Egawa et al., 2012). The findings in Chapter 3 of this thesis show reduced ER-
mitochondria contacts in iPSC-MNs at a level of maturity in which TDP-43 aggregates 
are expected in M337V but not G298S mutant cells (unpublished data, Jenny Greig e-
thesis), suggesting that disruption to ER-mitochondria signalling is likely to occur before 
TDP-43 aggregation. These iPSC-MNs present the opportunity to measure the 
development of insoluble TDP-43, damage to ER-mitochondria contacts and consequent 
cellular dysfunction in parallel over time.  
 
5.1.2 Are the functions of ER-mitochondria contacts altered in ALS? 
Cellular dysfunction, in particular to the processes that are regulated by ER-mitochondria 
signalling such as calcium signalling, ATP production, phospholipid synthesis, and 
inflammasome formation (Cali et al., 2013a; Missiroli et al., 2018; Rowland and Voeltz, 
2012) have already been implicated in ALS (Lau et al., 2018). In order to confirm the 
potential of correcting ER-mitochondria contacts as a therapeutic target and to facilitate 
testing for compounds which rescue cellular function, future studies should measure 
correlate disruption to these functions with changes in the VAPB-PTPIP51 interaction 
and ER-mitochondria contacts in ALS. iPSC-MNs present the opportunity do this and 
studies could use isogenic control cell lines, in which ALS-causing mutations in patient 
cells are genetically modified to the wild-type gene via CRISPR methods. This would 
enable comparisons between ALS and control cells with the same genetic background. 
 
5.1.2.1 Calcium signalling and energy metabolism 
Calcium signalling between ER and mitochondria is mediated by IP3R and VDAC at ER-
mitochondria contact sites (Szabadkai et al., 2006) and is disrupted by reduced VAPB-
PTPIP51 binding (De Vos et al., 2012). Further studies could measure the interaction 
between IP3R and VDAC in ALS post-mortem tissue and ALS patient cells using PLAs 
as in this study, to determine whether this functional interaction is also affected in ALS. 
   
In cells, changes in calcium exchange and cellular respiration have been measured as 
described previously (De Vos et al., 2012; Paillusson et al., 2017). Briefly, calcium 
exchange is measured via mitochondrial and cytosolic calcium levels upon stimulation 
of calcium release. Cellular respiration is investigated by measuring oxygen consumption 
upon treatment of electron transport chain uncouplers. These methods, used in iPSC-
MNs derived from patients and in isogenic controls, would provide a functional readout 
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for calcium exchange and ATP production that could be utilised in a search for 
compounds able to restore defective ER-mitochondrial signalling.  
 
5.1.2.2 Inflammation 
In ALS, as in many neurodegenerative diseases, inflammation has been considered as 
both a stressor and symptom of disease (Geloso et al., 2017; Komine and Yamanaka, 
2015). Formation of the inflammasome is reported to occur at MAM and subsequent 
inflammatory responses are therefore likely modulated by ER-mitochondria contacts 
(Missiroli et al., 2018; Zhou et al., 2011). This study measured VAPB-PTPIP51 
interactions in the soma of motor neurons, but it would be of interest to investigate ER-
mitochondria contacts in glial cells, and their role in microglia activation. This would 
require optimisation of glial markers and fluorescent PLA to be carried out in post-mortem 
tissue. Advances in iPSC differentiation mean that microglia-like cells could now be 
generated from ALS patient cells in which to measure ER-mitochondria contacts. These 
studies could compare between ALS patient and control donor or isogenic controls and 
between microglia-like and motor neuron cells.  
 
5.1.2.3 Synaptic activity 
VAPB-PTPIP51 binding and ER-mitochondria contact has been shown to regulate 
synaptic activity (Gomez-Suaga et al., 2019). Measuring VAPB-PTPIP51 interactions in 
synaptic regions and in response to stimulation of synaptic activity (e.g. via electrical 
stimulation), in ALS patient iPSC-MNs and control donor or isogenic control cells would 
indicate whether the regulation of synaptic activity by ER-mitochondria contact is affected 
in ALS.  
 
5.1.3 How are ER and mitochondrial proteins affected in ALS? 
5.1.3.1 TOM20 and mitochondrial protein accumulation 
The levels of mitochondrial proteins PTPIP51 and VDAC were not changed between 
ALS and control donor spinal cord tissue in this study, but the levels of mitochondrial 
protein TOM20 were increased in ALS donor tissue; this is in line with studies of SOD1 
ALS animal studies (Li et al., 2010). TDP-43 and FUS are both reported to bind to certain 
mitochondrial proteins and increase mitophagy (Davis et al., 2018; Deng et al., 2018). 
As discussed in 3.3.3, future studies may investigate whether mitophagy or dysfunction 
in mitochondrial proteins such as TOM20 is the cause of altered mitochondrial protein 
levels. These studies could include experimental manipulation of TOM20 function, or 





5.1.3.2 Sigma1R and ER proteins    
This study found that Sigma1R protein levels were not different between ALS and control 
donor post-mortem spinal cord tissue. Sigma1R functions to stabilise IP3R clustering 
(Hayashi and Su, 2007; Ryskamp et al., 2019) and the protein levels of neither IP3R nor 
its binding partner VDAC were altered in ALS tissues. These findings support reports 
that it is not changes in Sigma1R expression but altered Sigma1R function that plays a 
role in disease pathogenesis (Al-Saif et al., 2011; Gregianin et al., 2016; Luty et al., 
2010). Future studies may investigate whether expression of functional Sigma1R can 
rescue calcium signalling, by enhancing IP3R clustering, in ALS models such as TDP-
43 or FUS overexpressing cells.   
 
5.2 Phosphorylation as a modulator of ER-mitochondria contacts 
The studies described in Chapter 4 aimed to identify phosphorylation sites in VAPB and 
PTPIP51. Studies of in vitro phosphorylation with recombinant protein identified VAPB 
residues T143, T148 and T150 and PTPIP51 residue S77 as GSK-3β phosphorylation 
sites. A GAL4 2-hybrid assay with phospho-mimicking mutants suggested that 
phosphorylation of VAPB at residue T148 can alter its binding to PTPIP51, indicating 
that GSK-3β phosphorylation of VAPB may regulate ER-mitochondria contacts. Mass 
spectrometry studies of VAPB immunoprecipitated from cells confirmed the 
phosphorylation of these sites in cells and identified novel phosphorylation sites including 
the hypothesised AMPK phosphorylation site, VAPB S158, which is phosphorylated at a 
conserved residue in VAPA (Hoffman et al., 2015).  
 
5.2.1 Investigating the effect of kinases on ER-mitochondria contacts in ALS 
Having identified phosphorylation sites in VAPB and PTPIP51, it would next be useful to 
confirm whether the kinases responsible are indeed GSK-3β and AMPK. Quantitative 
phospho-proteomic mass spectrometry studies comparing VAPB and PTPIP51 from 
cells in which GSK-3β or AMPK activities have been experimentally manipulated would 
indicate whether GSK-3β or AMPK themselves increase phosphorylation of VAPB or 
PTPIP51 and at which sites. These methods involve specific labelling (e.g. isotopic 
labelling) of proteins in cells in which kinase activities are unaltered or elevated and/or 
reduced, followed by isolation and quantification of phosphorylation of the protein of 
interest in the different samples (Hennrich and Gavin, 2015). These studies could be 
complemented by investigating whether GSK-3β or AMPK activity is altered in ALS. 
Given that GSK-3β is activated by overexpression of TDP-43 or FUS (Stoica et al., 2014; 
Stoica et al., 2016), it may be hypothesised that it is increased in ALS patients. 
Investigating this could take the form of immunoblotting for the total and active 




GSK-3β activity has previously been shown to alter ER-mitochondria contacts (Stoica et 
al., 2014; Stoica et al., 2016) but the effect of AMPK activity on ER-mitochondria contacts 
is yet to be investigated. AMPK activity is implicated in ALS (Liu et al., 2015; Perera et 
al., 2014; Perera and Turner, 2016) and future studies may investigate the effect of 
AMPK activity on ER-mitochondria contacts. This could be investigated by measuring 
VAPB-PTPIP51 interactions using PLAs in cells treated with AMPK activator A-769662. 
It should also be determined whether modulation of AMPK activity can correct the effect 
of TDP-43 and FUS on ER-mitochondria contacts. Finally, there is evidence that GSK-
3β and AMPK activities are linked, though the precise details are not yet fully understood 
(Horike et al., 2008; Suzuki et al., 2013). Investigation into the effect of AMPK activity on 
GSK-3β activity, and vice versa, as potential modulators of ER-mitochondria contacts 
could be investigated. This would involve modulation of the activity of either kinase, 
monitoring of the activity of the other kinase and parallel measurement of VAPB-
PTPIP51 interactions.  
 
5.2.2 Investigating the role of phosphorylation on ER-mitochondria contacts 
The findings in this study provide the basis for further investigation into the effect of 
phosphorylation of VAPB on ER-mitochondria contacts, since phospho-mimicking at 
VAPB residue T148 is shown to reduce VAPB-PTPIP51 interactions. VAPB residues 
T148 and S158 should first be investigated for a role in ER-mitochondria contacts by the 
use of immunoprecipitation studies. GSK-3β activity should also be increased by over 
expression or reduced with selective inhibitors, and the alanine or aspartate mutants 
respectively transfected to determine if they rescue the effect of GSK-3β on ER-
mitochondria contacts. If these studies show that such mutants do rescue the effects of 
GSK-3β on ER-mitochondria contacts, then phospho-specific antibodies to these sites 
could be used to probe whether changes in their phosphorylation occurs in ALS donor 
tissues and in models of ALS. Prevention of phosphorylation of these sites could then be 
considered a potential therapeutic strategy.  
 
This study also found small clusters of phosphorylation sites in both VAPB and PTPIP51. 
These clusters may represent areas in which phosphorylation affects the structure of the 
protein and may be considered a basis for structural investigation into VAPB-PTPIP51 
binding. Determination of the structure of this interaction, for example by crystallography 
or nuclear magnetic resonance studies, would facilitate modelling of the effect of post 
translational modifications and small molecules on the interaction. This line of 





This thesis investigated two main hypotheses; that ER-mitochondria contacts are 
disrupted in humans with ALS and that this disruption is caused by phosphorylation of 
VAPB or PTPIP51, including via GSK-3β. This hypothesis is detailed in Figure 5.1, 
including the features of neurodegenerative disease which are affected by disruption to 
ER-mitochondria contacts. In the work presented in this thesis, phosphorylation sites, 
which may be GSK-3β targets, were identified in both VAPB and PTPIP51 and the 
VAPB-PTPIP51 interaction was found to be disrupted in ALS patient cells and tissue. A 
number of questions remain: How do ALS insults enhance GSK-3β activity? Are the 
phosphorylation sites identified in this work phosphorylated at higher levels in ALS 
patients? Finally the most important question, would preventing phosphorylation of 
VAPB or PTPIP51 act therapeutically for ALS patients? 
 
Figure 5.1: Schematic representation of the hypothesis underlying this thesis.  
In healthy cells, VAPB-PTPIP51 binding facilitates contacts between ER and 
mitochondrial membranes which regulate healthy signaling. In ALS, insults including 
TDP-43 and FUS overexpression increase GSK-3β activity. The work presented in this 
thesis showed that VAPB-PTPIP51 interactions are reduced in human ALS and identified 
phosphorylation sites in VAPB and PTPIP51 which are potential GSK-3β targets and 
may cause disrupted VAPB-PTPIP51 binding. Disrupted ER-mitochondria contacts lead 




In summary, the work in this thesis shows that the VAPB-PTPIP51 interaction is 
disrupted in ALS patient tissues and identifies novel phosphorylation sites that may affect 
binding of VAPB to PTPIP51. The discovery that the VAPB-PTPIP51 interaction is 
disrupted in ALS donor tissues and in ALS patient-derived iPSC-motor neurons 
recapitulates studies in ALS models and reveals a new feature of ALS in humans. As 
such, these findings lend strong support that correcting damaged ER-mitochondria 
signalling is a valid therapeutic target for ALS. Moreover, these findings reveal precise 
targets, VAPB and PTPIP51, suitable for drug screens to identify molecules capable of 
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